

OFFICE OF ENTERPRISE TECHNOLOGY SERVICES

P.O. BOX 119, HONOLULU, HAWAI'I 96810-0119 Ph: (808) 586-6000 | Fax: (808) 586-1922 ETS.HAWAII.GOV

May 18, 2022

The Honorable Ronald D. Kouchi, President, and Members of The Senate Thirty-First State Legislature Hawaii State Capitol, Room 409 Honolulu, Hawaii 96813

The Honorable Scott K. Saiki, Speaker, and Members of The House of Representatives Thirty-First State Legislature Hawaii State Capitol, Room 431 Honolulu, Hawaii 96813

Dear President Kouchi, Speaker Saiki, and Members of the Legislature:

Pursuant to HRS section 27-43.6, which requires the Chief Information Officer to submit applicable independent verification and validation (IV&V) reports to the Legislature within ten days of receiving the report, please find attached the report the Office of Enterprise Technology Services received for the State of Hawaii Department of Health Hawaii BHA Integrated Case Management System Project.

In accordance with HRS section 93-16, this report may be viewed electronically at http://ets.hawaii.gov (see "Reports").

Sincerely,

DOUGLAS MURDOCK Chief Information Officer

State of Hawai'i

Attachment (2)



Hawaii BHA Integrated Case Management System Project – *Phase 3*

Final IV&V Report for the period of

April 1 – April 30, 2022

Final submitted: May 13, 2022



Agenda

Executive Summary

IV&V Findings & Recommendations

Appendices

- A Rating Scales
- B Inputs
- C Project Trends





Executive Summary

A planned production deployment scheduled for April was postponed for early May due to issues found in the deployment planning process for R3.23. The Project continues to face multiple challenges with the existing staff shortages and has commenced focused resource management/planning sessions in April to address this issue.

The schedules for 'big boulder' functionality continued to slip in April and the Project's ability to deliver these functionalities by the end of the DDI period is in jeopardy.

IV&V will continue to closely monitor these items moving forward.

Feb	Mar	Apr	Category	IV&V Observations	
BHA deployment team member will be 50% allocated to a significant CAMHD/Medorate and the significant cannot be significant		IV&V continues to be concerned with the support of the BHA deployment team. A key BHA deployment team member will be 50% allocated to a significant CAMHD/MedQuest rate change initiative starting in June. The departure of a BHA deployment team member who transitioned to another role is being backfilled by another team member who will be new to deployment. Other mitigation efforts are in progress to address this concern. The criticality rating for this category remains Red (high) for the April reporting period.			
I A I I I I I I I I I I I I I I I I I I		There are no active findings in the User Story (US) Validation category which remains Green (low criticality) for the April reporting period. IV&V will continue to monitor the US development and validation process in upcoming reporting periods.			
Y	BHA plans to select an automated regression tool during May as additional demos continue to be scheduled. The outcome of the R3.22 RCA has resulted in numerous testing improvements to include data validation for bulk updates, joint testing for edge cases, and an increased level of smoke testing.		continue to be scheduled. The outcome of the R3.22 RCA has resulted in numerous testing improvements to include data validation for bulk updates, joint testing for edge		
· · · · · · · · · · · · · · · · · · ·		improvement in this area included an increased level of smoke testing in subsequent releases. As mentioned above, IV&V continues to be concerned about the support efforts			




Executive Summary

Feb	Mar	Apr	Category	IV&V Observations	
G	G	G	OJT and KT Sessions	The criticality rating for the OJT and KT Sessions category remains Green (low) for the April reporting period with no active findings.	
G	G	G	Targeted KT	This category remains Green (low criticality) for the April reporting period and IV&V will continue to monitor.	
G	G	G	Project Performance Metrics	There are no project performance metrics to report for April. IV&V will keep the criticality rating for this category a Green (low) and will continue to monitor this category moving forward.	
G	G	G	Organizational Maturity Assessment (OMA)	PCG conducted an Organizational Maturity Assessment with the BHA Team on April 4, 2022. A summary of the assessment and our recommendations are documented in Appendix C of this status report. The criticality rating for the Organization Maturity Assessment (OMA) category remains Green (low).	
Y	R	R	Project Management	The formal R3.22 RCA identified issues tied to requirements, coding, testing, and deployment errors. Associated action items to address these issues have been established. 'Big Boulder' prioritized features/functionality implementation schedules	



Executive Summary

As of the April 2022 reporting period, there are a total of seven (7) open findings – two High Issue, four Medium Issues, and one Low Issue spread across the Sprint Planning, Release / Deployment Planning, Test Practice Validation, and Project Management assessment areas.





Assessment Categories

Throughout this project, IV&V verifies and validates activities performed in the following process areas:

- Sprint Planning
- User Story Validation
- Test Practice Validation
- Release / Deployment Planning
- On-the-Job Training (OJT) and Knowledge Transfer (KT) Sessions
- Targeted Knowledge Transfer (KT)
- Project Performance Metrics
- Organizational Maturity Assessment
- Project Management



IV&V Findings & Recommendations Sprint Planning

#	Key Findings	Criticality Rating
	High Issue - The BHA Technical Team bandwidth may not be adequate to meet the needs of the project, which could compromise project productivity. The BHA Solution Architect returned from leave in early April, providing some relief in this area. A key BHA deployment team member will be approximately 50% allocated to a significant CAMHD/MedQuest rate change initiative starting in June. DDD is still awaiting approval authority to post its open IT position and the responsibilities for this position are currently being covered by existing DDD team members.	
7	The re-assignment of a DDD technical resource supporting deployments continues to put the current deployment support efforts at risk. R3.24 will not be deployed as a full solution upgrade due to resource constraints, altering plans to perform FSUs every other release. Due to increasing resource constraints, the project has reduced approximately 30% of the planned configuration and development velocity over the next 3 releases, directly affecting the implementation schedules of priority features in the latest roadmap. IV&V will continue to monitor the potential impacts of the resource issues on the project for this high criticality issue.	(†)

Recommendations	Status
BHA needs, and should pursue, additional Knowledge Transfer sessions on the updated Ca solution. Knowledge Transfer sessions should include complete documentation of the solution.	In progress
The Project should investigate mechanisms of increasing the bandwidth of the BHA Technic adding resources through new hires, or vendor contracts.	cal Team, either by



IV&V Findings & Recommendations Sprint Planning (cont'd)

Recommendations	
The Project should assess, where possible, if there are responsibilities of the BHA Technical Team that can be reassigned to other project staff.	In progress
The Project should evaluate where process inefficiencies can be addressed and streamlined to possibly free up the BHA Technical Team's availability.	In progress
The Project should consider the formation of a first level resource team to triage/address production defects in a timely manner, without disrupting new development work.	Completed
The Project should consider procurement of an online training toolset to support OCM and technical efforts to offset the need for in-person training.	Completed



Test Practice Validation

#	Key Findings	Criticality Rating
2	Medium Issue – As a result of regression testing not being consistently performed, production releases are breaking and/or deprecating existing functionality in the production environment. The formal RCA for R3.22 identified root causes of the associated defects that were tied to requirements, coding, testing, and deployment errors. Recommendations for testing improvements included data validation for bulk updates, joint testing for edge cases, and an increased level of smoke testing. BHA continued formal planning for the implementation of automated regression testing and attended multiple product demonstrations during April. Tool selection is currently planned for May and the regression test automation effort duration is still anticipated to be approximately 2-3 months for the initial setup. IV&V will continue to monitor this medium criticality issue.	M

Recommendations	Status
 Pursuing additional formal training in AzureDevOps for test automation at the earliest possible juncture and commence efforts to automate at least the 2 primary regression test scripts. 	In progress
 IV&V recommends DDD and CAMHD develop a common and consistent approach across divisions for regression testing. 	Completed
 Determine if current regression testing timeframes are adequate and if not, add more time to the pre- production regression test efforts for all release deployments. 	Completed



Test Practice Validation (cont'd)

Recommendations	Status
Updating the regression test scripts to ensure consistency with system configuration.	Completed
Modifying release schedules to allow for regression testing timeframes.	Completed
 Planning releases by functionality type to avoid unnecessary repetitive work being performed in any given section of the solution. 	Completed
 Performing regression testing after every release, or possibly every other release, or potentially tying regression tests to FSU releases. In addition, consider alternating the DDD and CAMHD scripts every other release. 	Completed
 Modifying regression test scripts to start AFTER case creation, limiting the time it takes to execute. (This recommendation was for a point in time and is no longer valid.) 	Completed
Implementing 'hard' code freeze dates as well as test environment deployment dates to ensure that testing and deployment activities are not rushed.	Completed
Modifying the deployment scripts based on information gained from previous release deployments.	Completed

Test Practice Validation (cont'd)

Recommendations	Status
Consulting with RSM to determine how the 'interim testing processes' can be improved until such time that automated testing is available for repeatable and complete industry standard regression testing.	Completed
 IV&V recommends performing an RCA in collaboration with RSM for the continued concerns with regression testing efforts. 	Completed



Release / Deployment Planning

#	Key Findings	Criticality Rating
18	Medium Issue - Due to ongoing deployment processes and technical execution issues, the Project may continue to encounter defects and challenges in meeting projected timelines for production and non-production deployments. The formal RCA for R3.22 determined that root causes of the associated defects included deployment errors. Recommendations for improvement in this area included an increased level of smoke testing in subsequent releases. BHA learned that Microsoft's latest direction is to deprecate patch-only releases and move to full solution upgrades for each release. The timing of this guidance is still to be determined. The release of R3.23 was delayed a week due to unexpected issues identified during Deployment Planning. It is currently anticipated to be promoted to production on 5/5/2022. IV&V notes that based on current resource constraints, the project has determined that R3.24 will not be deployed as a solution upgrade. IV&V will continue to monitor this medium criticality issue.	M
Rec	ommendations	Status
re	 Ensure there are adequate and qualified resources to support the current deployment processes. This may require the support from RSM resources to provide assistance and knowledge transfer for some of the more complex deployment components. 	
• A	As appropriate, consult with RSM on best practices that BHA could employ to support deployment.	

Release / Deployment Planning (cont'd)

Recommendations	Status
 Request the assistance of the RSM Solution Architect in reviewing and correcting issues associated with consistency of the configurations across environments, ensuring that the test environment is capable of testing ALL functions of any given release without the need for using multiple test environments. 	In Progress
 Request the assistance of the RSM Solution Architect in review of deployment scripts as a double check for accuracy and completeness prior to commencing deployment activities. 	In Progress
The Project Team should consider evaluating potential changes to improve/enhance existing processes and communications to address current release/deployment shortfalls.	In Progress
 IV&V recommends performing an RCA in collaboration with RSM for the continued concerns surrounding environment differences. 	In Progress
 IV&V recommends updating the Project's Configuration Management Plan to address the current needs of the Project. This should include specific checklists geared at ensuring repeatable promotional processes by DOH. 	In Progress
 Look at implementing 'hard' code freeze dates as well as test environment deployment dates to ensure that testing and deployment activities are not rushed. 	Completed
Ensure an operational and fully functional test environment is available to effectively conduct end-to-end regression testing prior to deploying a release to production.	Completed
 Work in collaboration with RSM to establish a transition plan for DOH to assume all deployment activities to ensure complete ownership of these processes. This should assist with consistency in approach and execution going forward. 	Completed



Release / Deployment Planning (cont'd)

Recommendations	Status
 Develop a plan to institutionalize the execution of "Smoke Testing" for promotions to non-production environments. This will help to ensure that all components needed to test have be deployed prior to the actual execution of test activities. 	
• Due to an error prone process of 'cherry picking' what is and what is not ready for deployment recommends that DOH and RSM collaborate to determine an improved manner for managing environments. (As a result of how the current development environment is being managed, 'components to deploy will continue to occur. This recommendation is closed.)	DOH



Project Management

#	Key Findings	Criticality Rating
14	Medium Issue - Due to multiple quality concerns, the Project may continue to face impactful system defects. The formal RCA for R3.22 determined that root causes of the associated defects were tied to requirements, coding, testing, and deployment errors. Recommendations for testing improvements included data validation for bulk updates, joint testing for edge cases ,and an increased level of smoke testing. IV&V will continue to monitor the quality of work for this medium criticality issue.	M

Recommendations	Status
Evaluate existing project staff skills and experience level to ensure they meet BHA support requirements.	Open
Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected.	In Progress
Assign dedicated resources to provide oversight of CAMHD Fiscal Processes.	In Progress
Monitor implemented improvements for effectiveness.	In Progress

Recommendations		
 IV&V recommends performing an RCA in collaboration with RSM after all future release deployments for continual quality improvement. 	Completed	
BHA and RSM to collaborate on the necessary revisions to the submitted design deliverables to increase level of detail and quality.	Completed	
 Perform typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. 	Completed	
 Dedicate sufficient time in between releases for BHA and RSM to execute/implement RCA correction actions to reduce the volume of unplanned rework. 	Completed	

#	Key Findings	Criticality Rating
12	Medium Issue – PII/PHI data in non-production environments. There were no substantive changes to this finding identified during April. A Security Assessment is still planned for the second quarter of 2022, which will likely require BHA to act on this finding in May or June 2022. IV&V continues to note that some of the automated regression tools being evaluated include data masking capabilities which will help to mitigate this issue. If the chosen tool does not include this capability, BHA plans to work with RSM for potential solutions. IV&V will continue to monitor this medium criticality issue.	M

Recommendations	Status
 IV&V recommends DOH consider limiting the volume of environments with PII/PHI data and access necessary to support development work, which should help minimize this risk. 	Open
• IV&V recommends if production data is necessary in any non-production environment that DOH establishes a plan for effectively managing the security of the PII/PHI data, including the potential masking of data.	In Progress
 IV&V recommends that DOH mitigates this finding by minimizing and/or masking PHI/PII data in designated non-production environments. 	In Progress



#	Key Findings	Criticality Rating
21	Low Issue – Unplanned rework may have an impact on delivering DDI functionality by the end of the DDI period. The planned R3.23 release was pushed out to early May 2022. As such, there are no available defect percentages for the April reporting period. IV&V will continue to monitor this low criticality finding.	•

Recommendations	Status
Reduce the amount of unplanned rework by continuing to focus on quality improvement measures.	In Progress
Strive for defect performance metric not to exceed 20% of all user story points in any given release.	In Progress



#	Key Findings	
	High Issue - The project schedules for 'big boulder' functionality development are slipping. The Project Roadmap for completion of high priority (big boulder) features continued to be re-evaluated and redetermined during April. Based on the latest roadmap information, implementation of key features are likely to extend beyond the DDI period. The Project's updated Draft Feature Roadmap currently includes the following:	
	R3.23 (4/28/2022) - Golden Record Project, DDD Provider Portal, Rollout, CAMHD Customer Portal MVP, Automated Testing, Dashboards and Reports, Critical DDD Power BI Reports, and Integration of the DDD Provider Portal.	
22	R3.24 (6/9/2022) - Golden Record Project, CAMHD Customer Portal MVP, Transition Billing Processes, MQD Eligibility Interface, IMHE Power App, Automated Testing, ePrescribe, Independent Security Assessment, Dashboards and reports, Critical DDD Power BI Reports, and Integration of the CAMHD Provider Portal.	(
	R3.25 (7/21/2022) - Transition Billing Processes, Automated Testing, ePrescribe, CAMHD Provider APIs, CAFAS Interface, Independent Security Assessment, Dashboards and Reports, Critical DDD Power BI Reports, and Integration of the Customer Portal.	
	R3.26 (9/1/2022) - Customer Portal V2 Release, ePrescribe, CAMHD Provider APIs, CAFAS Interface, Federal FHIR Compliance, Advanced Analytics Project, Updates to System Artifacts in preparation for Security Assessment, and Integration of the Customer Portal.	
	R3.27 (10/13/2022) - Customer Portal V2 Release, ePrescribe ,Federal FHIR Compliance, Advanced Analytics Project, and Dashboards and Reports.	



#	Key Findings	Criticality Rating
	R3.28 (12/01/2022) - Conversion of RSMs Instance of ADO, Advanced Analytics Project, Dashboards and Reports.	
	M&O 1 - HHIE ADT Interface, Conversion of RSMs Instance of ADO, Advanced Analytics Project.	
	M&O 2 - HHIE ADT Interface, and Conversion of RSMs Instance of ADO.	
	IV&V will continue to monitor changes to this high criticality issue.	

Recommendations	Status
 Extend the current DDI timeframe to allow for the completion of 'big boulder' interfaces functionality development. 	In Progress
BHA to add more resources to support the development of "big boulder' interfaces functionality.	Open

Project Performance Metrics

Metric	Description	IV&V Observations	IV&V Updates
Velocity	 Review and validate the velocity data as reported by the project Verify the project is on pace to hit the total target number of US/USP for Phase 3 	April – There were no production releases in April to report velocity performance metrics.	N/A



Project Performance Metrics (cont'd.)

Metric	Description	IV&V Observations	IV&V Updates
Defect Metrics	 Understand and track the following: Defects by category (bug fixes) US Points assigned to defects in a release vs US Points assigned to planned US in a release 	April – There were no production releases in April to report defect performance metrics.	N/A

Appendix A: IV&V Rating Scales

Appendix AIV&V Rating Scales

This appendix provides the details of each finding and recommendation identified by IV&V. Project stakeholders are encouraged to review the findings and recommendations log details as needed.


- See Findings and Recommendations Log (provided under separate cover)
- IV&V Assessment Category Rating Definitions

The assessment category is under control and the current scope can be delivered within the current schedule.

The assessment category's risks and issues have been identified, and mitigation activities are effective. The overall impact of risk and issues is minimal.

The assessment category is proceeding according to plan (< 30 days late).

The assessment category is under control but also actively addressing resource, schedule or scope challenges that have arisen. There is a clear plan to get back on track.



Schedule issues are emerging (> 30 days but < 60 days late).

Project Leadership attention is required to ensure the assessment category is under control.

The assessment category is not under control as there are serious problems with resources, schedule, or scope. A plan to get back on track is needed.

The assessment category's risks and issues pose significant challenges and require immediate mitigation and/or escalation. The project's ability to complete critical tasks and/or meet the project's objectives is compromised and is preventing the project from progressing forward.

Significant schedule issues exist (> 60 days late). Milestone and task completion dates will need to be re-planned.

Executive management and/or project sponsorship attention is required to bring the assessment category under control.



Appendix A

Finding Criticality Ratings

Criticality Rating	Definition
•	A high rating is assigned if there is a possibility of substantial impact to product quality, scope, cost, or schedule. A major disruption is likely, and the consequences would be unacceptable. A different approach is required. Mitigation strategies should be evaluated and acted upon immediately.
M	A medium rating is assigned if there is a possibility of moderate impact to product quality, scope, cost, or schedule. Some disruption is likely, and a different approach may be required. Mitigation strategies should be implemented as soon as feasible.
•	A low rating is assigned if there is a possibility of slight impact to product quality, scope, cost, or schedule. Minimal disruption is likely, and some oversight is most likely needed to ensure that the risk remains low. Mitigation strategies should be considered for implementation when possible.



Appendix B

Inputs

This appendix identifies the artifacts and activities that serve as the basis for the IV&V observations.

Meetings attended during the April 2022 reporting period:

- 1. Daily Scrum Meetings (selected)
- 2. Twice Weekly RSM Issues Meeting
- Weekly BHA-ITS Project Status Meeting
- 4. Bi-Weekly Check-in: CAMHD
- 5. Bi-Weekly Check-in: DDD
- 6. BHA IAPDU Planning Meeting
- IV&V Draft IV&V Status Review Meeting with DOH
- IV&V Draft IV&V Status Review Meeting with RSM and DOH
- 9. Attended various Automation Tool demonstrations.

Eclipse IV&V® Base Standards and Checklists

Artifacts reviewed during the April 2022 reporting period:

- Daily Scrum Notes (selected)
- 2. Twice Weekly Issues Meeting Notes (selected)





Appendix C: Project Trends

Organizational Maturity Assessment

Measure IV&V Observations

On April 4, 2022, PCG conducted an Organizational Maturity Assessment with the BHA Team. A summary of the assessment and our recommendations are documented below:

April 2022 Organizational Maturity Assessment Summary

Assessment Area	Apr 2022 Level	Target Level	Assessment	Recommendations		
Morale	3	3	CAMHD/DDD maintained a target level of 3 for this assessment period. From an overall BHA perspective though, the assessment level is a 2.	BHA organization need to work more cohesively to improve morale. BHA to look at establishing project governance to help define decision-making procedures and metrics for validating impacts to the project.		
Sustainable Pace	able Pace 2 3		Assessment level same as Oct 2021. Resource shortage issues continue to hamper the pace of work. There is still a dependency on the SI for supplementing project resources.	Work is sustainable but impacted by ongoing staff shortfalls. BHA to define specific action items to move from level 2 to 3.		
Cross Functional (Scrum Team)	al (Scrum 2 3		Assessment level slightly improved from last assessment.	BHA to identify gap skillsets and develop resource staff roadmap per PCG recommendation which will help to achieve target level. Rating impacted by resource shortage(s) as well as gaps in system knowledge and experience (i.e., Calculator).		



Organizational Maturity Assessment

Measure IV&V Observations

On April 4, 2022, PCG conducted an Organizational Maturity Assessment with the BHA Team. A summary of the assessment and our recommendations are documented below:

April 2022 Organizational Maturity Assessment Summary

Assessment Area	Apr 2022 Level	Target Level	Assessment	Recommendations
Self Organization	3	3	Target Level of 3 maintained for this assessment period.	Cross training improvements are still needed. There are upcoming meetings to address this need.
Shippability	3	4	The assessment level of 3 for this period is the same from the last assessment but short of the target level.	Establish action item to measure Shippability to assist with achieving the target level for this assessment area. BHA to address ongoing resource needs and the delays working with third-party vendors.
Product Management Strategy	3	3	Target Level of 3 maintained for this assessment period.	Determine action items for achieving ideal level 4 for continued maturity.
Team Level Product Management	3	3	Target Level of 3 maintained for this assessment period.	Determine action items for achieving ideal level 4 for continued maturity.
Cycle time of Backlog 2 3		Assessment Level of 2 is the same from the previous assessment period.	BHA to fully identify roadblocks beyond resource constraints in order to improve in this area and to achieve/exceed target Level of 3.	



Organizational Maturity Assessment - cont'd

April 2022 Organizational Maturity Assessment Summary								
Assessment Area	Apr 2022 Level	Target Level	Assessment	Recommendations				
Use Of INVEST (Independent, Negotiable, Valuable, Estimable, Small, and Testable)	3	4	Assessment Level of 3 is the same from the previous assessment period.	BHA to determine how to get to target level of 4. Apply INVEST to all user stories to achieve Target Level.				
Backlog Grooming	4	3	Assessment level of 4 exceeds target level.	Per BHA, there are always user stories ready to be worked on but not enough resources to work on them. BHA to address resource shortage.				
Vertical Slicing	3	3	Target Level of 3 achieved for this assessment period. Project strategically incorporates vertical slicing methodology into discovery sessions.	Determine action items for achieving ideal level 4 for continued maturity.				
Work In Progress	2	3	The assessment level for this period is 2 which is lower than the previous assessment. Resource shortages continue to impact ongoing DDI work.	BHA to address resource shortage.				
Reviews	3	4	The assessment level for this period is a 3 which is short of the target level. Resource shortages continue to impact expected reviews.	BHA to address resource shortage.				



Organizational Maturity Assessment - cont'd

April 2022 Organizational Maturity Assessment Summary							
Assessment Area	Apr 2022 Level	Target Level	Assessment	Recommendations			
Unit Testing (software)	2.625	3	Assessment level short of target level and lower than the previous assessment. Unit testing process improvements have been made but the project continues to struggle with quality issues.	Continue to enforce established unit testing standards and procedures.			

Appendix C Project Trends

Trend: Overall Project Health										
Process Area	2021/2022									
Process Area	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr
User Story Validation										
Test Practice Validation										
Sprint Planning										
Release / Deployment Planning										
OJT and KT Sessions										
Targeted KT										
Project Performance Metrics										
Organizational Maturity Metrics										
General Project Management										
Total Open Findings	10	8	8	9	8	8	8	7	7	7
Issue - high	4	2	1	2	1	1	1	1	1	1
Issue - medium	2	3	4	4	4	4	4	4	4	4
Issue - low	1	0	0	3	3	3	3	2	2	2
Risk - high	0	0	0	0	0	0	0	0	0	0
Risk - medium	0	0	0	0	0	0	0	0	0	0
Risk - low	0	0	0	0	0	0	0	0	0	0
Preliminary Concern	3	3	3	0	0	0	0	0	0	0





Solutions that Matter

ID	Date Identified	Finding	Finding Statement	Supporting Analysis	PCG Recommendation	Finding Update	Process Area	Finding Type	Priority	Status	Risk Owner	Closure Reason
1	12/31/2019	9 Detailed investigation into the	IV&V is currently investigating the	While having a high level roadmap is	As much as possible, the project	01/31/2020 - IV&V is closing this concern, and	Sprint Planning	Preliminary	N/A	Closed	Ramesh, Vijaya	Due to multiple new
		project's sprint planning processes	following topics as they relate to	good, the project should be able to	should identify what feature	will be tracking items related to Definition of		Concern			(PCG)	items being tracked
		and adoption of generally	Sprint Planning and the project's	identify what feature enhancements	enhancements will be targeted for	Done, roadmap, resourcing, and backlog						at a more granular
		accepted agile best practices.	overall approach to agile software	will be targeted for each planned	each Release and should clearly	grooming in new, separate findings.						level, this item has
			development: - IV&V acknowledges	release. This roadmap will help the	map out the roadmap out through							been closed.
			that the project is now planning three	project manage scope and	the last Phase 3 release in							
			sprints outs, however, it appears that	productivity. Relatedly, the	September 2020.Additionally, the							
			only a "high-level" sprint planning	"definition done" is an important	project should clearly define							
			roadmap has been produced, and it is	artifact to ensure that the project is	"Done" to ensure the project team							
			unclear exactly how the project is	successful. Otherwise, the project will								
			targeting features for each release	struggle to prioritize	and increase opportunities for							
			through the end of Mod 4 IV&V is	requests/enhancements and manage								
			not aware of how the project is	scope.	of done" will help provide the							
			currently defining "done" for Mod 3		project with guidance on how to							
			and Mod 4Additionally, in the January		stay within scope.							
			2020 reporting period, IV&V will seek		,							
			additional information and visibility									
			into the project's processes specific to	,								
			prioritizing requests and how user									
			stories in TFS are tagged to features,									
			as well as the realignment of project									
			development and configuration									
			resources to complete the scope of									
			Release 3.5.									
1 2	12/31/2019	As a result of regression testing	R3.3 introduced a defect that	Thorough vetting and validation of	Pursuing additional formal training	04/30/2022 - The formal RCA for R3.22	Test Practice Validation	Issue	Medium	Open	Darren	
2	12/31/2019	9 As a result of regression testing not being consistently performed,	R3.3 introduced a defect that deprecated features in production	Thorough vetting and validation of regression test cases is necessary to		04/30/2022 - The formal RCA for R3.22 identified root causes of the associated	Test Practice Validation	Issue	Medium	Open	Darren Macdonald	
2	12/31/2019	not being consistently performed,	deprecated features in production	regression test cases is necessary to	in AzureDevOps for test	identified root causes of the associated	Test Practice Validatio	Issue	Medium	Open		
2	12/31/2019	not being consistently performed, production releases are breaking	deprecated features in production specific to Integrated Support and Life	regression test cases is necessary to prevent both defects and the	in AzureDevOps for test automation at the earliest possible	identified root causes of the associated defects that were tied to requirements,	Test Practice Validatio	Issue	Medium	Open		
2	12/31/2019	not being consistently performed, production releases are breaking and/or deprecating existing	deprecated features in production specific to Integrated Support and Life Trajectory functionality. DDD has	regression test cases is necessary to prevent both defects and the deprecation of production	in AzureDevOps for test automation at the earliest possible juncture and commence efforts to	identified root causes of the associated defects that were tied to requirements, coding, testing, and deployment errors.	Test Practice Validation	Issue	Medium	Open		
2	12/31/2019	not being consistently performed, production releases are breaking	deprecated features in production specific to Integrated Support and Life Trajectory functionality. DDD has informed IV&V that there are other	regression test cases is necessary to prevent both defects and the	in AzureDevOps for test automation at the earliest possible juncture and commence efforts to	identified root causes of the associated defects that were tied to requirements,	Test Practice Validatio	Issue	Medium	Open		
2	12/31/2019	not being consistently performed, production releases are breaking and/or deprecating existing functionality in the production	deprecated features in production specific to Integrated Support and Life Trajectory functionality. DDD has informed IV&V that there are other examples of functionality being	regression test cases is necessary to prevent both defects and the deprecation of production functionality when a release is pushed live. When defects occur in	in AzureDevOps for test automation at the earliest possible juncture and commence efforts to automate at least the 2 primary	identified root causes of the associated defects that were tied to requirements, coding, testing, and deployment errors. Recommendations for testing improvements included data validation for bulk updates,	Test Practice Validation	Issue	Medium	Open		
2	12/31/2019	not being consistently performed, production releases are breaking and/or deprecating existing functionality in the production	deprecated features in production specific to Integrated Support and Life Trajectory functionality. DDD has informed IV&V that there are other	regression test cases is necessary to prevent both defects and the deprecation of production functionality when a release is pushed	in AzureDevOps for test automation at the earliest possible juncture and commence efforts to automate at least the 2 primary regression test scripts.	identified root causes of the associated defects that were tied to requirements, coding, testing, and deployment errors. Recommendations for testing improvements	Test Practice Validatio	Issue	Medium	Open		
2	12/31/2019	not being consistently performed, production releases are breaking and/or deprecating existing functionality in the production	deprecated features in production specific to Integrated Support and Life Trajectory functionality. DDD has informed IV&V that there are other examples of functionality being deprecated after a release, some of	regression test cases is necessary to prevent both defects and the deprecation of production functionality when a release is pushed live. When defects occur in production, the project should follow a defined and repeatable process for	in AzureDevOps for test automation at the earliest possible juncture and commence efforts to automate at least the 2 primary regression test scripts. IV&V recommends DDD and	identified root causes of the associated defects that were tied to requirements, coding, testing, and deployment errors. Recommendations for testing improvements included data validation for bulk updates, joint testing for edge cases, and an increased	Test Practice Validatio	Issue	Medium	Open		
2	12/31/2019	not being consistently performed, production releases are breaking and/or deprecating existing functionality in the production	deprecated features in production specific to Integrated Support and Life Trajectory functionality. DDD has informed IV&V that there are other examples of functionality being deprecated after a release, some of which are still being investigated. As of this report, IV&V has not evaluated	regression test cases is necessary to prevent both defects and the deprecation of production functionality when a release is pushed live. When defects occur in production, the project should follow a defined and repeatable process for determining the root cause of the	in AzureDevOps for test automation at the earliest possible juncture and commence efforts to automate at least the 2 primary regression test scripts. IV&V recommends DDD and CAMHD to develop a common and consistent approach across	identified root causes of the associated defects that were tied to requirements, coding, testing, and deployment errors. Recommendations for testing improvements included data validation for bulk updates, joint testing for edge cases, and an increased level of smoke testing. BHA continued formal planning for the	Test Practice Validatio	Issue	Medium	Open		
2	12/31/2019	not being consistently performed, production releases are breaking and/or deprecating existing functionality in the production	deprecated features in production specific to Integrated Support and Life Trajectory functionality. DDD has informed IV&V that there are other examples of functionality being deprecated after a release, some of which are still being investigated. As of this report, IV&V has not evaluated the project's root cause analysis (RCA)	regression test cases is necessary to prevent both defects and the deprecation of production functionality when a release is pushed live. When defects occur in production, the project should follow a defined and repeatable process for determining the root cause of the	in AzureDevOps for test automation at the earliest possible juncture and commence efforts to automate at least the 2 primary regression test scripts. IV&V recommends DDD and CAMHD to develop a common and consistent approach across divisions for performing regression	identified root causes of the associated defects that were tied to requirements, coding, testing, and deployment errors. Recommendations for testing improvements included data validation for bulk updates, joint testing for edge cases, and an increased level of smoke testing. BHA continued formal planning for the implementation of automated regression	Test Practice Validatio	Issue	Medium	Open		
2	12/31/2019	not being consistently performed, production releases are breaking and/or deprecating existing functionality in the production	deprecated features in production specific to Integrated Support and Life Trajectory functionality. DDD has informed IV&V that there are other examples of functionality being deprecated after a release, some of which are still being investigated. As of this report, IV&V has not evaluated the project's root cause analysis (RCA) process used to determine why such	regression test cases is necessary to prevent both defects and the deprecation of production functionality when a release is pushed live. When defects occur in production, the project should follow a defined and repeatable process for determining the root cause of the	in AzureDevOps for test automation at the earliest possible juncture and commence efforts to automate at least the 2 primary regression test scripts. IV&V recommends DDD and CAMHD to develop a common and consistent approach across divisions for performing regression testing.	identified root causes of the associated defects that were tied to requirements, coding, testing, and deployment errors. Recommendations for testing improvements included data validation for bulk updates, joint testing for edge cases, and an increased level of smoke testing. BHA continued formal planning for the implementation of automated regression testing and attended multiple product	Test Practice Validatio	Issue	Medium	Open		
2	12/31/2019	not being consistently performed, production releases are breaking and/or deprecating existing functionality in the production	deprecated features in production specific to Integrated Support and Life Trajectory functionality. DDD has informed IV&V that there are other examples of functionality being deprecated after a release, some of which are still being investigated. As of this report, IV&V has not evaluated the project's root cause analysis (RCA) process used to determine why such functionality was deprecated but will	regression test cases is necessary to prevent both defects and the deprecation of production functionality when a release is pushed live. When defects occur in production, the project should follow a defined and repeatable process for determining the root cause of the	in AzureDevOps for test automation at the earliest possible juncture and commence efforts to automate at least the 2 primary regression test scripts. IV&V recommends DDD and CAMHD to develop a common and consistent approach across divisions for performing regression testing. Determine if current regression	identified root causes of the associated defects that were tied to requirements, coding, testing, and deployment errors. Recommendations for testing improvements included data validation for bulk updates, joint testing for edge cases, and an increased level of smoke testing. BHA continued formal planning for the implementation of automated regression testing and attended multiple product demonstrations during April. Tool selection is	Test Practice Validatio	Issue	Medium	Open		
2	12/31/2019	not being consistently performed, production releases are breaking and/or deprecating existing functionality in the production	deprecated features in production specific to Integrated Support and Life Trajectory functionality. DDD has informed IV&V that there are other examples of functionality being deprecated after a release, some of which are still being investigated. As of this report, IV&V has not evaluated the project's root cause analysis (RCA) process used to determine why such	regression test cases is necessary to prevent both defects and the deprecation of production functionality when a release is pushed live. When defects occur in production, the project should follow a defined and repeatable process for determining the root cause of the	in AzureDevOps for test automation at the earliest possible juncture and commence efforts to automate at least the 2 primary regression test scripts. IV&V recommends DDD and CAMHD to develop a common and consistent approach across divisions for performing regression testing.	identified root causes of the associated defects that were tied to requirements, coding, testing, and deployment errors. Recommendations for testing improvements included data validation for bulk updates, joint testing for edge cases, and an increased level of smoke testing. BHA continued formal planning for the implementation of automated regression testing and attended multiple product	Test Practice Validatio	Issue	Medium	Open		
2	12/31/2019	not being consistently performed, production releases are breaking and/or deprecating existing functionality in the production	deprecated features in production specific to Integrated Support and Life Trajectory functionality. DDD has informed IV&V that there are other examples of functionality being deprecated after a release, some of which are still being investigated. As of this report, IV&V has not evaluated the project's root cause analysis (RCA) process used to determine why such functionality was deprecated but will discuss further with BHA in January	regression test cases is necessary to prevent both defects and the deprecation of production functionality when a release is pushed live. When defects occur in production, the project should follow a defined and repeatable process for determining the root cause of the	in AzureDevOps for test automation at the earliest possible juncture and commence efforts to automate at least the 2 primary regression test scripts. IV&V recommends DDD and CAMHD to develop a common and consistent approach across divisions for performing regression testing. Determine if current regression testing timeframes are adequate	identified root causes of the associated defects that were tied to requirements, coding, testing, and deployment errors. Recommendations for testing improvements included data validation for bulk updates, joint testing for edge cases, and an increased level of smoke testing. BHA continued formal planning for the implementation of automated regression testing and attended multiple product demonstrations during April. Tool selection is currently planned for May and the regression	Test Practice Validatio	Issue	Medium	Open		
2	12/31/2019	not being consistently performed, production releases are breaking and/or deprecating existing functionality in the production	deprecated features in production specific to Integrated Support and Life Trajectory functionality. DDD has informed IV&V that there are other examples of functionality being deprecated after a release, some of which are still being investigated. As of this report, IV&V has not evaluated the project's root cause analysis (RCA) process used to determine why such functionality was deprecated but will discuss further with BHA in January	regression test cases is necessary to prevent both defects and the deprecation of production functionality when a release is pushed live. When defects occur in production, the project should follow a defined and repeatable process for determining the root cause of the	in AzureDevOps for test automation at the earliest possible juncture and commence efforts to automate at least the 2 primary regression test scripts. IV&V recommends DDD and CAMHD to develop a common and consistent approach across divisions for performing regression testing. Determine if current regression testing timeframes are adequate and if not, add more time to the	identified root causes of the associated defects that were tied to requirements, coding, testing, and deployment errors. Recommendations for testing improvements included data validation for bulk updates, joint testing for edge cases, and an increased level of smoke testing. BHA continued formal planning for the implementation of automated regression testing and attended multiple product demonstrations during April. Tool selection is currently planned for May and the regression test automation effort duration is still anticipated to be approximately 2-3 months	Test Practice Validatio	Issue	Medium	Open		
2	12/31/2019	not being consistently performed, production releases are breaking and/or deprecating existing functionality in the production	deprecated features in production specific to Integrated Support and Life Trajectory functionality. DDD has informed IV&V that there are other examples of functionality being deprecated after a release, some of which are still being investigated. As of this report, IV&V has not evaluated the project's root cause analysis (RCA) process used to determine why such functionality was deprecated but will discuss further with BHA in January	regression test cases is necessary to prevent both defects and the deprecation of production functionality when a release is pushed live. When defects occur in production, the project should follow a defined and repeatable process for determining the root cause of the	in AzureDevOps for test automation at the earliest possible juncture and commence efforts to automate at least the 2 primary regression test scripts. IV&V recommends DDD and CAMHD to develop a common and consistent approach across divisions for performing regression testing. Determine if current regression testing timeframes are adequate and if not, add more time to the pre-production regression test	identified root causes of the associated defects that were tied to requirements, coding, testing, and deployment errors. Recommendations for testing improvements included data validation for bulk updates, joint testing for edge cases, and an increased level of smoke testing. BHA continued formal planning for the implementation of automated regression testing and attended multiple product demonstrations during April. Tool selection is currently planned for May and the regression test automation effort duration is still anticipated to be approximately 2-3 months	Test Practice Validatio	Issue	Medium	Open		
2	12/31/2019	not being consistently performed, production releases are breaking and/or deprecating existing functionality in the production	deprecated features in production specific to Integrated Support and Life Trajectory functionality. DDD has informed IV&V that there are other examples of functionality being deprecated after a release, some of which are still being investigated. As of this report, IV&V has not evaluated the project's root cause analysis (RCA) process used to determine why such functionality was deprecated but will discuss further with BHA in January	regression test cases is necessary to prevent both defects and the deprecation of production functionality when a release is pushed live. When defects occur in production, the project should follow a defined and repeatable process for determining the root cause of the	in AzureDevOps for test automation at the earliest possible juncture and commence efforts to automate at least the 2 primary regression test scripts. IV&V recommends DDD and CAMHD to develop a common and consistent approach across divisions for performing regression testing. Determine if current regression testing timeframes are adequate and if not, add more time to the pre-production regression test efforts for all release deployments	identified root causes of the associated defects that were tied to requirements, coding, testing, and deployment errors. Recommendations for testing improvements included data validation for bulk updates, joint testing for edge cases, and an increased level of smoke testing. BHA continued formal planning for the implementation of automated regression testing and attended multiple product demonstrations during April. Tool selection is currently planned for May and the regression test automation effort duration is still anticipated to be approximately 2-3 months for the initial setup. IV&V will continue to	Test Practice Validatio	Issue	Medium	Open		
2	12/31/2019	not being consistently performed, production releases are breaking and/or deprecating existing functionality in the production	deprecated features in production specific to Integrated Support and Life Trajectory functionality. DDD has informed IV&V that there are other examples of functionality being deprecated after a release, some of which are still being investigated. As of this report, IV&V has not evaluated the project's root cause analysis (RCA) process used to determine why such functionality was deprecated but will discuss further with BHA in January	regression test cases is necessary to prevent both defects and the deprecation of production functionality when a release is pushed live. When defects occur in production, the project should follow a defined and repeatable process for determining the root cause of the	in AzureDevOps for test automation at the earliest possible juncture and commence efforts to automate at least the 2 primary regression test scripts. IV&V recommends DDD and CAMHD to develop a common and consistent approach across divisions for performing regression testing. Determine if current regression testing timeframes are adequate and if not, add more time to the pre-production regression test efforts for all release deployments Updating the regression test	identified root causes of the associated defects that were tied to requirements, coding, testing, and deployment errors. Recommendations for testing improvements included data validation for bulk updates, joint testing for edge cases, and an increased level of smoke testing. BHA continued formal planning for the implementation of automated regression testing and attended multiple product demonstrations during April. Tool selection is currently planned for May and the regression test automation effort duration is still anticipated to be approximately 2-3 months for the initial setup. IV&V will continue to monitor this medium criticality issue.	Test Practice Validatio	Issue	Medium	Open		
2	12/31/2019	not being consistently performed, production releases are breaking and/or deprecating existing functionality in the production	deprecated features in production specific to Integrated Support and Life Trajectory functionality. DDD has informed IV&V that there are other examples of functionality being deprecated after a release, some of which are still being investigated. As of this report, IV&V has not evaluated the project's root cause analysis (RCA) process used to determine why such functionality was deprecated but will discuss further with BHA in January	regression test cases is necessary to prevent both defects and the deprecation of production functionality when a release is pushed live. When defects occur in production, the project should follow a defined and repeatable process for determining the root cause of the	in AzureDevOps for test automation at the earliest possible juncture and commence efforts to automate at least the 2 primary regression test scripts. IV&V recommends DDD and CAMHD to develop a common and consistent approach across divisions for performing regression testing. Determine if current regression testing timeframes are adequate and if not, add more time to the pre-production regression test efforts for all release deployments Updating the regression test scripts to ensure consistency with	identified root causes of the associated defects that were tied to requirements, coding, testing, and deployment errors. Recommendations for testing improvements included data validation for bulk updates, joint testing for edge cases, and an increased level of smoke testing. BHA continued formal planning for the implementation of automated regression testing and attended multiple product demonstrations during April. Tool selection is currently planned for May and the regression test automation effort duration is still anticipated to be approximately 2-3 months for the initial setup. IV&V will continue to monitor this medium criticality issue. 03/31/2022 - R3.22 was promoted to	Test Practice Validation	Issue	Medium	Open		
2	12/31/2019	not being consistently performed, production releases are breaking and/or deprecating existing functionality in the production	deprecated features in production specific to Integrated Support and Life Trajectory functionality. DDD has informed IV&V that there are other examples of functionality being deprecated after a release, some of which are still being investigated. As of this report, IV&V has not evaluated the project's root cause analysis (RCA) process used to determine why such functionality was deprecated but will discuss further with BHA in January	regression test cases is necessary to prevent both defects and the deprecation of production functionality when a release is pushed live. When defects occur in production, the project should follow a defined and repeatable process for determining the root cause of the	in AzureDevOps for test automation at the earliest possible juncture and commence efforts to automate at least the 2 primary regression test scripts. IV&V recommends DDD and CAMHD to develop a common and consistent approach across divisions for performing regression testing. Determine if current regression testing timeframes are adequate and if not, add more time to the pre-production regression test efforts for all release deployments Updating the regression test scripts to ensure consistency with system configuration.	identified root causes of the associated defects that were tied to requirements, coding, testing, and deployment errors. Recommendations for testing improvements included data validation for bulk updates, joint testing for edge cases, and an increased level of smoke testing. BHA continued formal planning for the implementation of automated regression testing and attended multiple product demonstrations during April. Tool selection is currently planned for May and the regression test automation effort duration is still anticipated to be approximately 2-3 months for the initial setup. IV&V will continue to monitor this medium criticality issue. 03/31/2022 - R3.22 was promoted to production on 3/17/2022. There were five (5)		Issue	Medium	Open		
2	12/31/2019	not being consistently performed, production releases are breaking and/or deprecating existing functionality in the production	deprecated features in production specific to Integrated Support and Life Trajectory functionality. DDD has informed IV&V that there are other examples of functionality being deprecated after a release, some of which are still being investigated. As of this report, IV&V has not evaluated the project's root cause analysis (RCA) process used to determine why such functionality was deprecated but will discuss further with BHA in January	regression test cases is necessary to prevent both defects and the deprecation of production functionality when a release is pushed live. When defects occur in production, the project should follow a defined and repeatable process for determining the root cause of the	in AzureDevOps for test automation at the earliest possible juncture and commence efforts to automate at least the 2 primary regression test scripts. IV&V recommends DDD and CAMHD to develop a common and consistent approach across divisions for performing regression testing. Determine if current regression testing timeframes are adequate and if not, add more time to the pre-production regression test efforts for all release deployments Updating the regression test scripts to ensure consistency with system configuration. Modifying release schedules to	identified root causes of the associated defects that were tied to requirements, coding, testing, and deployment errors. Recommendations for testing improvements included data validation for bulk updates, joint testing for edge cases, and an increased level of smoke testing. BHA continued formal planning for the implementation of automated regression testing and attended multiple product demonstrations during April. Tool selection is currently planned for May and the regression test automation effort duration is still anticipated to be approximately 2-3 months for the initial setup. IV&V will continue to monitor this medium criticality issue. 03/31/2022 - R3.22 was promoted to production on 3/17/2022. There were five (5) defects resulting from this deployment. Two		Issue	Medium	Open		
2	12/31/2019	not being consistently performed, production releases are breaking and/or deprecating existing functionality in the production	deprecated features in production specific to Integrated Support and Life Trajectory functionality. DDD has informed IV&V that there are other examples of functionality being deprecated after a release, some of which are still being investigated. As of this report, IV&V has not evaluated the project's root cause analysis (RCA) process used to determine why such functionality was deprecated but will discuss further with BHA in January	regression test cases is necessary to prevent both defects and the deprecation of production functionality when a release is pushed live. When defects occur in production, the project should follow a defined and repeatable process for determining the root cause of the	in AzureDevOps for test automation at the earliest possible juncture and commence efforts to automate at least the 2 primary regression test scripts. IV&V recommends DDD and CAMHD to develop a common and consistent approach across divisions for performing regression testing. Determine if current regression testing timeframes are adequate and if not, add more time to the pre-production regression test efforts for all release deployments Updating the regression test scripts to ensure consistency with system configuration. Modifying release schedules to allow for regression testing	identified root causes of the associated defects that were tied to requirements, coding, testing, and deployment errors. Recommendations for testing improvements included data validation for bulk updates, joint testing for edge cases, and an increased level of smoke testing. BHA continued formal planning for the implementation of automated regression testing and attended multiple product demonstrations during April. Tool selection is currently planned for May and the regression test automation effort duration is still anticipated to be approximately 2-3 months for the initial setup. IV&V will continue to monitor this medium criticality issue. 03/31/2022 - R3.22 was promoted to production on 3/17/2022. There were five (5) defects resulting from this deployment. Two were critical, one was high, and remaining two		Issue	Medium	Open		
2	12/31/2019	not being consistently performed, production releases are breaking and/or deprecating existing functionality in the production	deprecated features in production specific to Integrated Support and Life Trajectory functionality. DDD has informed IV&V that there are other examples of functionality being deprecated after a release, some of which are still being investigated. As of this report, IV&V has not evaluated the project's root cause analysis (RCA) process used to determine why such functionality was deprecated but will discuss further with BHA in January	regression test cases is necessary to prevent both defects and the deprecation of production functionality when a release is pushed live. When defects occur in production, the project should follow a defined and repeatable process for determining the root cause of the	in AzureDevOps for test automation at the earliest possible juncture and commence efforts to automate at least the 2 primary regression test scripts. IV&V recommends DDD and CAMHD to develop a common and consistent approach across divisions for performing regression testing. Determine if current regression testing timeframes are adequate and if not, add more time to the pre-production regression test efforts for all release deployments Updating the regression test scripts to ensure consistency with system configuration. Modifying release schedules to allow for regression testing timeframes	identified root causes of the associated defects that were tied to requirements, coding, testing, and deployment errors. Recommendations for testing improvements included data validation for bulk updates, joint testing for edge cases, and an increased level of smoke testing. BHA continued formal planning for the implementation of automated regression testing and attended multiple product demonstrations during April. Tool selection is currently planned for May and the regression test automation effort duration is still anticipated to be approximately 2-3 months for the initial setup. IV&V will continue to monitor this medium criticality issue. 03/31/2022 - R3.22 was promoted to production on 3/17/2022. There were five (5) defects resulting from this deployment. Two were critical, one was high, and remaining two were medium defects. A Mid Sprint		Issue	Medium	Open		
2	12/31/2019	not being consistently performed, production releases are breaking and/or deprecating existing functionality in the production	deprecated features in production specific to Integrated Support and Life Trajectory functionality. DDD has informed IV&V that there are other examples of functionality being deprecated after a release, some of which are still being investigated. As of this report, IV&V has not evaluated the project's root cause analysis (RCA) process used to determine why such functionality was deprecated but will discuss further with BHA in January	regression test cases is necessary to prevent both defects and the deprecation of production functionality when a release is pushed live. When defects occur in production, the project should follow a defined and repeatable process for determining the root cause of the	in AzureDevOps for test automation at the earliest possible juncture and commence efforts to automate at least the 2 primary regression test scripts. IV&V recommends DDD and CAMHD to develop a common and consistent approach across divisions for performing regression testing. Determine if current regression testing timeframes are adequate and if not, add more time to the pre-production regression test efforts for all release deployments Updating the regression test scripts to ensure consistency with system configuration. Modifying release schedules to allow for regression testing timeframes Planning releases by functionality type to avoid unnecessary	identified root causes of the associated defects that were tied to requirements, coding, testing, and deployment errors. Recommendations for testing improvements included data validation for bulk updates, joint testing for edge cases, and an increased level of smoke testing. BHA continued formal planning for the implementation of automated regression testing and attended multiple product demonstrations during April. Tool selection is currently planned for May and the regression test automation effort duration is still anticipated to be approximately 2-3 months for the initial setup. IV&V will continue to monitor this medium criticality issue. 03/31/2022 - R3.22 was promoted to production on 3/17/2022. There were five (5) defects resulting from this deployment. Two were critical, one was high, and remaining two were medium defects. A Mid Sprint Deployment was deployed on 3/31/2022 to		Issue	Medium	Open		
2	12/31/2019	not being consistently performed, production releases are breaking and/or deprecating existing functionality in the production	deprecated features in production specific to Integrated Support and Life Trajectory functionality. DDD has informed IV&V that there are other examples of functionality being deprecated after a release, some of which are still being investigated. As of this report, IV&V has not evaluated the project's root cause analysis (RCA) process used to determine why such functionality was deprecated but will discuss further with BHA in January	regression test cases is necessary to prevent both defects and the deprecation of production functionality when a release is pushed live. When defects occur in production, the project should follow a defined and repeatable process for determining the root cause of the	in AzureDevOps for test automation at the earliest possible juncture and commence efforts to automate at least the 2 primary regression test scripts. IV&V recommends DDD and CAMHD to develop a common and consistent approach across divisions for performing regression testing. Determine if current regression testing timeframes are adequate and if not, add more time to the pre-production regression test efforts for all release deployments Updating the regression test scripts to ensure consistency with system configuration. Modifying release schedules to allow for regression testing timeframes Planning releases by functionality type to avoid unnecessary	identified root causes of the associated defects that were tied to requirements, coding, testing, and deployment errors. Recommendations for testing improvements included data validation for bulk updates, joint testing for edge cases, and an increased level of smoke testing. BHA continued formal planning for the implementation of automated regression testing and attended multiple product demonstrations during April. Tool selection is currently planned for May and the regression test automation effort duration is still anticipated to be approximately 2-3 months for the initial setup. IV&V will continue to monitor this medium criticality issue. 03/31/2022 - R3.22 was promoted to production on 3/17/2022. There were five (5) defects resulting from this deployment. Two were medium defects. A Mid Sprint Deployment was deployed on 3/31/2022 to fix the critical and high defects and replace a		Issue	Medium	Open		
	12/31/2019	not being consistently performed, production releases are breaking and/or deprecating existing functionality in the production	deprecated features in production specific to Integrated Support and Life Trajectory functionality. DDD has informed IV&V that there are other examples of functionality being deprecated after a release, some of which are still being investigated. As of this report, IV&V has not evaluated the project's root cause analysis (RCA) process used to determine why such functionality was deprecated but will discuss further with BHA in January	regression test cases is necessary to prevent both defects and the deprecation of production functionality when a release is pushed live. When defects occur in production, the project should follow a defined and repeatable process for determining the root cause of the	in AzureDevOps for test automation at the earliest possible juncture and commence efforts to automate at least the 2 primary regression test scripts. IV&V recommends DDD and CAMHD to develop a common and consistent approach across divisions for performing regression testing. Determine if current regression testing timeframes are adequate and if not, add more time to the pre-production regression test efforts for all release deployments Updating the regression test scripts to ensure consistency with system configuration. Modifying release schedules to allow for regression testing timeframes Planning releases by functionality type to avoid unnecessary repetitive work being performed ir any given section of the solution.	identified root causes of the associated defects that were tied to requirements, coding, testing, and deployment errors. Recommendations for testing improvements included data validation for bulk updates, joint testing for edge cases, and an increased level of smoke testing. BHA continued formal planning for the implementation of automated regression testing and attended multiple product demonstrations during April. Tool selection is currently planned for May and the regression test automation effort duration is still anticipated to be approximately 2-3 months for the initial setup. IV&V will continue to monitor this medium criticality issue. 03/31/2022 - R3.22 was promoted to production on 3/17/2022. There were five (5) defects resulting from this deployment. Two were critical, one was high, and remaining two were medium defects. A Mid Sprint Deployment was deployed on 3/31/2022 to fix the critical and high defects and replace a deprecated Dataverse connector. An initial		Issue	Medium	Open		

3	12/31/2019 Usage of open source	JavaScript IV&V learned in December 202	9 that Open source tools and frameworks	IV&V recommends BHA work to	08/31/2020 - IV&V is unaware of any	Targeted KT	Risk	Low	Closed	Darren	RSM has
	framework for develo	· ·	· ·	establish a reliable and repeatable	additional KT gaps being identified by DOH,	raigetea iti	T. Control of the Con	2011	Ciosca	Macdonald	successfully held
	ongoing maintenance		5 5	process for keeping abreast of	and as such, is closing this finding.07/31/2020						several KT sessions
	Calculator 3.0 require	the state of the s		communal updates and support	- The Project resolved the majority of the						for this technology
	take a proactive appr			opportunities for a new suite of	outstanding Calculator 3.0 defects during July						and functionality,
	support and security.	support community is small. IN			which was implemented in the mid-sprint						and DOH staff have
		concerns include: - The availab		The state of the s	release on 7/17/2020. The final Calculator 3.0						stated that it was
		reliable support for Vue.JS - T	ne with support models, other than	targeted KT sessions with RSM on	Knowledge Transfer session was conducted						well received.
		project's understanding of any	known those offered through the tool's	maintaining Calculator 3.0 via a	on 7/17/2020. IV&V recommends BHA to						
		vulnerabilities with Vue.JS, and	community. Because of this, the	suite of tools, and determine wha	identify and communicate any additional KT						
		development of a process to re	emain organization bears the weight of	additional skillsets, training,	gaps to RSM during the month of August. If no						
		current on vulnerabilities disco	vered seeking out reliable help and support	t, and/or resources are needed to	additional needs are identified, IV&V will close						
		by the support community 1	he RSM as well as much take a proactive	support BHA's long-term	this finding. 06/30/2020 - The project						
		lead for Calculator 3.0 went or	approach to security and identifying	ownership of Calculator 3.0 -	continued to focus attention on the Calculator						
		extended parental leave in De	cember any vulnerabilities in the tools.	Completed	3.0 defects during the month of June. RSM						
		2019IV&V acknowledges that	BHA has		conducted another Calculator 3.0 Knowledge						
		downloaded Vue.JS to start ge	tting		Transfer session on 6/26/2020 and scheduled						
		familiar with it.			a final session for 7/17/2020. 05/31/2020 -						
					The project continued to focus attention on						
					the Calculator 3.0 user stories and defects						
					during the month of May. RSM conducted						
					another Calculator 3.0 Knowledge Transfer						
					session on 5/29/2020 which IV&V attended.						
					This session included the new C3.0 year-end						
					changes. Additional KT sessions is planned for						
					and IV&V will continue to monitor this project						
					component during June. 04/30/2020 - The						
4	1/31/2020 Due to the project no	t following a There have been several defec	ts A complete, up to date, and	IVV recommends documenting	12/31/2020 - IV&V has closed this issue as the	Release/Denloyment	Iccup	Medium	Closed	Darren	Key finding has
		= -				itelease/ Deployment	13300	iviculum	Closed		
	detailed deployment	script, the pushed to production with Pha	sse 3 documented deployment script is	deployment scripts for both the	related recommendations below has been	neicase, beployment	13300	iviedidiii	Ciosea	Macdonald	been addressed and
	detailed deployment project may continue	script, the pushed to production with Phato releases. Some of the defects	documented deployment script is needed to ensure the repeatability	deployment scripts for both the patch method and the full solution	related recommendations below has been completed. A subsequent medium issue	ncicase/ Deployment	113346	Wediam	Closeu		been addressed and proposed IV&V
	detailed deployment project may continue experience defects re	script, the pushed to production with Pha to releases. Some of the defects lated to introduced to production have	documented deployment script is needed to ensure the repeatability been and stability of DOH's production	deployment scripts for both the patch method and the full solution upgrade method. The script(s)	related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address	ncicase, beployment	issue	Wediam	cioseu		been addressed and proposed IV&V recommendations
	detailed deployment project may continue	to pushed to production with Pha- releases. Some of the defects lated to introduced to production have narrowed down to environme	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by	related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical	necess, sepioyment	13300	Weddin	Closed		been addressed and proposed IV&V recommendations have been
	detailed deployment project may continue experience defects re	to pushed to production with Phare to releases. Some of the defects introduced to production have narrowed down to environme promotional activities. In these	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by step procedure that walks through	related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10	nelease, beployment	13300	Weddin	ciosed		been addressed and proposed IV&V recommendations have been completed. A
	detailed deployment project may continue experience defects re	to pushed to production with Phare to releases. Some of the defects introduced to production have narrowed down to environme promotional activities. In these instances, the DEV and TEST	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades),	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by step procedure that walks through from start to finish of the	related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020.	nciesse, Deployment	issuc	Weddin	ciosed		been addressed and proposed IV&V recommendations have been completed. A subsequent finding
	detailed deployment project may continue experience defects re	script, the to pushed to production with Phar releases. Some of the defects introduced to production have narrowed down to environme promotional activities. In these instances, the DEV and TEST environments were not in sync	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by step procedure that walks through from start to finish of the deployment process and involve	related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were	necess, Deployment	15300	Wedulii	Closed		been addressed and proposed IV&V recommendations have been completed. A subsequent finding #19 has been
	detailed deployment project may continue experience defects re	script, the to pushed to production with Phar releases. Some of the defects introduced to production have narrowed down to environme promotional activities. In these instances, the DEV and TEST environments were not in synthe production environment (in the production environment).	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), twith missing	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by stop procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure	related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes	necess, Deployment	15300	Wedulii	Closed		been addressed and proposed IV&V recommendations have been completed. A subsequent finding #19 has been created to address
	detailed deployment project may continue experience defects re	to pushed to production with Phare to releases. Some of the defects introduced to production have narrowed down to environme promotional activities. In these instances, the DEV and TEST environments were not in synthe production environment (in business rules, missing compo	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), twith missing entrs, cript will help ensure that mistakes	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish	related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of	necess, Deployment	13300	Weddin	Closed		been addressed and proposed IV&V recommendations have been completed. A subsequent finding #19 has been created to address on-going
	detailed deployment project may continue experience defects re	to releases. Some of the defects introduced to production have narrowed down to environme promotional activities. In these instances, the DEV and TEST environments were not in synthe production environment (in business rules, missing compomissing dependencies, etc.). IN	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary	related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business	needsey Deployment	13300	Meduli	Closed		been addressed and proposed IV&V recommendations have been completed. A subsequent finding #19 has been created to address on-going deployment
	detailed deployment project may continue experience defects re	to releases. Some of the defects introduced to production have narrowed down to environme promotional activities. In these instances, the DEV and TEST environments were not in synthe production environment (in business rules, missing compomissing dependencies, etc.). IN aware that DOH staff shadowe	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality d RSM is not mistakenly deprecated when	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are	related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues.	necess, Deployment	13300	Wedun	Closed		been addressed and proposed IV&V recommendations have been completed. A subsequent finding #19 has been created to address on-going deployment processes and
	detailed deployment project may continue experience defects re	to releases. Some of the defects introduced to production have narrowed down to environme promotional activities. In these instances, the DEV and TEST environments were not in sync the production environment (I business rules, missing compo missing dependencies, etc.). I aware that DOH staff shadowe staff for all deployment release	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take place.	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the	related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of	necess, Deployment	13300	Wedun	Closed		been addressed and proposed IV&V recommendations have been completed. A subsequent finding #19 has been created to address on-going deployment processes and technical execution
	detailed deployment project may continue experience defects re	script, the to releases. Some of the defects lated to introduced to production have narrowed down to environme promotional activities. In these instances, the DEV and TEST environments were not in sync the production environment (in business rules, missing compo missing dependencies, etc.). IN aware that DOH staff shadowe staff for all deployment release during Phase 2 with RSM provi	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take place.	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer	related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the	necess, Deployment	13300	Wedun	Closed		been addressed and proposed IV&V recommendations have been completed. A subsequent finding #19 has been created to address on-going deployment processes and
	detailed deployment project may continue experience defects re	script, the to releases. Some of the defects lated to introduced to production have narrowed down to environme promotional activities. In these instances, the DEV and TEST environments were not in sync the production environment (I business rules, missing compo missing dependencies, etc.). IN aware that DOH staff shadowe staff for all deployment release during Phase 2 with RSM provinstruction and DOH staff phys	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take place.	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by should be in the form of a step-by from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal and the start of all developer deployment task notes, with a goal start of the start of all developer deployment task notes, with a goal start of the start of	related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the I deployment, resulting in contacts being	necess, Deployment	13300	Meduli	Closed		been addressed and proposed IV&V recommendations have been completed. A subsequent finding #19 has been created to address on-going deployment processes and technical execution
	detailed deployment project may continue experience defects re	script, the to releases. Some of the defects lated to introduced to production have narrowed down to environme promotional activities. In these instances, the DEV and TEST environments were not in synthe production environment (in business rules, missing compomissing dependencies, etc.). I aware that DOH staff shadows staff for all deployment releaseduring Phase 2 with RSM provinstruction and DOH staff physexecuting the tasks and activit	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take place.	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goo of eliminating any potential	related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the I deployment, resulting in contacts being deprecated from the Circle of Support in	necess, Deployment	13300	Weduli	Closed		been addressed and proposed IV&V recommendations have been completed. A subsequent finding #19 has been created to address on-going deployment processes and technical execution
	detailed deployment project may continue experience defects re	script, the to releases. Some of the defects introduced to production have narrowed down to environme promotional activities. In these instances, the DEV and TEST environments were not in synthe production environment (Inbusiness rules, missing compomissing dependencies, etc.). IN aware that DOH staff shadowe staff for all deployment releas during Phase 2 with RSM provinstruction and DOH staff physexecuting the tasks and activitively bear of the staff or Phase 3, it is un	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take place.	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goo of eliminating any potential ambiguity to the Deployment	related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the I deployment, resulting in contacts being deprecated from the Circle of Support in Inspire. It is unclear if any other deployment	necess, pepioyment	13300	Meduli	Closed		been addressed and proposed IV&V recommendations have been completed. A subsequent finding #19 has been created to address on-going deployment processes and technical execution
	detailed deployment project may continue experience defects re	script, the to releases. Some of the defects releases. Some of the defects introduced to production have narrowed down to environme promotional activities. In these instances, the DEV and TEST environments were not in synt the production environment (Inbusiness rules, missing compormissing dependencies, etc.). In aware that DOH staff shadowe staff for all deployment released uring Phase 2 with RSM provinstruction and DOH staff physexecuting the tasks and activities whether a complete, up to dat	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take place.	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goof eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and	related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the I deployment, resulting in contacts being deprecated from the Circle of Support in Inspire. It is unclear if any other deployment issues may have also contributed to the new	necess, Deployment	13300	WCGUIII	Closed		been addressed and proposed IV&V recommendations have been completed. A subsequent finding #19 has been created to address on-going deployment processes and technical execution
	detailed deployment project may continue experience defects re	script, the to releases. Some of the defects introduced to production have narrowed down to environme promotional activities. In these instances, the DEV and TEST environments were not in synthe production environment (Inbusiness rules, missing compomissing dependencies, etc.). IN aware that DOH staff shadowe staff for all deployment releas during Phase 2 with RSM provinstruction and DOH staff physexecuting the tasks and activitively bear of the staff or Phase 3, it is un	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take place. ding ically less via clear e, and t, or	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goo of eliminating any potential ambiguity to the Deployment	related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the I deployment, resulting in contacts being deprecated from the Circle of Support in Inspire. It is unclear if any other deployment	necess, Deployment	13300	Wedun	Closed		been addressed and proposed IV&V recommendations have been completed. A subsequent finding #19 has been created to address on-going deployment processes and technical execution
	detailed deployment project may continue experience defects re	script, the to releases. Some of the defects releases. Some of the defects introduced to production have narrowed down to environme promotional activities. In these instances, the DEV and TEST environments were not in synthe production environment (in business rules, missing compormissing dependencies, etc.). In aware that DOH staff shadowe staff for all deployment release during Phase 2 with RSM provinstruction and DOH staff physe executing the tasks and activities keyboard. For Phase 3, it is un whether a complete, up to dat documented deployment scription.	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take place.	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a good eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of	related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the I deployment, resulting in contacts being deprecated from the Circle of Support in Inspire. It is unclear if any other deployment issues may have also contributed to the new defects. Deployment corrections were applied	necess, Deployment	13300	Weduli	Closed		been addressed and proposed IV&V recommendations have been completed. A subsequent finding #19 has been created to address on-going deployment processes and technical execution
	detailed deployment project may continue experience defects re	script, the to releases. Some of the defects introduced to production have narrowed down to environme promotional activities. In these instances, the DEV and TEST environments were not in sync the production environment (in business rules, missing compo missing dependencies, etc.). In aware that DOH staff shadowe staff for all deployment release during Phase 2 with RSM provinstruction and DOH staff physe executing the tasks and activit keyboard. For Phase 3, it is un whether a complete, up to dat documented deployment script deployment notes, are being to the defects of	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take place.	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goo of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of deployment processes and	related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the I deployment, resulting in contacts being deprecated from the Circle of Support in Inspire. It is unclear if any other deployment issues may have also contributed to the new defects. Deployment corrections were applied in a mid sprint release on 11/27/2020. Based	necess, Deployment	13300	Weduli	Closed		been addressed and proposed IV&V recommendations have been completed. A subsequent finding #19 has been created to address on-going deployment processes and technical execution
	detailed deployment project may continue experience defects re	script, the to releases. Some of the defects introduced to production have narrowed down to environme promotional activities. In these instances, the DEV and TEST environments were not in sync the production environment (in business rules, missing compo missing dependencies, etc.). In aware that DOH staff shadowe staff for all deployment release during Phase 2 with RSM provinstruction and DOH staff physe executing the tasks and activit keyboard. For Phase 3, it is un whether a complete, up to dat documented deployment script deployment notes, are being to the defects of	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take place.	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goo of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of deployment processes and	related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the deployment, resulting in contacts being deprecated from the Circle of Support in Inspire. It is unclear if any other deployment issues may have also contributed to the new defects. Deployment corrections were applied in a mid sprint release on 11/27/2020. Based on the recurrence of this finding, IV&V has	necess, pepidyment	13300	Weduli	Closed		been addressed and proposed IV&V recommendations have been completed. A subsequent finding #19 has been created to address on-going deployment processes and technical execution
	detailed deployment project may continue experience defects re	script, the to releases. Some of the defects introduced to production have narrowed down to environme promotional activities. In these instances, the DEV and TEST environments were not in sync the production environment (in business rules, missing compo missing dependencies, etc.). In aware that DOH staff shadowe staff for all deployment release during Phase 2 with RSM provinstruction and DOH staff physe executing the tasks and activit keyboard. For Phase 3, it is un whether a complete, up to dat documented deployment script deployment notes, are being to the defects of	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take place.	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goo of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of deployment processes and	related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the deployment, resulting in contacts being deprecated from the Circle of Support in Inspire. It is unclear if any other deployment issues may have also contributed to the new defects. Deployment corrections were applied in a mid sprint release on 11/27/2020. Based on the recurrence of this finding, IV&V has changed this Risk to an Issue and will continue	necess, pepidyment	13300	Weduli	Closed		been addressed and proposed IV&V recommendations have been completed. A subsequent finding #19 has been created to address on-going deployment processes and technical execution
	detailed deployment project may continue experience defects re	script, the to releases. Some of the defects introduced to production have narrowed down to environme promotional activities. In these instances, the DEV and TEST environments were not in sync the production environment (in business rules, missing compo missing dependencies, etc.). In aware that DOH staff shadowe staff for all deployment release during Phase 2 with RSM provinstruction and DOH staff physe executing the tasks and activit keyboard. For Phase 3, it is un whether a complete, up to dat documented deployment script deployment notes, are being to the defects of	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take place.	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goo of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of deployment processes and	related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the I deployment, resulting in contacts being deprecated from the Circle of Support in Inspire. It is unclear if any other deployment issues may have also contributed to the new defects. Deployment corrections were applied in a mid sprint release on 11/27/2020. Based on the recurrence of this finding, IV&V has changed this Risk to an Issue and will continue to monitor until resolved. 10/31/2020 - The	necess, pepidyment	13300	Weduli	Closed		been addressed and proposed IV&V recommendations have been completed. A subsequent finding #19 has been created to address on-going deployment processes and technical execution
	detailed deployment project may continue experience defects re	script, the to releases. Some of the defects introduced to production have narrowed down to environme promotional activities. In these instances, the DEV and TEST environments were not in sync the production environment (in business rules, missing compo missing dependencies, etc.). In aware that DOH staff shadowe staff for all deployment release during Phase 2 with RSM provinstruction and DOH staff physe executing the tasks and activit keyboard. For Phase 3, it is un whether a complete, up to dat documented deployment script deployment notes, are being to the defects of	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take place.	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goo of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of deployment processes and	related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the I deployment, resulting in contacts being deprecated from the Circle of Support in Inspire. It is unclear if any other deployment issues may have also contributed to the new defects. Deployment corrections were applied in a mid sprint release on 11/27/2020. Based on the recurrence of this finding, IV&V has changed this Risk to an Issue and will continue to monitor until resolved. 10/31/2020 - The RSM and DOH Teams have collaborated to	necess, Deployment	13300		Closed		been addressed and proposed IV&V recommendations have been completed. A subsequent finding #19 has been created to address on-going deployment processes and technical execution
	detailed deployment project may continue experience defects re	script, the to releases. Some of the defects introduced to production have narrowed down to environme promotional activities. In these instances, the DEV and TEST environments were not in sync the production environment (in business rules, missing compo missing dependencies, etc.). In aware that DOH staff shadowe staff for all deployment release during Phase 2 with RSM provinstruction and DOH staff physe executing the tasks and activit keyboard. For Phase 3, it is un whether a complete, up to dat documented deployment script deployment notes, are being to the defects of	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take place.	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goo of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of deployment processes and	related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the I deployment, resulting in contacts being deprecated from the Circle of Support in Inspire. It is unclear if any other deployment issues may have also contributed to the new defects. Deployment corrections were applied in a mid sprint release on 11/27/2020. Based on the recurrence of this finding, IV&V has changed this Risk to an Issue and will continue to monitor until resolved. 10/31/2020 - The RSM and DOH Teams have collaborated to develop a detailed Production Deployment	necess, pepidyment	13300		Closed		been addressed and proposed IV&V recommendations have been completed. A subsequent finding #19 has been created to address on-going deployment processes and technical execution

5			BHA does not have a documented 'Definition of Done' (DOD) for the BHA Top 100 User Stories of for Phase 3. Because of this, it is unclear how proposed functionality/features are prioritized for each sprint, and throughout Phase 3.	The 'Definition of Done" document guides the Project's vision, business, and technical goals that are important inputs for stakeholders to develop a Roadmap for Phase 3. Without the 'Definition of Done' document, the project is likely to struggle to prioritize proposed functionality/features which may be equally important but are at odds with each other.	IV&V recommends that the project create this document and socialize this with project team before end	02/29/2020 - The project created and documented the Phase 3 Definition of Done t and socialized it in February. IV&V recommends the project continually review and update the Definition of Done, adjusting tas/if necessary. IV&V will continue to monitor the project's adherence to Definition of Done and progress against it but is closing out this concern as of the February report.	Project Management	Preliminary Concern	N/A	Closed	Ramesh, Vijaya (PCG)	Definition of Done completed and socialized.
6	1/31/2020	The lack of consistent backlog grooming could result in the project backlog having obsolete, non-estimated, and poorly defined user stories.	The backlog of defects, requests, and user stories continues to grow. Currently, there are approximately 429 defects and requests, of which almost 200 have a status of 'New'. IVV notes that a large percentage of the backlogged work items do not have user story points estimated. Many of the items listed in the backlog are old, and some may have had needs or requirements change over time or may now be obsolete. IV&V notes that DDD and CAMHD have initiated this effort and agreed to prioritize grooming the backlog by the end of February.	A comprehensive, up-to-date backlog is a primary tenet of agile software development. If a backlog is carrying work items that may not ever be completed for any reason, they should be removed from the backlog to ensure its viability.	IVV recommends that CAMHD and DDD groom the backlog to bring it as current and accurate as possible. This should include deprecating items no longer needed, and fully defining those items that are not yet fully defined, readying them for configuration or developer resources. To the extent feasible, BHA should involve RSM SMEs in this process, if only for the interim to get "caught up" on grooming efforts. (Closed)VV recommends that the project consider utilizing an age-based methodology for the deprecation of 'older' user stories in the backlog that may no longer be applicable or needed by the Product Owners and developing a process for periodic cleansing of the backlog using the same methodology. (Closed)	that release planning efforts are not delayed. 04/30/2020 - The project reported that 97% of the original backlog has been	Project Management	Risk	Low	Closed	Darren Macdonald	The project has demonstrated they are consistently grooming the backlog.

7 1/31/202	0 The BHA Technical Team	The BHA Technical Team plays a role	The BHA Technical Team leads the	BHA needs, and should pursue,	04/30/2022 - The BHA Solution Architect	Sprint Planning	Issue	High	Open	Darren	
	bandwidth may not be adequate	that is critical to project success.	efforts of all technical DOH staff on	additional Knowledge Transfer	returned from leave in early April, providing					Macdonald	
	to meet the needs of the project,	Currently, the responsibilities	the project. As such, the Team's time	sessions on the updated Calculator	some relief in this area. A key BHA						
	which could compromise project	associated with the BHA Technical	is both extremely valuable and scarce.	3.0 solution	deployment team member will be						
	productivity.	Team have expanded beyond their	If the Team's expected workload	The Project should investigate	approximately 50% allocated to a significant						
		collective available bandwidth. IV&V	exceeds bandwidth, the project could	mechanisms of increasing the	CAMHD/MedQuest rate change initiative						
		notes that BHA began addressing this	experience bottlenecks. Optimization	bandwidth of the BHA Technical	starting in June. DDD is still awaiting approval						
		bandwidth issue, which includes	of the BHA Technical Team's time is to	Team, either by adding resources	authority to post its open IT position and the						
		increased collaboration with key RSM	the benefit of the project and plays a	through new hires, or vendor	responsibilities for this position are currently						
		resources, and are working to	critical role in the project's ability to	contracts.	being covered by existing DDD team						
		potentially change the structure of the	hit performance targets and achieve	The Project should assess, where	members.						
		Technical Team.	the Phase 3 definition of done.	possible, if there are	The re-assignment of a DDD technical						
				responsibilities of the BHA	resource supporting deployments continues						
				Technical Team that can be	to put the current deployment support efforts						
				reassigned to other project staff.	at risk. R3.24 will not be deployed as a full						
				The Project should evaluate where	solution upgrade due to resource constraints,						
				process inefficiencies can be	altering plans to perform FSUs every other						
				addressed and streamlined to	release. Due to increasing resource						
				possibly free up the BHA Technical	constraints, the project has reduced						
				Team's availability.	approximately 30% of the planned						
				The Project should consider the	configuration and development velocity over						
				formation of a first level resource	the next 3 releases, directly affecting the						
				team to triage/address production							
				defects in a timely manner,	in the latest roadmap. IV&V will continue to						
				without disrupting new	monitor the potential impacts of the resource						
				development work.	issues on the project for this high criticality						
				The Project should consider	issue.						
8 1/31/202	0 The lack of a Product Roadmap	BHA does not have a single, definitive	A Roadmap is a tool that guides an	IV&V understands that the Project		Project Management	Preliminary	N/A	Closed	Ramesh, Vijaya	Product Roadmap
	that provides direction on the top	Product Roadmap for Phase 3 that	agile project on what	is in the process of creating a Short	defined the Phase 3 Product Roadmap and		Concern			(PCG)	aligned with
	product features to be delivered in	addresses the functionalities,	functionalities/features are targeted	Term; Mid Term, and Long Term	aligned it with the Phase 3 Definition of Done.						Definition of Done
	the near term (next 3 months),	features, and / or enhancements to be	to be built and released and when	Roadmap. IV&V recommends the	IV&V recommends the project continually						
	, ,	built in order to fully address BHA's	users can have access to these	Project complete this by the end of	review and update both the Product Roadmap						
	'	business needs. IV&V met with RSM	functionalities. Without a defined	February 2020 to understand if	and Definition of Done, adjusting as						
	Project's scope and schedule.	and BHA on this topic in January, and	Roadmap the project may not be able	1	necessary. IV&V will continue to monitor the						
		notes that the project is actively	to effectively scope the top features	(resources, budget) that may	project's adherence to the Product Roadmap						
		working to address this concern.	to be released within Phase 3 and	hinder the project from releasing	and progress against it but is closing out this						
			ensure the correct resources are	the needed	concern as of the February report.						
			available to accomplish the goal of	functionalities/features targeted							
			each sprint and the Phase.	for Phase 3 as documented in the							
				Definition of Done.							

	9	3/31/2020	The COVID-19 pandemic and the	On 3/23/2020, the Governor issued a	DOH stakeholder participation in key	- IV&V recommends BHA to ramp	04/30/2021 - The Project continues to	Project Management	Risk	Low	Closed	Darren	The Project
	-	0,00,000	related "stay at home" order could	"stay at home, work from home	activities could be significantly	up efforts to setup, train, and	maintain its ability to operate with staff					Macdonald	continues to
			*	order" that has reduced state	hindered, not only by required	assist stakeholders on remote	working remotely, effectively overcoming the						maintain its ability
				departments ability to be fully	remote work by DOH and SI staff, but		"stay at home, work from home order" that						to operate with
				functional as the large majority of	also by the flood of activities that	every effort to help them to	reduced BHA's ability to be fully functional in						staff working
			_	state workers will be required to work	•	become highly functional with	the office. The potential DDD and CAMHD						remotely,
				from home/remotely at least until the	· ·	~ /	budget challenges reported in March were						effectively
				end of April and some offices may be	providing services due to the resulting		also overcome during April, providing fiscal						overcoming the
				completely shut down until that time	economic impacts to citizens. Some		relief to BHA. As such, IV&V is closing this						"stay at home, work
				as well. Unclear if the order will	stakeholders may be unable (due to	DOH create a detailed,	finding.03/31/2021 - The Project continued to						from home order"
				extend beyond that date.	stricter shutdown policies) or	documented risk mitigation	maintain its ability to operate with staff						that reduced BHA's
				,	unwilling to perform these activities	strategy and plan that is reviewed	working remotely, while COVID-related						ability to be fully
					during this chaotic time. Planned SI	regularly and revised to address	responsibilities continue to grow for CAMHD						functional in the
					on-site visits will also likely be	the current state of the COVID-19	Leadership. The Governor announced that						office. The
					changed to remote which could	threat and related impacts over	potential furloughs and/or layoffs of State						potential DDD and
					reduce the effectiveness of their	the next 6 to 12 months - In	workers will no longer be necessary based on						CAMHD budget
					project activities. Going forward	Progress - IV&V recommends	the signing of the American Rescue Plan. IV&V						challenges reported
					most if not all project activities will	updates to the OCM Plan to	has reduced the priority of this finding from						in March were also
					more than likely be conducted	include any new activities or	Medium to Low and will continue to monitor						overcome during
					remotely until this crisis passes.	updates to planned activities to aid	moving forward. 02/28/2021 - As reported in						April, providing
						the organization through this	January, there were no substantive changes						fiscal relief to BHA.
						COVID-19 situation in the short	observed for this finding in February. The						
						and long term - Open	Project continued to maintain its ability to						
							operate with staff working remotely. IV&V						
							continues to note that there may be potential						
							future budget actions by the Governor due to						
							projected State budget shortfalls, including						
1	10	5/31/2020	The lack of design reviews for	There were a couple incidents during	If all requirements within a functional	IV&V recommends (and DOH has	07/31/2020 - The Project continues to to		Preliminary	N/A	Closed		This process change
			complex user stories has resulted	May where the code promoted to	design are not met, users could	commenced) conducting technical	spend additional time on the designs of		Concern				to spend extra time
			in the promotion of incomplete	production did not fully meet all	experience the inability to complete	design reviews for complex user	complex user stories during June to ensure						on the design of
			solutions into production.	requirements of associated user	required processes, resulting in	stories prior to development to	requirements and user story components						complex user
				stories for CAMHD Progress Notes.	incomplete data collection and	ensure designs are complete and	were fully captured in design sessions. This						stories to ensure
				The components that were developed	potential issues in service delivery.	all requirements associated with	process change has proven successful, and as						that all
				and implemented were functional,		the design are met. IV&V observed	such, IV&V recommends closing this						requirements are
				however the effort was complicated		this activity has been implemented	concern.06/30/2020 - IV&V acknowledges the						represented has
				by additional requirements being		by DOH in the month of May.	Project Team continued to spend additional						proven to be
				added during development that			time on the designs of complex user stories						successful.
				necessitated additional changes to the			during June to ensure requirements and user						
				design. IV&V will continue to monitor			story components were fully captured in						
				the design review activity for large			design sessions. IV&V will continue to						
				user stories moving forward			monitor in July.						

may have a continued negative effect on user adoption, training, and overall OCM activities. are hampered based on staffing and overall OCM activities. by the interms of system workflow, provide their insights and input, follow up, etc. To assist in OCM activities, DDD has defined the need for an interactive defined the need for an interactive training tool to support Inspire. by the interms of system workflow, and analytical efforts using the data and analytical efforts. IV&V recommends DOH perform a can never be understated. It is clearly a best practice that best that all staff us phere of influence to increase user adoption and training. This includes procurement of the online is a very helpful training tools for DDD staff and providers. As such, IV&V is closing this unitary includes using the data determined that the toolset training tool to support Inspire. are hampered based on staffing shortages. DDD has stated that its user is best practice that best that all staff sheer of influence to increase user adoption and training. This includes procurement of the online is a very helpful training toolset of free time determined that the toolset training toolset for in-person training, and adding from the videos produced within the toolset and have determined that the toolset training toolset for the ordinary includes procurement of the online is a very helpful training toolset story includes providers. As such, IV&V is closing this finding.02/28/2021 - Training videos using the new toolset were nearing completion by the end of February. DOH is currently reviewing the drafts of the second set of videos and helpful train toolset.	11	7/31/2020 DDD Project resource shortages	The user adoption and training efforts	The significance and impact of OCM	IV&V recommends that BHA does	03/31/2021 - The DDD staff who've been part	Project Management	Risk	N/A	Closed	Darren	The DDD staff
offer on sure dispetition, training and developed CVM arthrition. In the contract depetition, training and developed CVM arthrition. In the contract deptition of the contra						· ·	.,		,			who've been part of
willing the years in the full late according warring for years of pillon state of the colors as easy height stated good one pillon state of the colors and the resignation and page, following the transplant and page, following the colors and the resignation of the colors and the resignation of the colors and the resignation of the pillon state of the colors and the resignation of the pillon state of the colors and the resignation of the pillon state of the colors and the colors and the pillon state of the colors and the c			shortages. DDD has stated that its	a best practice that best that all staff	sphere of influence to increase	quality of the videos produced within the						the review process
In terms of system workflow, provide to the form of long, follows, to follow control for the control form of long in the long		and overall OCM activities.	users have been found to not be	utilize the solution in the same	user adoption and training. This	toolset and have determined that the toolset						are pleased with the
the maybe and mays, fallow appet. To assist no OMA schildre, DOM schildre, and schildre, and schildre, DOM schildr			utilizing the system to its fullest extent	manner. Variations in how the	includes procurement of the online	is a very helpful training tool for DDD staff and						quality of the videos
To asset in CLM activities, DID has defined first suring the data difference that he adoption and the contract of the contract			in terms of system workflow, provide	system is utilized by its users is likely	training toolsets to offset the need	providers. As such, IV&V is closing this						produced within the
officed the noted for a interactive primiting tool to apport Inspire. If the product of the pro			their insights and input, follow up, etc.	to cause variations in data collection	for in-person training, and adding	finding.02/28/2021 - Training videos using the						toolset, and have
rating tool to support inspire. It is a sup			To assist in OCM activities, DDD has	and analytical efforts using the data	staff as needed to support OCM	new toolset were nearing completion by the						determined that the
potable meeting and to provide standards on the specific variations as it is not but they system is currently being used by the but acr community. Consequently, users would be view and the but acr community. Consequently, users would be view and the but acr community. Consequently, users would be view and the but acr community of the but acr community. Consequently, users would be view and the but acr community of the control of the sufficient time to determine work products and suddiscisal reflective training to close information of the sufficient time to determine work products and suddiscisal reflective training to close information of the sufficient time to determine the support of the substance of the			defined the need for an interactive	collected.	and technical efforts. IV&V	end of February. DOH is currently reviewing						toolset is a very
people waitains as to how the system is currently with the user community. Consequently, user would be provided with contractive the system is currently as the provided with the system is controlled by the user community. Consequently, user would be provided with contractive the system is controlled by the user would be provided with contractive the system is controlled by the system is system is controlled by the system is system is system is system. The system is system. The system is system is system is system is system i			training tool to support Inspire.		recommends DOH perform a	the drafts of the second set of videos and						helpful training tool
pydem is currently being used by the user community. Consequently, users would be provided with custor community and the provided with custor community. Consequently, users would be provided with the community of the consequently and the consequently and the consequently of the consequently and the consequently and the consequently with the cons					detailed investigation of the	work is progressing well. IV&V will continue to						for DDD staff and
the user community. Consequently, users would be provided with constructive fleedback on the threat woolder laddersing user adoption and saffing shortages for three task fleedback on the vestioned has deficient part and possible and saffing shortages for three task fleedback on the vestioned state of the saffing shortages for three task fleedback on the vestioned state of the saffing shortages for three task elegists activities which the vestioned state of the saffing shortages for three task units the interactive training tools. And the providers and saffing shortages for three task elegists and visits and saffing shortages for three tasks only the interactive training tools. The saffing shortage state and special special state of the saffing shortages for the saffing shortages state and special speci												providers.
Consequently, users would be provided with various training to a starting sharings and starting sharing content start with the provided by subtractive feedback on how the system should be subtractive problems on starting sharing toolse! and the starting of the starting					, , ,							
production where yeters should be will lead where gaps exist. The silky lead to additional refresher training to oblight gaps. 12 8/31/7020 PV/PHI data in non production refresher to neet project needs. Generally this is not a good security practice as the presence of PI/PHI data is non-production environment. 18 PV/PHI data currently exist in a non-production environment on neet project needs. Generally this is not a good security practice as the presence of PI/PHI data is non-production environment on the production environment that Due environment					The state of the s							
The second of the comment of the c						_						
should be utilized where gaps exist. This will likely lead to additional refresher training to occurrenced in amount and has attained good progress. The use of this tool is expected to door incomenced in amount where the special provises one bandwidth relief for DDD staff members responsible for orboarding new staff members responsibl					T .							
12 2 3/31/2020 PII/PHI data in non-production environments 1/2 2 3/31/2020 PII/PHI data in non-production environments 1/2 2 3/31/2020 PII/PHI data in non-production environments 1/2 3/31/2020 PII/PHI data in non-production environments 1/2 3/31/2020 PII/PHI data in non-production environment to meet project eneeds. Generally this is non-production environment to meet project each ground security practice as the pressure of the organization open to highly and access necessary to support devices environments 1/2 3/31/2020 1/2 1												
additional refresher training to close identified system knowledge paps. 12 8/31/2000 PII/PHI data in non-production environments increasing the organization open to highly targeted social engineering states, increasing the organization open to highly targeted social engineering states, heavy regulatory fines, and loss of client trust and loyalty. 12 8/31/2000 PII/PHI data in non-production environment to more than the programation open to highly argeted social engineering states, and social engineering stat												
close identified system knowledge apps. Comparison of the properties of the prope					*							
members responsible for onboarding new staff members and provides, and to provide refresher training to osisting staff members. VizX will continue to monitor this findings/2/31/2002. The contract to procure the interactive training too osisting staff members. VizX will continue to monitor this findings/2/31/2002. The contract to procure the interactive training tools for onboarding the original staff members. VizX will continue to monitor this findings/2/31/2002. The contract to procure the interactive training tools for original staff members. VizX will continue to monitor this findings/2/31/2002. The contract to procure the interactive training tools of the original staff indings/2/31/2002. The contract to procure the interactive training tools of the original staff indings/3/31/2002. The contract to procure the interactive training tools of the original staff indings/3/31/2002. The contract to procure the interactive training tools of the original staff indings/3/31/2002. The contract to procure the interactive training tools of the original staff indings/3/31/2002. The contract to procure the interactive training tools of the original staff indings/3/31/2002. The contract to procure the interactive training tools of the original staff indings/3/31/2002. The contract to procure the interactive training tools of the original staff indings/3/31/2002. The contract to procure the interactive training tools of the original staff indings/3/31/2002. The contract to procure the interactive training tools of the original staff indings/3/31/2002. The contract to procure the interactive training tools of the original staff indings/3/31/2002. The contract to procure the indings to the finding indings of the staff indings/3/31/2002. The contract to procure the indings to the finding indings of the submitted for the staff indings/3/31/3002. The contract to procure the indings of the submitted indings and analysis to the finding indings of the submitted for the staff indings/3/31/3002. The contract to procure the indings o												
staff members and providers, and to provide refersher training to setting staff members. IV&V will continue to monitor this findings/2/31/2020 - The contract to production environments or monitor that project needs. Societally his is not production environments in one-production environments in one-production environments in creases the potential for theft, loss or exposure thus increasing the organization open to highly targeted social eleves the organization open to highly targeted social engineering stracks, heavy regulatory fines, and loss of client trust and loyalty. Selection of the composition open to highly targeted social engineering stracks, heavy regulatory fines, and loss of client trust and loyalty. Selection of the composition open to highly targeted social engineering stracks, heavy regulatory fines, and loss of client trust and loyalty. Selection of the composition open to highly targeted social engineering stracks, heavy regulatory fines, and loss of client trust and loyalty. Selection open to highly targeted social engineering stracks, heavy regulatory fines, and loss of client trust and loyalty. Selection open to highly targeted social engineering stracks, heavy regulatory fines, and loss of client trust and loyalty. Selection open to highly targeted social engineering stracks, heavy regulatory fines, and loss of client trust and loyalty. Selection open to highly targeted social engineering stracks, heavy regulatory fines, and loss of client trust and loyalty. Selection open to highly targeted social engineering stracks, heavy regulatory fines, and loss of client trust and loyalty. Selection open to highly targeted social engineering stracks, heavy regulatory fines, and loss of client trust and loyalty. Selection open to highly targeted social engineering stracks, heavy regulatory fines, and loss of client trust and loyalty. Selection open to highly defined unique developments with production of the automated regression tools being evaluated include data making explaints with the d					,	l'						
12 8/31/2020 PII/PHI data in non-production environments Vi&V has been made aware that PII/PHI data currently exist in a non-production environment to meet project needs. Generally this is not a good security practice as the project needs. Generally this is not a good security practice as the project needs. Generally this is not a good security practice as the project needs of PII/PHI data in non-production environments in creases the potential for theft, loss or exposure that increases the potential for theft, loss or exposure that increases the potential for theft, loss or exposure that the organization's risk. Failure to secure PII/PHI data leaves the erganization's risk. Failure to secure PII/PHI data leaves the erganization's risk. Failure to secure PII/PHI data leaves the erganization's risk. Failure to secure PII/PHI data leaves the erganization's risk. Failure to secure PII/PHI data leaves the erganization's risk. Failure to secure PII/PHI data leaves the erganization's risk. Failure to secure PII/PHI data leaves the erganization's risk. Failure to secure PII/PHI data leaves the erganization's risk. Failure to secure PII/PHI data leaves the erganization's risk. Failure to secure PII/PHI data leaves the erganization's risk. Failure to secure PII/PHI data leaves the erganization gene to highly targeted social engineering attacks, heavy regulatory fines, and loss of client trust and loyalty. Vi&V recommends DOH consider limiting the volume of environments to this finding identified during April. And accordant of the sequence of PII/PHI data leaves the organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client trust and loyalty. Vi&V recommends DOH consider limiting the volume of environments that DOH and the organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client trust and loyalty. Vi&V recommends DOH consider limiting the volume of environments that DOH and the organization open to highly targe					gaps.							
12 8/31/2020 PII/PHI data in non-production environments PII/PHI data currently exist in a non-production environment to meet project needs. Generally this in comparison open to highly arranged social engineering attacks, heavy regulatory fines, and loss of client trust and loyalty. Ballure to secure PII/PHI data leaves the organization's risk. Failure to secure PII/PHI data leaves the organization's risk. Failure to secure PII/PHI data leaves the organization's risk. Failure to secure PII/PHI data leaves the organization's risk. Failure to secure PII/PHI data leaves the organization's risk. Failure to secure PII/PHI data leaves the organization's risk. Failure to secure PII/PHI data leaves the organization's risk. Failure to secure PII/PHI data leaves the organization's risk. Failure to secure PII/PHI data leaves the organization's risk. Failure to secure PII/PHI data leaves the organization's risk. Failure to secure PII/PHI data leaves the organization's risk. Failure to secure PII/PHI data leaves the organization's risk. Failure to secure PII/PHI data leaves the organization's risk. Failure to secure PII/PHI data leaves the organization's risk. Failure to secure PII/PHI data leaves the organization's risk. Failure to secure PII/PHI data leaves the organization's risk. Failure to secure PII/PHI data leaves the organization's risk. Failure to secure PII/PHI data leaves the organization's risk. Failure to secure PII/PHI data leaves the organization's risk. Failure to secure PII/PHI data leaves the organization open to highly the representation open to highly that production detail the production data in designated on the production detail the security of the pii/PHI data leaves the organization open to highly the production detail designated on production environments. NEW recommends IP/PHI data leaves the organization open to highly the production development with PII/PHI data leaves the organization open to highly the production device the organization open to highly the production device the production de												
12 8/31/2020 PII/PHI data in non-production environments with pii/PHI data currently exist in a non-production environment sure project needs. Generally this is not a good security practice as the prosence of PII/PHI data in non-production environment sure prosecute of the presence of PII/PHI data in non-production environment sure presence of the presence of the prosecution of the production data is necessary in any non-production environment that DOH stages described by the graphilities of the production data is necessary in any non-production environment that DOH stages described by the graphilities of client trust and loyalty. In the presence of the production and as the presence of t												
12 8/31/2020 PII/PHI data in non-production environments N&V has been made aware that environments N&V has been made aware that environments N&V recommends DOH consider												
12 8/31/2020 Pil/PHI data in non-production environments V&V recommends DOH consider limiting the volume of production environment to meet project needs. Generally this is not a good security practice as the presence of PII/PHI data in on-production environments increasing the organization's risk. Failure to secure PII/PHI data in on-production environments increasing the organization's risk. Failure to secure PII/PHI data in on-production environments increasing the organization's risk. Failure to secure PII/PHI data in secessary in any non-production environments increasing the organization's risk. Failure to secure PII/PHI data in secessary in any non-production environments increasing the organization's risk. Failure to secure PII/PHI data leaves the organization open to highly and the project meets of PII/PHI data in on-production environments increases the potential for their, loss or exposure thus increasing the organization's risk. Failure to secure PII/PHI data in clude this capability. Periodic data is necessary in any non-production environment that DOH the stabilishes a plan for effectively managing the security of the PII/PHI data, including the potential masking of data. N&V recommends DOH consider limiting the volume of limiting the volume of the such that some of the sutomated regression tools being valuated include data masking capabilities which will help to mitigate this issue. If the data masking capabilities which will help to mitigate this issue. If the potential substitution is to not the thing the security of the potential masking of data. N&V recommends DOH consider limiting the volume of the second quarter of 2022, which will likely very devaluated include data masking capabilities which will help to mitigate this issue. If the data masking capabilities which will help to mitigate this issue. If the potential substitution is the potential strate is the potential strate is the potential masking of data. N&V recommends DOH consider will likely very the second quarter of 2022, wh												
environments PII/PHI data currently exist in a non- production environment to meet project needs. Generally this is not a good security practice as the presence of PII/PHI data in non-production environments increases the potential for theft, loss or exposure thus increasing the organization's risk. Failure to secure PII/PHI data leaves the organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client trust and loyalty. Immiting the volume of environments with PII/PHI data and access necessary to support development work, which should help minimize this risk. IV&V recommends if production data is necessary in any non- production environment that DOH establishes a plan for effectively managing the security of the PII/PHI data, including the production environment that DOH mitigates this finding by minimizing and/or masking PHI/PHI data in designated non-production environments. PII/PHI data incurrently exsessment is still planned for the second quarter of 2022, which will likely require BHA to act on this finding identified during April. A Security Assessment is still planned for the second quarter of 2022, which will likely require BHA to act on this finding identified during April. A Security Assessment is still planned for the second quarter of 2022, which will likely require BHA to act on this finding in May or June 2022. IV&V continues to note that a solutions. IV&V will continue to minimating and/or masking PHI/PHI data in designated on-production environments. PII/PHI data in designated on-production which will help to minimating and/or masking PHI/PHI data in designated on-production environments. PII/PHI data in designated on-production which will help to minimating and/or masking PHI/PHI data in designated on-production environments. PII/PHI data in the volume of evelopment work, which should the planning the production environments with PII/PHI data in check and accessored the planned for the second uncertainty Assessment is still planned for the sec	_								-	_		
and access necessary to support development work, which should help minimize this risk, leavy regulatory fines, and loss of some of FII/PHI data in non-production environments increasing the organization's risk. Failure to secure II/PHI data leaves the operation open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client trust and loyalty. Increasing the organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client trust and loyalty. Increasing the organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client trust and loyalty. Increasing the organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client trust and loyalty. Increasing the organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client trust and loyalty. Increasing the organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client trust and loyalty. Increasing the organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client trust and loyalty. Increasing the organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of the strong trust of the production environment that DOH mitigates this finding by minimizing and/or masking of data. Increasing the security of the potential masking of data. Increasing the security of the potential masking of data. Increasing the security of the potential masking of data. Increasing the security of the potential masking of data. Increasing the security of the potential masking of data. Increasing the security of the potential masking of data. Increasing the security of the potential masking of data. Increasing the security of the potential masking of data. Increasing the security of the potential masking of data. Increasing the security of the potential mask	12			**			Project Management	Issue	Medium	Open		
project needs. Generally this is not a good security practice as the presence of PII/PHI data in non-production environments. project needs. Generally this is not a good security practice as the presence of PII/PHI data in designated non-production environments. project needs. Generally this is not a good security practice as the presence of PII/PHI data in non-production environments. project needs. Generally this is not a good security practice as the presence of the utomated regression tools being of the automated regression tools being evaluated include data masking capabilities with will help to mitigate this issue. production environment that DOH establishes a plan for effectively managing the security of the PII/PHI data, including the potential masking of data. IVAV recommends that DOH mitigate this finding by minimizing and/or masking PHI/PII data in designated non-production environments. project needs the presence of development work, which should help minimizing this risk. IVAV recommends that DOH mitigate this finding in May or June 2022. IVAV notes that some of the automated regression tools being evaluated include data masking and part masking of the properties of the automated regression tools being avaluated include data masking and part masking of the automated regression tools being avaluated include at the succession of the automated regression tools being avaluated include at the succession of the automated regression tools being avaluated include at the succession of the			· ·		_						iviacdonaid	
good security practice as the presence of PII/PHI data in non-production environments increases the potential for theft, loss or exposure thus increasing the organization's risk. Failure to secure PII/PHI data leaves the organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client trust and loyalty. development work, which should help minimize this risk. IV&V recommends if production data is necessary in any non-production environment that DOH witigate this issue. If the chosen tool does not include this capabilities which will help to mitigate this issue. IV&V will likely require BHA and so of the automated regression tools being evaluated include data masking capabilities which will continue to monitor this medium criticality issue. require BHA to act on this finding in May or June 2022. IV&V continues to note that some of the automated regression tools being evaluated include data masking capabilities which will help to mitigate this issue. IV&V will continue to monitor this medium criticality issue. require BHA to act on this finding in May or June 2022. IV&V continues to note that some of the automated regression tools being evaluated include data masking capabilities which will help to mitigate this issue. IV&V will continue to monitor this medium criticality issue.			l'	0 0 ,								
of PII/PHI data in non-production environments increases the potential for theft, loss or exposure thus increasing the organization's risk. Failure to secure PII/PHI data leaves the organization open to highly targeted social engineering attacks, heavy regulatory fines, and loyalty. It was recommended in the production environment that DOH mitigates this finding by minimizing and/or masking PHI/PII data in designated non-production environments. In the promiting and you want to so the that some of the automated regression tools being evaluated include data masking capabilities well-unded include data masking capabilities well-unded include data masking capabilities well-unded this capability, the data including the establishes a plan for effectively managing the security of the PII/PHI data, including the potential masking of data. IV&V recommends that DOH mitigates this finding by minimizing and/or masking PHI/PII data in designated non-production environments. If was very continues to note that a some tool does not include this capabilities which will help to mitigate this issue. If the chosen tool does not include this capabilities which will chelp to mitigate this issue. If the chosen tool does not include this capabilities which will chelp to mitigate this issue. If the chosen tool does not include this capabilities which will chelp to mitigate this issue in the automated regression tools being evaluated include data masking capabilities with will help to mitigate this issue.						1						
environments increases the potential for theft, loss or exposure thus increasing the organization's risk. Failure to secure PII/PHI data leaves the organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client trust and loyalty. INEXY recommends if production environment that DOH of mitigates this issue. INEXY recommends if production environment that DOH of mitigates this issue. INEXY recommends that DOH of the automated regression tools being evaluated include data masking capabilities will help to mitigate this issue. If the evaluated include data masking capabilities will help to mitigate this issue. INEXY recommends that DOH of the automated regression tools being evaluated include data masking capabilities will help to mitigate this issue. INEXY recommends that not include this capability, BHA plans to work with RSM for potential solutions. INEX will continue to monitor this medium criticality issue. INEXY recommends that DOH of the automated regression tools being evaluated include data masking capabilities will help to mitigate this issue. INEXY will continue to monitor this medium criticality issue.				chefft trust and loyalty.		1 .						
for theft, loss or exposure thus Increasing the organization's risk. Failure to secure PII/PHI data leaves the organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client trust and loyalty. In the potential masking of data. In the potential masking capabilities which will help to mitigate this issue. It is tower with RSM for potential solutions. IV&V will continue to monitor this medium criticality issue. In the potential solution to work with RSM for potential solutions. IV&V will continue to monitor this medium criticality issue. In the potential solution to work with RSM for potential solutions. IV&V will continue to monitor this medium criticality issue. In the potential solution to work with RSM for potential solutions in the potential solution to work with RSM for potential solutions. IV&V will continue to monitor this medium criticality issue. In the potential solution to work with RSM for potential solutions in the potential solution to make the potential solution to a					· ·							
increasing the organization's risk. Failure to secure PII/PHI data leaves the organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client trust and loyalty. In the potential masking of data. In t			l '		· ·	-						
Failure to secure PII/PHI data leaves the organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client trust and loyalty. Beta plan for effectively managing the security of the PII/PHI data, including the potential masking of data. IV&V recommends that DOH mitigates this finding by minimizing and/or masking PHI/PII data in designated non-production environments. Beta blishes a plan for effectively managing the security of the BHA plans to work with RSM for potential solutions. IV&V will continue to monitor this medium criticality issue. Chosen tool does not include this capability, BHA plans to work with RSM for potential solutions. IV&V will continue to monitor this medium criticality issue.												
the organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client trust and loyalty. BHA plans to work with RSM for potential solutions. IV&V will continue to monitor this medium criticality issue. O3/31/2022 - IV&V continues to note that a Security Assessment is planned for the second minimizing and/or masking PHI/PII data in designated non-production environments. BHA plans to work with RSM for potential solutions. IV&V will continue to monitor this medium criticality issue. O3/31/2022 - IV&V continues to note that a Security Assessment is planned for the second quarter of 2022, which will likely require BHA to act on this finding in May or June 2022. IV&V notes that some of the automated regression tools being evaluated include data masking capabilities which will help to mitigate this issue. IV&V will continue to monitor this medium criticality issue.					ľ							
targeted social engineering attacks, heavy regulatory fines, and loss of client trust and loyalty. PII/PHI data, including the potential masking of data. IV&V recommends that DOH mitigates this finding by minimizing and/or masking PHI/PII data in designated non-production environments. PII/PHI data, including the potential masking of data. IV&V recommends that DOH o3/31/2022 - IV&V continues to note that a security Assessment is planned for the second quarter of 2022, which will likely require BHA to act on this finding in May or June 2022. IV&V notes that some of the automated regression tools being evaluated include data masking capabilities which will help to mittigate this issue. IV&V will continue to monitor this medium criticality issue.			· ·		· · · · · · · · · · · · · · · · · · ·							
heavy regulatory fines, and loss of client trust and loyalty. Note that the potential masking of data. Description of the second witigates this finding by minimizing and/or masking PHI/PII data in designated non-production environments. Note that a continues to note that a continues that a continues to note that a continues th			, , ,			1 .						
client trust and loyalty. IV&V recommends that DOH mitigates this finding by minimizing and/or masking PHI/PII data in designated non-production environments. O3/31/2022 - IV&V continues to note that a Security Assessment is planned for the second quarter of 2022, which will likely require BHA to act on this finding in May or June 2022. IV&V notes that some of the automated regression tools being evaluated include data masking capabilities which will help to mitigate this issue. IV&V will continue to monitor this medium criticality issue.												
mitigates this finding by minimizing and/or masking PHI/PII data in designated non-production environments. Security Assessment is planned for the second quarter of 2022, which will likely require BHA to act on this finding in May or June 2022. IV&V notes that some of the automated regression tools being evaluated include data masking capabilities which will help to mitigate this issue. IV&V will continue to monitor this medium criticality issue.			' - '		l'	· · · · · · · · · · · · · · · · · · ·						
minimizing and/or masking PHI/PII data in designated non-production environments. Value V												
data in designated non-production environments. It o act on this finding in May or June 2022. IV&V notes that some of the automated regression tools being evaluated include data masking capabilities which will help to mitigate this issue. IV&V will continue to monitor this medium criticality issue.												
environments. IV&V notes that some of the automated regression tools being evaluated include data masking capabilities which will help to mitigate this issue. IV&V will continue to monitor this medium criticality issue.						1.						
regression tools being evaluated include data masking capabilities which will help to mitigate this issue. IV&V will continue to monitor this medium criticality issue.												
masking capabilities which will help to mitigate this issue. IV&V will continue to monitor this medium criticality issue.												
mitigate this issue. IV&V will continue to monitor this medium criticality issue.						_ ~						
monitor this medium criticality issue.												
						_						
						02/28/2022 - The effort to address this issue						
remains on hold until additional staff are						remains on hold until additional staff are						
available. IV&V continues to note that a						available. IV&V continues to note that a						
Security Assessment is planned for the first						Security Assessment is planned for the first						
quarter of 2022, which will likely require BHA						quarter of 2022, which will likely require BHA						

13	8/31/2020 Project not able to access Activity	The Project recently deployed audit	The unavailability of activity logs may	IV&V recommends that DHS	03/31/2021 - Per BHA, this finding is no longer	Release/Deployment I	Risk	N/A	Closed	Darren	Finding has been
	Logs	log functionality into production	hamper the investigation of future	continues to collaborate with	an issue and recommends closure. IV&V is					Macdonald	resolved.
		whereby these logs can be accessed	security breaches.	Microsoft until the activity logging	closing this finding.02/28/2021 - BHA						
		and exported as needed. However,		feature is available in all BHA non-	continued this effort in February despite a						
		IV&V was made aware access to		production environments.	workaround being necessary from Microsoft						
		activity logging for users with just			due to a layering issue. Based on continued						
		view permissions will not be available			delays, it is unclear when this important						
		from Microsoft in the public sector			security activity will be completed. IV&V will						
		environment until the end of			continue to monitor this finding. (Per Kamu,						
		September 2020. The unavailability of			this status information did not correctly						
		these specific activity logs could			reflect the issue as the layering issue has no						
		potentially hamper the investigation			relation to the activity logs.)01/31/2021 - The						
		of future security events until			implementation effort for this activity moved						
		implemented.			forward in January. Some of the entities will						
					have activity logging completed in the						
					planned early February Release 3.12, while						
					others will be delayed until Release 3.13. IVV						
					will continue to monitor. 12/31/2020 - The						
					planning effort for identifying the entities that						
					will require activation of the new activity logs						
					was completed during December. The						
					implementation effort has been prioritized for						
					inclusion in Release 3.12. IV&V will continue						
					to monitor this finding until implemented.						
					11/30/2020 - The DOH technical team has						
					commenced the analytical effort to determine						
					•						
					which entities to activate the logging features						
14	9/30/2020 Due to multiple quality concerns,	System defects identified in August	The identified quality issues have	Evaluate existing project staff skills	04/30/2022 - The formal RCA for R3.22	Project Management	Issue	Medium	Open	Darren	
14	the project may continue to face	that affected claims were due to multi-	negatively affected DOH billing	and experience level to ensure	04/30/2022 - The formal RCA for R3.22 determined that root causes of the associated	Project Management	Issue	Medium	Open	Darren Macdonald	
14		that affected claims were due to multi- faceted quality issues were	negatively affected DOH billing processes and DOH has stated these	and experience level to ensure they meet BHA support	04/30/2022 - The formal RCA for R3.22 determined that root causes of the associated defects were requirement, coding, testing,	Project Management	Issue	Medium	Open		
14	the project may continue to face	that affected claims were due to multi- faceted quality issues were individually addressed during this	negatively affected DOH billing processes and DOH has stated these are the most impactful defects	and experience level to ensure they meet BHA support requirements.	04/30/2022 - The formal RCA for R3.22 determined that root causes of the associated defects were requirement, coding, testing, and deployment errors. Recommendations	Project Management	Issue	Medium	Open		
14	the project may continue to face	that affected claims were due to multi- faceted quality issues were individually addressed during this reporting period. IV&V notes that	negatively affected DOH billing processes and DOH has stated these	and experience level to ensure they meet BHA support requirements. Perform revenue neutrality fiscal	04/30/2022 - The formal RCA for R3.22 determined that root causes of the associated defects were requirement, coding, testing, and deployment errors. Recommendations for improvement were noted, including data	Project Management	Issue	Medium	Open		
14	the project may continue to face	that affected claims were due to multi- faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still	negatively affected DOH billing processes and DOH has stated these are the most impactful defects	and experience level to ensure they meet BHA support requirements. Perform revenue neutrality fiscal balance testing on a quarterly	04/30/2022 - The formal RCA for R3.22 determined that root causes of the associated defects were requirement, coding, testing, and deployment errors. Recommendations for improvement were noted, including data validation for bulk updates, joint testing for	Project Management	Issue	Medium	Open		
14	the project may continue to face	that affected claims were due to multi- faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited	negatively affected DOH billing processes and DOH has stated these are the most impactful defects	and experience level to ensure they meet BHA support requirements. Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as	04/30/2022 - The formal RCA for R3.22 determined that root causes of the associated defects were requirement, coding, testing, and deployment errors. Recommendations for improvement were noted, including data validation for bulk updates, joint testing for edge cases, and an increased level of smoke	Project Management	Issue	Medium	Open		
14	the project may continue to face	that affected claims were due to multi- faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project	negatively affected DOH billing processes and DOH has stated these are the most impactful defects	and experience level to ensure they meet BHA support requirements. Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected.	04/30/2022 - The formal RCA for R3.22 determined that root causes of the associated defects were requirement, coding, testing, and deployment errors. Recommendations for improvement were noted, including data validation for bulk updates, joint testing for edge cases, and an increased level of smoke testing. IV&V will continue to monitor the	Project Management	Issue	Medium	Open		
14	the project may continue to face	that affected claims were due to multi- faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a	negatively affected DOH billing processes and DOH has stated these are the most impactful defects	and experience level to ensure they meet BHA support requirements. Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. Assign dedicated resources to	04/30/2022 - The formal RCA for R3.22 determined that root causes of the associated defects were requirement, coding, testing, and deployment errors. Recommendations for improvement were noted, including data validation for bulk updates, joint testing for edge cases, and an increased level of smoke testing. IV&V will continue to monitor the quality of work for this medium criticality	Project Management	Issue	Medium	Open		
14	the project may continue to face	that affected claims were due to multi- faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project	negatively affected DOH billing processes and DOH has stated these are the most impactful defects	and experience level to ensure they meet BHA support requirements. Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. Assign dedicated resources to provide oversight of CAMHD Fiscal	04/30/2022 - The formal RCA for R3.22 determined that root causes of the associated defects were requirement, coding, testing, and deployment errors. Recommendations for improvement were noted, including data validation for bulk updates, joint testing for edge cases, and an increased level of smoke testing. IV&V will continue to monitor the quality of work for this medium criticality issue. The formal RCA for R3.22 determined	Project Management	Issue	Medium	Open		
14	the project may continue to face	that affected claims were due to multi- faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of	negatively affected DOH billing processes and DOH has stated these are the most impactful defects	and experience level to ensure they meet BHA support requirements. Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. Assign dedicated resources to provide oversight of CAMHD Fiscal Processes.	04/30/2022 - The formal RCA for R3.22 determined that root causes of the associated defects were requirement, coding, testing, and deployment errors. Recommendations for improvement were noted, including data validation for bulk updates, joint testing for edge cases, and an increased level of smoke testing. IV&V will continue to monitor the quality of work for this medium criticality issue. The formal RCA for R3.22 determined that root causes of the associated defects	Project Management	Issue	Medium	Open		
14	the project may continue to face	that affected claims were due to multi- faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to	negatively affected DOH billing processes and DOH has stated these are the most impactful defects	and experience level to ensure they meet BHA support requirements. Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. Assign dedicated resources to provide oversight of CAMHD Fiscal Processes. Monitor implemented	04/30/2022 - The formal RCA for R3.22 determined that root causes of the associated defects were requirement, coding, testing, and deployment errors. Recommendations for improvement were noted, including data validation for bulk updates, joint testing for edge cases, and an increased level of smoke testing. IV&V will continue to monitor the quality of work for this medium criticality issue. The formal RCA for R3.22 determined that root causes of the associated defects were tied to requirements, coding, testing,	Project Management	Issue	Medium	Open		
14	the project may continue to face	that affected claims were due to multi- faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to associated testing processes. These	negatively affected DOH billing processes and DOH has stated these are the most impactful defects	and experience level to ensure they meet BHA support requirements. Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. Assign dedicated resources to provide oversight of CAMHD Fiscal Processes. Monitor implemented improvements for effectiveness.	04/30/2022 - The formal RCA for R3.22 determined that root causes of the associated defects were requirement, coding, testing, and deployment errors. Recommendations for improvement were noted, including data validation for bulk updates, joint testing for edge cases, and an increased level of smoke testing. IV&V will continue to monitor the quality of work for this medium criticality issue. The formal RCA for R3.22 determined that root causes of the associated defects were tied to requirements, coding, testing, and deployment errors. Recommendations for	Project Management	Issue	Medium	Open		
14	the project may continue to face	that affected claims were due to multi- faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to associated testing processes. These currently include:Performing Revenue	negatively affected DOH billing processes and DOH has stated these are the most impactful defects	and experience level to ensure they meet BHA support requirements. Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. Assign dedicated resources to provide oversight of CAMHD Fiscal Processes. Monitor implemented improvements for effectiveness. IV&V recommends performing an	04/30/2022 - The formal RCA for R3.22 determined that root causes of the associated defects were requirement, coding, testing, and deployment errors. Recommendations for improvement were noted, including data validation for bulk updates, joint testing for edge cases, and an increased level of smoke testing. IV&V will continue to monitor the quality of work for this medium criticality issue. The formal RCA for R3.22 determined that root causes of the associated defects were tied to requirements, coding, testing, and deployment errors. Recommendations for testing improvements included data	Project Management	Issue	Medium	Open		
14	the project may continue to face	that affected claims were due to multi- faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to associated testing processes. These currently include:Performing Revenue Neutrality Testing to ensure expected	negatively affected DOH billing processes and DOH has stated these are the most impactful defects	and experience level to ensure they meet BHA support requirements. Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. Assign dedicated resources to provide oversight of CAMHD Fiscal Processes. Monitor implemented improvements for effectiveness. IV&V recommends performing an RCA in collaboration with RSM	04/30/2022 - The formal RCA for R3.22 determined that root causes of the associated defects were requirement, coding, testing, and deployment errors. Recommendations for improvement were noted, including data validation for bulk updates, joint testing for edge cases, and an increased level of smoke testing. IV&V will continue to monitor the quality of work for this medium criticality issue. The formal RCA for R3.22 determined that root causes of the associated defects were tied to requirements, coding, testing, and deployment errors. Recommendations for testing improvements included data validation for bulk updates, joint testing for	Project Management	Issue	Medium	Open		
14	the project may continue to face	that affected claims were due to multi- faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue streams are largely	negatively affected DOH billing processes and DOH has stated these are the most impactful defects	and experience level to ensure they meet BHA support requirements. Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. Assign dedicated resources to provide oversight of CAMHD Fiscal Processes. Monitor implemented improvements for effectiveness. IV&V recommends performing an RCA in collaboration with RSM after all future release	04/30/2022 - The formal RCA for R3.22 determined that root causes of the associated defects were requirement, coding, testing, and deployment errors. Recommendations for improvement were noted, including data validation for bulk updates, joint testing for edge cases, and an increased level of smoke testing. IV&V will continue to monitor the quality of work for this medium criticality issue. The formal RCA for R3.22 determined that root causes of the associated defects were tied to requirements, coding, testing, and deployment errors. Recommendations for testing improvements included data validation for bulk updates, joint testing for edge cases , and an increased level of smoke	Project Management	Issue	Medium	Open		
14	the project may continue to face	that affected claims were due to multi- faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to associated testing processes. These currently include:Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to the	negatively affected DOH billing processes and DOH has stated these are the most impactful defects	and experience level to ensure they meet BHA support requirements. Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. Assign dedicated resources to provide oversight of CAMHD Fiscal Processes. Monitor implemented improvements for effectiveness. IV&V recommends performing an RCA in collaboration with RSM after all future release deployments for continual quality	04/30/2022 - The formal RCA for R3.22 determined that root causes of the associated defects were requirement, coding, testing, and deployment errors. Recommendations for improvement were noted, including data validation for bulk updates, joint testing for edge cases, and an increased level of smoke testing. IV&V will continue to monitor the quality of work for this medium criticality issue. The formal RCA for R3.22 determined that root causes of the associated defects were tied to requirements, coding, testing, and deployment errors. Recommendations for testing improvements included data validation for bulk updates, joint testing for edge cases , and an increased level of smoke testing. IV&V will continue to monitor the	Project Management	Issue	Medium	Open		
14	the project may continue to face	that affected claims were due to multi- faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to associated testing processes. These currently include:Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to the next. Conducting System Integration	negatively affected DOH billing processes and DOH has stated these are the most impactful defects	and experience level to ensure they meet BHA support requirements. Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. Assign dedicated resources to provide oversight of CAMHD Fiscal Processes. Monitor implemented improvements for effectiveness. IV&V recommends performing an RCA in collaboration with RSM after all future release deployments for continual quality improvement.	04/30/2022 - The formal RCA for R3.22 determined that root causes of the associated defects were requirement, coding, testing, and deployment errors. Recommendations for improvement were noted, including data validation for bulk updates, joint testing for edge cases, and an increased level of smoke testing. IV&V will continue to monitor the quality of work for this medium criticality issue. The formal RCA for R3.22 determined that root causes of the associated defects were tied to requirements, coding, testing, and deployment errors. Recommendations for testing improvements included data validation for bulk updates, joint testing for edge cases, and an increased level of smoke testing. IV&V will continue to monitor the quality of work for this medium criticality	Project Management	Issue	Medium	Open		
14	the project may continue to face	that affected claims were due to multi- faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to associated testing processes. These currently include:Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to the next. Conducting System Integration Testing, User Acceptance Testing,	negatively affected DOH billing processes and DOH has stated these are the most impactful defects	and experience level to ensure they meet BHA support requirements. Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. Assign dedicated resources to provide oversight of CAMHD Fiscal Processes. Monitor implemented improvements for effectiveness. IV&V recommends performing an RCA in collaboration with RSM after all future release deployments for continual quality improvement. BHA and RSM to collaborate on the	04/30/2022 - The formal RCA for R3.22 determined that root causes of the associated defects were requirement, coding, testing, and deployment errors. Recommendations for improvement were noted, including data validation for bulk updates, joint testing for edge cases, and an increased level of smoke testing. IV&V will continue to monitor the quality of work for this medium criticality issue. The formal RCA for R3.22 determined that root causes of the associated defects were tied to requirements, coding, testing, and deployment errors. Recommendations for testing improvements included data validation for bulk updates, joint testing for edge cases, and an increased level of smoke testing. IV&V will continue to monitor the quality of work for this medium criticality issue.	Project Management	Issue	Medium	Open		
14	the project may continue to face	that affected claims were due to multi- faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to associated testing processes. These currently include:Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to the next. Conducting System Integration Testing, User Acceptance Testing, Performance Testing, and Regression	negatively affected DOH billing processes and DOH has stated these are the most impactful defects	and experience level to ensure they meet BHA support requirements. Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. Assign dedicated resources to provide oversight of CAMHD Fiscal Processes. Monitor implemented improvements for effectiveness. IV&V recommends performing an RCA in collaboration with RSM after all future release deployments for continual quality improvement. BHA and RSM to collaborate on the necessary revisions to the	04/30/2022 - The formal RCA for R3.22 determined that root causes of the associated defects were requirement, coding, testing, and deployment errors. Recommendations for improvement were noted, including data validation for bulk updates, joint testing for edge cases, and an increased level of smoke testing. IV&V will continue to monitor the quality of work for this medium criticality issue. The formal RCA for R3.22 determined that root causes of the associated defects were tied to requirements, coding, testing, and deployment errors. Recommendations for testing improvements included data validation for bulk updates, joint testing for edge cases, and an increased level of smoke testing. IV&V will continue to monitor the quality of work for this medium criticality issue. 03/31/2022 - The R3.22 release promoted to	Project Management	Issue	Medium	Open		
14	the project may continue to face	that affected claims were due to multi- faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to associated testing processes. These currently include:Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to the next. Conducting System Integration Testing, User Acceptance Testing, Performance Testing, and Regression Testing for Release 3.10. IV&V will	negatively affected DOH billing processes and DOH has stated these are the most impactful defects	and experience level to ensure they meet BHA support requirements. Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. Assign dedicated resources to provide oversight of CAMHD Fiscal Processes. Monitor implemented improvements for effectiveness. IV&V recommends performing an RCA in collaboration with RSM after all future release deployments for continual quality improvement. BHA and RSM to collaborate on the necessary revisions to the submitted design deliverables to	04/30/2022 - The formal RCA for R3.22 determined that root causes of the associated defects were requirement, coding, testing, and deployment errors. Recommendations for improvement were noted, including data validation for bulk updates, joint testing for edge cases, and an increased level of smoke testing. IV&V will continue to monitor the quality of work for this medium criticality issue. The formal RCA for R3.22 determined that root causes of the associated defects were tied to requirements, coding, testing, and deployment errors. Recommendations for testing improvements included data validation for bulk updates, joint testing for edge cases, and an increased level of smoke testing. IV&V will continue to monitor the quality of work for this medium criticality issue. 03/31/2022 - The R3.22 release promoted to production on 3/17/2022 resulted in several	Project Management	Issue	Medium	Open		
14	the project may continue to face	that affected claims were due to multi- faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to associated testing processes. These currently include:Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to the next. Conducting System Integration Testing, User Acceptance Testing, Performance Testing, and Regression Testing for Release 3.10. IV&V will continue to monitor the testing efforts	negatively affected DOH billing processes and DOH has stated these are the most impactful defects	and experience level to ensure they meet BHA support requirements. Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. Assign dedicated resources to provide oversight of CAMHD Fiscal Processes. Monitor implemented improvements for effectiveness. IV&V recommends performing an RCA in collaboration with RSM after all future release deployments for continual quality improvement. BHA and RSM to collaborate on the necessary revisions to the submitted design deliverables to increase level of detail and quality.	04/30/2022 - The formal RCA for R3.22 determined that root causes of the associated defects were requirement, coding, testing, and deployment errors. Recommendations for improvement were noted, including data validation for bulk updates, joint testing for edge cases, and an increased level of smoke testing. IV&V will continue to monitor the quality of work for this medium criticality issue. The formal RCA for R3.22 determined that root causes of the associated defects were tied to requirements, coding, testing, and deployment errors. Recommendations for testing improvements included data validation for bulk updates, joint testing for edge cases, and an increased level of smoke testing. IV&V will continue to monitor the quality of work for this medium criticality issue. 03/31/2022 - The R3.22 release promoted to production on 3/17/2022 resulted in several quality issues to include two critical, one high,	Project Management	Issue	Medium	Open		
14	the project may continue to face	that affected claims were due to multi- faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to associated testing processes. These currently include:Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to the next. Conducting System Integration Testing, User Acceptance Testing, Performance Testing, and Regression Testing for Release 3.10. IV&V will continue to monitor the testing efforts throughout the balance of Release	negatively affected DOH billing processes and DOH has stated these are the most impactful defects	and experience level to ensure they meet BHA support requirements. Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. Assign dedicated resources to provide oversight of CAMHD Fiscal Processes. Monitor implemented improvements for effectiveness. IV&V recommends performing an RCA in collaboration with RSM after all future release deployments for continual quality improvement. BHA and RSM to collaborate on the submitted design deliverables to increase level of detail and quality. Perform typical project testing	04/30/2022 - The formal RCA for R3.22 determined that root causes of the associated defects were requirement, coding, testing, and deployment errors. Recommendations for improvement were noted, including data validation for bulk updates, joint testing for edge cases, and an increased level of smoke testing. IV&V will continue to monitor the quality of work for this medium criticality issue. The formal RCA for R3.22 determined that root causes of the associated defects were tied to requirements, coding, testing, and deployment errors. Recommendations for testing improvements included data validation for bulk updates, joint testing for edge cases, and an increased level of smoke testing. IV&V will continue to monitor the quality of work for this medium criticality issue. 03/31/2022 - The R3.22 release promoted to production on 3/17/2022 resulted in several quality issues to include two critical, one high, and two medium defects. A Mid Sprint	Project Management	Issue	Medium	Open		
14	the project may continue to face	that affected claims were due to multi- faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to associated testing processes. These currently include:Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to the next. Conducting System Integration Testing, User Acceptance Testing, Performance Testing, and Regression Testing for Release 3.10. IV&V will continue to monitor the testing efforts throughout the balance of Release 3.10 and validate that enhanced	negatively affected DOH billing processes and DOH has stated these are the most impactful defects	and experience level to ensure they meet BHA support requirements. Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. Assign dedicated resources to provide oversight of CAMHD Fiscal Processes. Monitor implemented improvements for effectiveness. IV&V recommends performing an RCA in collaboration with RSM after all future release deployments for continual quality improvement. BHA and RSM to collaborate on the necessary revisions to the submitted design deliverables to increase level of detail and quality. Perform typical project testing including System Integration, User	04/30/2022 - The formal RCA for R3.22 determined that root causes of the associated defects were requirement, coding, testing, and deployment errors. Recommendations for improvement were noted, including data validation for bulk updates, joint testing for edge cases, and an increased level of smoke testing. IV&V will continue to monitor the quality of work for this medium criticality issue. The formal RCA for R3.22 determined that root causes of the associated defects were tied to requirements, coding, testing, and deployment errors. Recommendations for testing improvements included data validation for bulk updates, joint testing for edge cases, and an increased level of smoke testing. IV&V will continue to monitor the quality of work for this medium criticality issue. 03/31/2022 - The R3.22 release promoted to production on 3/17/2022 resulted in several quality issues to include two critical, one high, and two medium defects. A Mid Sprint Deployment on 3/31/2022 was needed to fix	Project Management	Issue	Medium	Open		
14	the project may continue to face	that affected claims were due to multi- faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to associated testing processes. These currently include:Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to the next. Conducting System Integration Testing, User Acceptance Testing, Performance Testing, and Regression Testing for Release 3.10. IV&V will continue to monitor the testing efforts throughout the balance of Release 3.10 and validate that enhanced quality processes, including industry	negatively affected DOH billing processes and DOH has stated these are the most impactful defects	and experience level to ensure they meet BHA support requirements. Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. Assign dedicated resources to provide oversight of CAMHD Fiscal Processes. Monitor implemented improvements for effectiveness. IV&V recommends performing an RCA in collaboration with RSM after all future release deployments for continual quality improvement. BHA and RSM to collaborate on the necessary revisions to the submitted design deliverables to increase level of detail and quality. Perform typical project testing including System Integration, User Acceptance, Performance, and	04/30/2022 - The formal RCA for R3.22 determined that root causes of the associated defects were requirement, coding, testing, and deployment errors. Recommendations for improvement were noted, including data validation for bulk updates, joint testing for edge cases, and an increased level of smoke testing. IV&V will continue to monitor the quality of work for this medium criticality issue. The formal RCA for R3.22 determined that root causes of the associated defects were tied to requirements, coding, testing, and deployment errors. Recommendations for testing improvements included data validation for bulk updates, joint testing for edge cases, and an increased level of smoke testing. IV&V will continue to monitor the quality of work for this medium criticality issue. 03/31/2022 - The R3.22 release promoted to production on 3/17/2022 resulted in several quality issues to include two critical, one high, and two medium defects. A Mid Sprint Deployment on 3/31/2022 was needed to fix critical and high defects and replace a	Project Management	Issue	Medium	Open		
14	the project may continue to face	that affected claims were due to multi- faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to associated testing processes. These currently include:Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to the next. Conducting System Integration Testing, User Acceptance Testing, Performance Testing, and Regression Testing for Release 3.10. IV&V will continue to monitor the testing efforts throughout the balance of Release 3.10 and validate that enhanced	negatively affected DOH billing processes and DOH has stated these are the most impactful defects	and experience level to ensure they meet BHA support requirements. Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. Assign dedicated resources to provide oversight of CAMHD Fiscal Processes. Monitor implemented improvements for effectiveness. IV&V recommends performing an RCA in collaboration with RSM after all future release deployments for continual quality improvement. BHA and RSM to collaborate on the necessary revisions to the submitted design deliverables to increase level of detail and quality. Perform typical project testing including System Integration, User	04/30/2022 - The formal RCA for R3.22 determined that root causes of the associated defects were requirement, coding, testing, and deployment errors. Recommendations for improvement were noted, including data validation for bulk updates, joint testing for edge cases, and an increased level of smoke testing. IV&V will continue to monitor the quality of work for this medium criticality issue. The formal RCA for R3.22 determined that root causes of the associated defects were tied to requirements, coding, testing, and deployment errors. Recommendations for testing improvements included data validation for bulk updates, joint testing for edge cases, and an increased level of smoke testing. IV&V will continue to monitor the quality of work for this medium criticality issue. 03/31/2022 - The R3.22 release promoted to production on 3/17/2022 resulted in several quality issues to include two critical, one high, and two medium defects. A Mid Sprint Deployment on 3/31/2022 was needed to fix	Project Management	Issue	Medium	Open		

15	10/5/2020 Usage of Semantics and IDM for	The project noted its intent to obtain	Default	Default	01/31/2021 - The project has made great	Targeted KT	Preliminary	N/A	Closed	Darren	The project has
13	development and ongoing	more targeted knowledge transfer of	Delauit	Delauit	strides addressing this concern. A Semantics	~	Concern	IN/A	Closed	Macdonald	made good
	maintenance of the system	both the Semantics Reporting and			Layer KT session was conducted on 1/29/21		Concern			Macaonala	progress
	requires BHA to take a proactive	IDM tools. IV&V will continue to			and multiple IDM and Semantic Layer sessions						establishing and
	approach to support of these	monitor this concern.			has been scheduled in February. IV&V is						initial execution of
	tools.				closing this finding as we no longer view this						the IDM and
	1				item as a concern.12/31/2020 - IV&V is aware						Semantics Layer KT
					that an overview of the Semantics Layer KT						plan.
					session was held on 12/16/20. The planning						
					effort will result in additional Semantic Layer						
					and IDM KT sessions in the coming months.						
					IV&V will continue to monitor this						
					finding.11/30/2020 - The project conducted						
					two high-level overview sessions of the						
					Semantic Layer Reporting tools during						
					November. One session was focused on the						
					overall Semantic Layer, and the second						
					session was focused on Semantic Layer						
					Security. Additional targeted Knowledge						
					Transfer sessions on the Semantic Layer tools						
					will need to be provided by RSM; however,						
					these have not been scheduled. IV&V will						
					continue to monitor this finding.10/31/2020 -						
					The project intends to obtain more targeted						
					knowledge transfer for both the Semantics						
					Reporting and IDM tools and will be planning						
					and scheduling these sessions with the RSM						
16	10/27/2020 The bandwidth of CAMHD	CAMHD has been provided with an	CAMDH Leadership participation in	IV&V recommends CAMHD look	06/30/2021 - As anticipated, the CAMHD	Project Management	Risk	N/A	Closed	Darren	CAMHD Leadership
16	10/27/2020 The bandwidth of CAMHD Leadership is being hampered by	CAMHD has been provided with an approval to commence planning	CAMDH Leadership participation in key activities could be significantly	IV&V recommends CAMHD look for opportunities to augment the	06/30/2021 - As anticipated, the CAMHD Leadership time dedicated to the Project has	Project Management	Risk	N/A	Closed	Darren Macdonald	CAMHD Leadership time dedicated to
16		•	key activities could be significantly	for opportunities to augment the		Project Management	Risk	N/A	Closed		
16	Leadership is being hampered by	approval to commence planning	key activities could be significantly	for opportunities to augment the	Leadership time dedicated to the Project has	Project Management	Risk	N/A	Closed		time dedicated to
16	Leadership is being hampered by planning tasks and activities for	approval to commence planning efforts for expansion of the project for	key activities could be significantly hindered by the flood of activities that	for opportunities to augment the tmanagement staffing for planning	Leadership time dedicated to the Project has returned to normal and expected levels. As	Project Management	Risk	N/A	Closed		time dedicated to the project has
16	Leadership is being hampered by planning tasks and activities for assessing project expansion to	approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD	key activities could be significantly hindered by the flood of activities that could occur as the department	for opportunities to augment the tmanagement staffing for planning	Leadership time dedicated to the Project has returned to normal and expected levels. As such, IV&V is closing this finding. 05/31/2021 -	Project Management	Risk	N/A	Closed		time dedicated to the project has
16	Leadership is being hampered by planning tasks and activities for assessing project expansion to	approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of	key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project to	for opportunities to augment the tmanagement staffing for planning	Leadership time dedicated to the Project has returned to normal and expected levels. As such, IV&V is closing this finding. 05/31/2021 - As anticipated, CAMHD Leadership time spent	Project Management	Risk	N/A	Closed		time dedicated to the project has
16	Leadership is being hampered by planning tasks and activities for assessing project expansion to	approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this	key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project to	for opportunities to augment the tmanagement staffing for planning	Leadership time dedicated to the Project has returned to normal and expected levels. As such, IV&V is closing this finding. 05/31/2021 - As anticipated, CAMHD Leadership time spent on efforts outside of the Inspire Project	Project Management	Risk	N/A	Closed		time dedicated to the project has
16	Leadership is being hampered by planning tasks and activities for assessing project expansion to	approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this	key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project to	for opportunities to augment the tmanagement staffing for planning	Leadership time dedicated to the Project has returned to normal and expected levels. As such, IV&V is closing this finding. 05/31/2021 - As anticipated, CAMHD Leadership time spent on efforts outside of the Inspire Project reduced during May. This level of effort	Project Management	Risk	N/A	Closed		time dedicated to the project has
16	Leadership is being hampered by planning tasks and activities for assessing project expansion to	approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this	key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project to	for opportunities to augment the tmanagement staffing for planning	Leadership time dedicated to the Project has returned to normal and expected levels. As such, IV&V is closing this finding. 05/31/2021 - As anticipated, CAMHD Leadership time spent on efforts outside of the Inspire Project reduced during May. This level of effort decreased to approximately 10% of available time in May, largely for the planning of the Max/Inspire divisional expansion effort. As	Project Management	Risk	N/A	Closed		time dedicated to the project has
16	Leadership is being hampered by planning tasks and activities for assessing project expansion to	approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this	key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project to	for opportunities to augment the tmanagement staffing for planning	Leadership time dedicated to the Project has returned to normal and expected levels. As such, IV&V is closing this finding. 05/31/2021 - As anticipated, CAMHD Leadership time spent on efforts outside of the Inspire Project reduced during May. This level of effort decreased to approximately 10% of available time in May, largely for the planning of the Max/Inspire divisional expansion effort. As such, IV&V is reducing the priority of this		Risk	N/A	Closed		time dedicated to the project has
16	Leadership is being hampered by planning tasks and activities for assessing project expansion to	approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this	key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project to	for opportunities to augment the tmanagement staffing for planning	Leadership time dedicated to the Project has returned to normal and expected levels. As such, IV&V is closing this finding. 05/31/2021 - As anticipated, CAMHD Leadership time spent on efforts outside of the Inspire Project reduced during May. This level of effort decreased to approximately 10% of available time in May, largely for the planning of the Max/Inspire divisional expansion effort. As such, IV&V is reducing the priority of this finding from Medium to Low and will continue		Risk	N/A	Closed		time dedicated to the project has
16	Leadership is being hampered by planning tasks and activities for assessing project expansion to	approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this	key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project to	for opportunities to augment the tmanagement staffing for planning	Leadership time dedicated to the Project has returned to normal and expected levels. As such, IV&V is closing this finding. 05/31/2021 - As anticipated, CAMHD Leadership time spent on efforts outside of the Inspire Project reduced during May. This level of effort decreased to approximately 10% of available time in May, largely for the planning of the Max/Inspire divisional expansion effort. As such, IV&V is reducing the priority of this finding from Medium to Low and will continue to monitor.04/30/2021 - CAMHD Leadership		Risk	N/A	Closed		time dedicated to the project has
16	Leadership is being hampered by planning tasks and activities for assessing project expansion to	approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this	key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project to	for opportunities to augment the tmanagement staffing for planning	Leadership time dedicated to the Project has returned to normal and expected levels. As such, IV&V is closing this finding. 05/31/2021 - As anticipated, CAMHD Leadership time spent on efforts outside of the Inspire Project reduced during May. This level of effort decreased to approximately 10% of available time in May, largely for the planning of the Max/Inspire divisional expansion effort. As such, IV&V is reducing the priority of this finding from Medium to Low and will continue to monitor.04/30/2021 - CAMHD Leadership time spent on efforts outside of the INSPIRE		Risk	N/A	Closed		time dedicated to the project has
16	Leadership is being hampered by planning tasks and activities for assessing project expansion to	approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this	key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project to	for opportunities to augment the tmanagement staffing for planning	Leadership time dedicated to the Project has returned to normal and expected levels. As such, IV&V is closing this finding. 05/31/2021 - As anticipated, CAMHD Leadership time spent on efforts outside of the Inspire Project reduced during May. This level of effort decreased to approximately 10% of available time in May, largely for the planning of the Max/Inspire divisional expansion effort. As such, IV&V is reducing the priority of this finding from Medium to Low and will continue to monitor.04/30/2021 - CAMHD Leadership time spent on efforts outside of the INSPIRE Project continued to increase during early		Risk	N/A	Closed		time dedicated to the project has
16	Leadership is being hampered by planning tasks and activities for assessing project expansion to	approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this	key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project to	for opportunities to augment the tmanagement staffing for planning	Leadership time dedicated to the Project has returned to normal and expected levels. As such, IV&V is closing this finding. 05/31/2021 - As anticipated, CAMHD Leadership time spent on efforts outside of the Inspire Project reduced during May. This level of effort decreased to approximately 10% of available time in May, largely for the planning of the Max/Inspire divisional expansion effort. As such, IV&V is reducing the priority of this finding from Medium to Low and will continue to monitor.04/30/2021 - CAMHD Leadership time spent on efforts outside of the INSPIRE Project continued to increase during early April but has decreased at the end of the		Risk	N/A	Closed		time dedicated to the project has
16	Leadership is being hampered by planning tasks and activities for assessing project expansion to	approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this	key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project to	for opportunities to augment the tmanagement staffing for planning	Leadership time dedicated to the Project has returned to normal and expected levels. As such, IV&V is closing this finding. 05/31/2021 - As anticipated, CAMHD Leadership time spent on efforts outside of the Inspire Project reduced during May. This level of effort decreased to approximately 10% of available time in May, largely for the planning of the Max/Inspire divisional expansion effort. As such, IV&V is reducing the priority of this finding from Medium to Low and will continue to monitor.04/30/2021 - CAMHD Leadership time spent on efforts outside of the INSPIRE Project continued to increase during early April but has decreased at the end of the month. Approximately 60-70% of Leadership		Risk	N/A	Closed		time dedicated to the project has
16	Leadership is being hampered by planning tasks and activities for assessing project expansion to	approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this	key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project to	for opportunities to augment the tmanagement staffing for planning	Leadership time dedicated to the Project has returned to normal and expected levels. As such, IV&V is closing this finding. 05/31/2021 - As anticipated, CAMHD Leadership time spent on efforts outside of the Inspire Project reduced during May. This level of effort decreased to approximately 10% of available time in May, largely for the planning of the Max/Inspire divisional expansion effort. As such, IV&V is reducing the priority of this finding from Medium to Low and will continue to monitor.04/30/2021 - CAMHD Leadership time spent on efforts outside of the INSPIRE Project continued to increase during early April but has decreased at the end of the month. Approximately 60-70% of Leadership time was spent on Phase 4 Planning, COVID		Risk	N/A	Closed		time dedicated to the project has
16	Leadership is being hampered by planning tasks and activities for assessing project expansion to	approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this	key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project to	for opportunities to augment the tmanagement staffing for planning	Leadership time dedicated to the Project has returned to normal and expected levels. As such, IV&V is closing this finding. 05/31/2021 - As anticipated, CAMHD Leadership time spent on efforts outside of the Inspire Project reduced during May. This level of effort decreased to approximately 10% of available time in May, largely for the planning of the Max/Inspire divisional expansion effort. As such, IV&V is reducing the priority of this finding from Medium to Low and will continue to monitor.04/30/2021 - CAMHD Leadership time spent on efforts outside of the INSPIRE Project continued to increase during early April but has decreased at the end of the month. Approximately 60-70% of Leadership time was spent on Phase 4 Planning, COVID Remediation, and the new Vaccine		Risk	N/A	Closed		time dedicated to the project has
16	Leadership is being hampered by planning tasks and activities for assessing project expansion to	approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this	key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project to	for opportunities to augment the tmanagement staffing for planning	Leadership time dedicated to the Project has returned to normal and expected levels. As such, IV&V is closing this finding. 05/31/2021 - As anticipated, CAMHD Leadership time spent on efforts outside of the Inspire Project reduced during May. This level of effort decreased to approximately 10% of available time in May, largely for the planning of the Max/Inspire divisional expansion effort. As such, IV&V is reducing the priority of this finding from Medium to Low and will continue to monitor.04/30/2021 - CAMHD Leadership time spent on efforts outside of the INSPIRE Project continued to increase during early April but has decreased at the end of the month. Approximately 60-70% of Leadership time was spent on Phase 4 Planning, COVID Remediation, and the new Vaccine		Risk	N/A	Closed		time dedicated to the project has
16	Leadership is being hampered by planning tasks and activities for assessing project expansion to	approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this	key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project to	for opportunities to augment the tmanagement staffing for planning	Leadership time dedicated to the Project has returned to normal and expected levels. As such, IV&V is closing this finding. 05/31/2021 - As anticipated, CAMHD Leadership time spent on efforts outside of the Inspire Project reduced during May. This level of effort decreased to approximately 10% of available time in May, largely for the planning of the Max/Inspire divisional expansion effort. As such, IV&V is reducing the priority of this finding from Medium to Low and will continue to monitor.04/30/2021 - CAMHD Leadership time spent on efforts outside of the INSPIRE Project continued to increase during early April but has decreased at the end of the month. Approximately 60-70% of Leadership time was spent on Phase 4 Planning, COVID Remediation, and the new Vaccine Registration application efforts. The CAMHD level of effort is anticipated to decrease to		Risk	N/A	Closed		time dedicated to the project has
16	Leadership is being hampered by planning tasks and activities for assessing project expansion to	approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this	key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project to	for opportunities to augment the tmanagement staffing for planning	Leadership time dedicated to the Project has returned to normal and expected levels. As such, IV&V is closing this finding. 05/31/2021 - As anticipated, CAMHD Leadership time spent on efforts outside of the Inspire Project reduced during May. This level of effort decreased to approximately 10% of available time in May, largely for the planning of the Max/Inspire divisional expansion effort. As such, IV&V is reducing the priority of this finding from Medium to Low and will continue to monitor.04/30/2021 - CAMHD Leadership time spent on efforts outside of the INSPIRE Project continued to increase during early April but has decreased at the end of the month. Approximately 60-70% of Leadership time was spent on Phase 4 Planning, COVID Remediation, and the new Vaccine Registration application efforts. The CAMHD level of effort is anticipated to decrease to approximately 20% in May as DOH has hired a		Risk	N/A	Closed		time dedicated to the project has
16	Leadership is being hampered by planning tasks and activities for assessing project expansion to	approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this	key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project to	for opportunities to augment the tmanagement staffing for planning	Leadership time dedicated to the Project has returned to normal and expected levels. As such, IV&V is closing this finding. 05/31/2021 - As anticipated, CAMHD Leadership time spent on efforts outside of the Inspire Project reduced during May. This level of effort decreased to approximately 10% of available time in May, largely for the planning of the Max/Inspire divisional expansion effort. As such, IV&V is reducing the priority of this finding from Medium to Low and will continue to monitor.04/30/2021 - CAMHD Leadership time spent on efforts outside of the INSPIRE Project continued to increase during early April but has decreased at the end of the month. Approximately 60-70% of Leadership time was spent on Phase 4 Planning, COVID Remediation, and the new Vaccine Registration application efforts. The CAMHD level of effort is anticipated to decrease to approximately 20% in May as DOH has hired a Project Manager in April who will be		Risk	N/A	Closed		time dedicated to the project has
16	Leadership is being hampered by planning tasks and activities for assessing project expansion to	approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this	key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project to	for opportunities to augment the tmanagement staffing for planning	Leadership time dedicated to the Project has returned to normal and expected levels. As such, IV&V is closing this finding. 05/31/2021 - As anticipated, CAMHD Leadership time spent on efforts outside of the Inspire Project reduced during May. This level of effort decreased to approximately 10% of available time in May, largely for the planning of the Max/Inspire divisional expansion effort. As such, IV&V is reducing the priority of this finding from Medium to Low and will continue to monitor.04/30/2021 - CAMHD Leadership time spent on efforts outside of the INSPIRE Project continued to increase during early April but has decreased at the end of the month. Approximately 60-70% of Leadership time was spent on Phase 4 Planning, COVID Remediation, and the new Vaccine Registration application efforts. The CAMHD level of effort is anticipated to decrease to approximately 20% in May as DOH has hired a Project Manager in April who will be dedicated to the Vaccine Registration Project,		Risk	N/A	Closed		time dedicated to the project has
16	Leadership is being hampered by planning tasks and activities for assessing project expansion to	approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this	key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project to	for opportunities to augment the tmanagement staffing for planning	Leadership time dedicated to the Project has returned to normal and expected levels. As such, IV&V is closing this finding. 05/31/2021 - As anticipated, CAMHD Leadership time spent on efforts outside of the Inspire Project reduced during May. This level of effort decreased to approximately 10% of available time in May, largely for the planning of the Max/Inspire divisional expansion effort. As such, IV&V is reducing the priority of this finding from Medium to Low and will continue to monitor.04/30/2021 - CAMHD Leadership time spent on efforts outside of the INSPIRE Project continued to increase during early April but has decreased at the end of the month. Approximately 60-70% of Leadership time was spent on Phase 4 Planning, COVID Remediation, and the new Vaccine Registration application efforts. The CAMHD level of effort is anticipated to decrease to approximately 20% in May as DOH has hired a Project Manager in April who will be dedicated to the Vaccine Registration Project, instead of BHA resources IV&V will continue		Risk	N/A	Closed		time dedicated to the project has
16	Leadership is being hampered by planning tasks and activities for assessing project expansion to	approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this	key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project to	for opportunities to augment the tmanagement staffing for planning	Leadership time dedicated to the Project has returned to normal and expected levels. As such, IV&V is closing this finding. 05/31/2021 - As anticipated, CAMHD Leadership time spent on efforts outside of the Inspire Project reduced during May. This level of effort decreased to approximately 10% of available time in May, largely for the planning of the Max/Inspire divisional expansion effort. As such, IV&V is reducing the priority of this finding from Medium to Low and will continue to monitor.04/30/2021 - CAMHD Leadership time spent on efforts outside of the INSPIRE Project continued to increase during early April but has decreased at the end of the month. Approximately 60-70% of Leadership time was spent on Phase 4 Planning, COVID Remediation, and the new Vaccine Registration application efforts. The CAMHD level of effort is anticipated to decrease to approximately 20% in May as DOH has hired a Project Manager in April who will be dedicated to the Vaccine Registration Project,		Risk	N/A	Closed		time dedicated to the project has

17	11/30/2020	Due to consistent technical issues	The IDM and Semantic layer efforts	Default	IV&V recommends the project to	08/31/2021 -The number of issues requiring	Release/Deployment	Iccup	N/A	Closed	Darren	The volume of
17	11/30/2020	requiring escalation to Microsoft,	have experienced several delays	Deladit	continue to monitor the status of	assistance from Microsoft continues to remain	Release/ Deployment	issue	N/A		Macdonald	interactions needed
		, -	attributable to issues escalated to		outstanding Microsoft tickets and	limited, and as such, IV&V is closing this					iviacuonaiu	with Microsoft
		, ,	Microsoft. The issues have ranged		to escalate the priority of these	finding. 07/31/2021 - While the number of						remains low and
		•	from administrative / communication		tickets as deemed necessary.	issues requiring assistance from Microsoft						manageable. This
			(entering issues into the Commercial		tickets as deemed necessary.	remains limited, interactions with Microsoft						condition is no
			support instance vs the Government			are increasing again due to the interface						longer impeding
			Cloud support instance), to several			functionality planned for implementation in						project progress.
			key technical issues requiring			the current and remaining DD&I releases. The						
			assistance to resolve. To date, these			FHIR API interface has required multiple						
			support needs have added over a			interactions with Microsoft that have resulted						
			month to the IDM and Semantic Layer			in unplanned schedule slippages for the FHIR						
			project schedules.			API implementation. IV&V will continue to						
						monitor this finding. 06/30/2021 - The						
						number of issues requiring assistance from						
						Microsoft continues to be low with only two						
						known items open. As such, IV&V is reducing						
						the priority of this finding to low and will						
						continue to monitor.05/31/2021 - There is						
						only one open Microsoft ticket affecting the						
						attachment of Claims to the Batch. As such,						
						IV&V is reducing the criticality of this finding						
						from High to Medium and will continue to						
						monitor. 04/30/2021 - BHA continues to work						
						with Microsoft on technical issues as they						
						arise in the Government Community Cloud						
						(GCC) instance. The issue with fields being						
18	12/31/2020	Due to on-going deployment	There have been several defects	Repeatable documented release and	Ensure there are adequate and	04/30/2022 - The formal RCA for R3.22	Release/Deployment	Issue	Medium	Open	Darren	
18	12/31/2020		There have been several defects pushed to production with Phase 3	Repeatable documented release and deployment will help ensure that	Ensure there are adequate and qualified resources to support the	04/30/2022 - The formal RCA for R3.22 determined that root causes of the associated		Issue	Medium		Darren Macdonald	
18	12/31/2020			'	· ·			Issue	Medium			
18	12/31/2020	processes and technical execution	pushed to production with Phase 3	deployment will help ensure that	qualified resources to support the	determined that root causes of the associated		Issue	Medium			
18	12/31/2020	processes and technical execution issues, the Project may continue	pushed to production with Phase 3 releases. Some of the defects	deployment will help ensure that mistakes are minimized, and that	qualified resources to support the current deployment processes.	determined that root causes of the associated defects included deployment errors.		Issue	Medium			
18	12/31/2020	processes and technical execution issues, the Project may continue to encounter defects and challenges in meeting projected	pushed to production with Phase 3 releases. Some of the defects introduced to production have been	deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly	qualified resources to support the current deployment processes. This may require the support from	determined that root causes of the associated defects included deployment errors. Recommendations for improvement in this area included an increased level of smoke		Issue	Medium			
18	12/31/2020	processes and technical execution issues, the Project may continue to encounter defects and challenges in meeting projected	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental	deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take	qualified resources to support the current deployment processes. This may require the support from RSM resources to provide	determined that root causes of the associated defects included deployment errors. Recommendations for improvement in this area included an increased level of smoke		Issue	Medium			
18	12/31/2020	processes and technical execution issues, the Project may continue to encounter defects and challenges in meeting projected timelines for production and non-production deployments.	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these	deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take	qualified resources to support the current deployment processes. This may require the support from RSM resources to provide assistance and knowledge transfer	determined that root causes of the associated defects included deployment errors. Recommendations for improvement in this area included an increased level of smoke testing in subsequent releases.		Issue	Medium			
18	12/31/2020	processes and technical execution issues, the Project may continue to encounter defects and challenges in meeting projected timelines for production and non-production deployments.	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST	deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take	qualified resources to support the current deployment processes. This may require the support from RSM resources to provide assistance and knowledge transfer for some of the more complex deployment components.	determined that root causes of the associated defects included deployment errors. Recommendations for improvement in this area included an increased level of smoke testing in subsequent releases. BHA learned that Microsoft's latest direction		Issue	Medium			
18	12/31/2020	processes and technical execution issues, the Project may continue to encounter defects and challenges in meeting projected timelines for production and non-production deployments.	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with	deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take	qualified resources to support the current deployment processes. This may require the support from RSM resources to provide assistance and knowledge transfer for some of the more complex deployment components.	determined that root causes of the associated defects included deployment errors. Recommendations for improvement in this area included an increased level of smoke testing in subsequent releases. BHA learned that Microsoft's latest direction is to deprecate patch-only releases and move to full solution upgrades for each release. The		issue	Medium			
18	12/31/2020	processes and technical execution issues, the Project may continue to encounter defects and challenges in meeting projected timelines for production and non-production deployments.	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing	deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take	qualified resources to support the current deployment processes. This may require the support from RSM resources to provide assistance and knowledge transfer for some of the more complex deployment components. Work in collaboration with RSM to	determined that root causes of the associated defects included deployment errors. Recommendations for improvement in this area included an increased level of smoke testing in subsequent releases. BHA learned that Microsoft's latest direction is to deprecate patch-only releases and move to full solution upgrades for each release. The timing of this guidance is still to be		Issue	Medium			
18	12/31/2020	processes and technical execution issues, the Project may continue to encounter defects and challenges in meeting projected timelines for production and non-production deployments.	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components,	deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take	qualified resources to support the current deployment processes. This may require the support from RSM resources to provide assistance and knowledge transfer for some of the more complex deployment components. Work in collaboration with RSM to establish a transition plan for DOH	determined that root causes of the associated defects included deployment errors. Recommendations for improvement in this area included an increased level of smoke testing in subsequent releases. BHA learned that Microsoft's latest direction is to deprecate patch-only releases and move to full solution upgrades for each release. The timing of this guidance is still to be		Issue	Medium			
18	12/31/2020	processes and technical execution issues, the Project may continue to encounter defects and challenges in meeting projected timelines for production and non-production deployments.	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is	deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take	qualified resources to support the current deployment processes. This may require the support from RSM resources to provide assistance and knowledge transfer for some of the more complex deployment components. Work in collaboration with RSM to establish a transition plan for DOH to assume all deployment activities	determined that root causes of the associated defects included deployment errors. Recommendations for improvement in this area included an increased level of smoke testing in subsequent releases. BHA learned that Microsoft's latest direction is to deprecate patch-only releases and move to full solution upgrades for each release. The timing of this guidance is still to be determined.		Issue	Medium			
18	12/31/2020	processes and technical execution issues, the Project may continue to encounter defects and challenges in meeting projected timelines for production and non-production deployments.	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM	deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take	qualified resources to support the current deployment processes. This may require the support from RSM resources to provide assistance and knowledge transfer for some of the more complex deployment components. Work in collaboration with RSM to establish a transition plan for DOH to assume all deployment activities to ensure complete ownership of	determined that root causes of the associated defects included deployment errors. Recommendations for improvement in this area included an increased level of smoke testing in subsequent releases. BHA learned that Microsoft's latest direction is to deprecate patch-only releases and move to full solution upgrades for each release. The timing of this guidance is still to be determined. The release of R3.23 was delayed a week due		Issue	Medium			
18	12/31/2020	processes and technical execution issues, the Project may continue to encounter defects and challenges in meeting projected timelines for production and non-production deployments.	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing	deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take	qualified resources to support the current deployment processes. This may require the support from RSM resources to provide assistance and knowledge transfer for some of the more complex deployment components. Work in collaboration with RSM to establish a transition plan for DOH to assume all deployment activities to ensure complete ownership of these processes. This should assist with consistency in approach and	determined that root causes of the associated defects included deployment errors. Recommendations for improvement in this area included an increased level of smoke testing in subsequent releases. BHA learned that Microsoft's latest direction is to deprecate patch-only releases and move to full solution upgrades for each release. The timing of this guidance is still to be determined. The release of R3.23 was delayed a week due to unexpected issues identified during Deployment Planning. It is currently		Issue	Medium			
18	12/31/2020	processes and technical execution issues, the Project may continue to encounter defects and challenges in meeting projected timelines for production and non-production deployments.	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically	deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take	qualified resources to support the current deployment processes. This may require the support from RSM resources to provide assistance and knowledge transfer for some of the more complex deployment components. Work in collaboration with RSM to establish a transition plan for DOH to assume all deployment activities to ensure complete ownership of these processes. This should assist with consistency in approach and execution going forward.	determined that root causes of the associated defects included deployment errors. Recommendations for improvement in this area included an increased level of smoke testing in subsequent releases. BHA learned that Microsoft's latest direction is to deprecate patch-only releases and move to full solution upgrades for each release. The timing of this guidance is still to be determined. The release of R3.23 was delayed a week due to unexpected issues identified during Deployment Planning. It is currently anticipated to be promoted to production on		Issue	Medium			
18	12/31/2020	processes and technical execution issues, the Project may continue to encounter defects and challenges in meeting projected timelines for production and non-production deployments.	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via	deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take	qualified resources to support the current deployment processes. This may require the support from RSM resources to provide assistance and knowledge transfer for some of the more complex deployment components. Work in collaboration with RSM to establish a transition plan for DOH to assume all deployment activities to ensure complete ownership of these processes. This should assist with consistency in approach and execution going forward. As appropriate, consult with RSM	determined that root causes of the associated defects included deployment errors. Recommendations for improvement in this area included an increased level of smoke testing in subsequent releases. BHA learned that Microsoft's latest direction is to deprecate patch-only releases and move to full solution upgrades for each release. The timing of this guidance is still to be determined. The release of R3.23 was delayed a week due to unexpected issues identified during Deployment Planning. It is currently anticipated to be promoted to production on 5/5/2022.		Issue	Medium			
18	12/31/2020	processes and technical execution issues, the Project may continue to encounter defects and challenges in meeting projected timelines for production and non-production deployments.	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear	deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take	qualified resources to support the current deployment processes. This may require the support from RSM resources to provide assistance and knowledge transfer for some of the more complex deployment components. Work in collaboration with RSM to establish a transition plan for DOH to assume all deployment activities to ensure complete ownership of these processes. This should assist with consistency in approach and execution going forward. As appropriate, consult with RSM on best practices that BHA could	determined that root causes of the associated defects included deployment errors. Recommendations for improvement in this area included an increased level of smoke testing in subsequent releases. BHA learned that Microsoft's latest direction is to deprecate patch-only releases and move to full solution upgrades for each release. The timing of this guidance is still to be determined. The release of R3.23 was delayed a week due to unexpected issues identified during Deployment Planning. It is currently anticipated to be promoted to production on 5/5/2022.		Issue	Medium			
18	12/31/2020	processes and technical execution issues, the Project may continue to encounter defects and challenges in meeting projected timelines for production and non-production deployments.	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and	deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take	qualified resources to support the current deployment processes. This may require the support from RSM resources to provide assistance and knowledge transfer for some of the more complex deployment components. Work in collaboration with RSM to establish a transition plan for DOH to assume all deployment activities to ensure complete ownership of these processes. This should assist with consistency in approach and execution going forward. As appropriate, consult with RSM on best practices that BHA could employ to support deployment.	determined that root causes of the associated defects included deployment errors. Recommendations for improvement in this area included an increased level of smoke testing in subsequent releases. BHA learned that Microsoft's latest direction is to deprecate patch-only releases and move to full solution upgrades for each release. The timing of this guidance is still to be determined. The release of R3.23 was delayed a week due to unexpected issues identified during Deployment Planning. It is currently anticipated to be promoted to production on 5/5/2022. IV&V notes that based on current resource constraints, the project has determined that		Issue	Medium			
18	12/31/2020	processes and technical execution issues, the Project may continue to encounter defects and challenges in meeting projected timelines for production and non-production deployments.	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented deployment script, or	deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take	qualified resources to support the current deployment processes. This may require the support from RSM resources to provide assistance and knowledge transfer for some of the more complex deployment components. Work in collaboration with RSM to establish a transition plan for DOH to assume all deployment activities to ensure complete ownership of these processes. This should assist with consistency in approach and execution going forward. As appropriate, consult with RSM on best practices that BHA could employ to support deployment. Request the assistance of the RSM	determined that root causes of the associated defects included deployment errors. Recommendations for improvement in this area included an increased level of smoke testing in subsequent releases. BHA learned that Microsoft's latest direction is to deprecate patch-only releases and move to full solution upgrades for each release. The timing of this guidance is still to be determined. The release of R3.23 was delayed a week due to unexpected issues identified during Deployment Planning. It is currently anticipated to be promoted to production on 5/5/2022. IV&V notes that based on current resource constraints, the project has determined that R3.24 will not be deployed as a solution		Issue	Medium			
18	12/31/2020	processes and technical execution issues, the Project may continue to encounter defects and challenges in meeting projected timelines for production and non-production deployments.	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented deployment script, or deployment notes, are being utilized	deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take	qualified resources to support the current deployment processes. This may require the support from RSM resources to provide assistance and knowledge transfer for some of the more complex deployment components. Work in collaboration with RSM to establish a transition plan for DOH to assume all deployment activities to ensure complete ownership of these processes. This should assist with consistency in approach and execution going forward. As appropriate, consult with RSM on best practices that BHA could employ to support deployment. Request the assistance of the RSM Solution Architect in reviewing and	determined that root causes of the associated defects included deployment errors. Recommendations for improvement in this area included an increased level of smoke testing in subsequent releases. BHA learned that Microsoft's latest direction is to deprecate patch-only releases and move to full solution upgrades for each release. The timing of this guidance is still to be determined. The release of R3.23 was delayed a week due to unexpected issues identified during Deployment Planning. It is currently anticipated to be promoted to production on 5/5/2022. IV&V notes that based on current resource constraints, the project has determined that R3.24 will not be deployed as a solution upgrade. IV&V will continue to monitor this		Issue	Medium			
18	12/31/2020	processes and technical execution issues, the Project may continue to encounter defects and challenges in meeting projected timelines for production and non-production deployments.	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented deployment script, or	deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take	qualified resources to support the current deployment processes. This may require the support from RSM resources to provide assistance and knowledge transfer for some of the more complex deployment components. Work in collaboration with RSM to establish a transition plan for DOH to assume all deployment activities to ensure complete ownership of these processes. This should assist with consistency in approach and execution going forward. As appropriate, consult with RSM on best practices that BHA could employ to support deployment. Request the assistance of the RSM Solution Architect in reviewing and correcting issues associated with	determined that root causes of the associated defects included deployment errors. Recommendations for improvement in this area included an increased level of smoke testing in subsequent releases. BHA learned that Microsoft's latest direction is to deprecate patch-only releases and move to full solution upgrades for each release. The timing of this guidance is still to be determined. The release of R3.23 was delayed a week due to unexpected issues identified during Deployment Planning. It is currently anticipated to be promoted to production on 5/5/2022. IV&V notes that based on current resource constraints, the project has determined that R3.24 will not be deployed as a solution upgrade. IV&V will continue to monitor this medium criticality issue.		Issue	Medium			
18	12/31/2020	processes and technical execution issues, the Project may continue to encounter defects and challenges in meeting projected timelines for production and non-production deployments.	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented deployment script, or deployment notes, are being utilized	deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take	qualified resources to support the current deployment processes. This may require the support from RSM resources to provide assistance and knowledge transfer for some of the more complex deployment components. Work in collaboration with RSM to establish a transition plan for DOH to assume all deployment activities to ensure complete ownership of these processes. This should assist with consistency in approach and execution going forward. As appropriate, consult with RSM on best practices that BHA could employ to support deployment. Request the assistance of the RSM Solution Architect in reviewing and correcting issues associated with consistency of the configurations	determined that root causes of the associated defects included deployment errors. Recommendations for improvement in this area included an increased level of smoke testing in subsequent releases. BHA learned that Microsoft's latest direction is to deprecate patch-only releases and move to full solution upgrades for each release. The timing of this guidance is still to be determined. The release of R3.23 was delayed a week due to unexpected issues identified during Deployment Planning. It is currently anticipated to be promoted to production on 5/5/2022. IV&V notes that based on current resource constraints, the project has determined that R3.24 will not be deployed as a solution upgrade. IV&V will continue to monitor this medium criticality issue. 03/31/2022 - R3.22 was promoted to		Issue	Medium			
18	12/31/2020	processes and technical execution issues, the Project may continue to encounter defects and challenges in meeting projected timelines for production and non-production deployments.	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented deployment script, or deployment notes, are being utilized	deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take	qualified resources to support the current deployment processes. This may require the support from RSM resources to provide assistance and knowledge transfer for some of the more complex deployment components. Work in collaboration with RSM to establish a transition plan for DOH to assume all deployment activities to ensure complete ownership of these processes. This should assist with consistency in approach and execution going forward. As appropriate, consult with RSM on best practices that BHA could employ to support deployment. Request the assistance of the RSM Solution Architect in reviewing and correcting issues associated with consistency of the configurations across environments, ensuring	determined that root causes of the associated defects included deployment errors. Recommendations for improvement in this area included an increased level of smoke testing in subsequent releases. BHA learned that Microsoft's latest direction is to deprecate patch-only releases and move to full solution upgrades for each release. The timing of this guidance is still to be determined. The release of R3.23 was delayed a week due to unexpected issues identified during Deployment Planning. It is currently anticipated to be promoted to production on 5/5/2022. IV&V notes that based on current resource constraints, the project has determined that R3.24 will not be deployed as a solution upgrade. IV&V will continue to monitor this medium criticality issue. 03/31/2022 - R3.22 was promoted to production on 3/17/2022. There were reports		Issue	Medium			
18	12/31/2020	processes and technical execution issues, the Project may continue to encounter defects and challenges in meeting projected timelines for production and non-production deployments.	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented deployment script, or deployment notes, are being utilized	deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take	qualified resources to support the current deployment processes. This may require the support from RSM resources to provide assistance and knowledge transfer for some of the more complex deployment components. Work in collaboration with RSM to establish a transition plan for DOH to assume all deployment activities to ensure complete ownership of these processes. This should assist with consistency in approach and execution going forward. As appropriate, consult with RSM on best practices that BHA could employ to support deployment. Request the assistance of the RSM Solution Architect in reviewing and correcting issues associated with consistency of the configurations across environments, ensuring that the test environment is	determined that root causes of the associated defects included deployment errors. Recommendations for improvement in this area included an increased level of smoke testing in subsequent releases. BHA learned that Microsoft's latest direction is to deprecate patch-only releases and move to full solution upgrades for each release. The timing of this guidance is still to be determined. The release of R3.23 was delayed a week due to unexpected issues identified during Deployment Planning. It is currently anticipated to be promoted to production on 5/5/2022. IV&V notes that based on current resource constraints, the project has determined that R3.24 will not be deployed as a solution upgrade. IV&V will continue to monitor this medium criticality issue. 03/31/2022 - R3.22 was promoted to production on 3/17/2022. There were reports of five (5) defects resulting from this		Issue	Medium			
18	12/31/2020	processes and technical execution issues, the Project may continue to encounter defects and challenges in meeting projected timelines for production and non-production deployments.	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented deployment script, or deployment notes, are being utilized	deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take	qualified resources to support the current deployment processes. This may require the support from RSM resources to provide assistance and knowledge transfer for some of the more complex deployment components. Work in collaboration with RSM to establish a transition plan for DOH to assume all deployment activities to ensure complete ownership of these processes. This should assist with consistency in approach and execution going forward. As appropriate, consult with RSM on best practices that BHA could employ to support deployment. Request the assistance of the RSM Solution Architect in reviewing and correcting issues associated with consistency of the configurations across environments, ensuring that the test environment is capable of testing ALL functions of	determined that root causes of the associated defects included deployment errors. Recommendations for improvement in this area included an increased level of smoke testing in subsequent releases. BHA learned that Microsoft's latest direction is to deprecate patch-only releases and move to full solution upgrades for each release. The timing of this guidance is still to be determined. The release of R3.23 was delayed a week due to unexpected issues identified during Deployment Planning. It is currently anticipated to be promoted to production on 5/5/2022. IV&V notes that based on current resource constraints, the project has determined that R3.24 will not be deployed as a solution upgrade. IV&V will continue to monitor this medium criticality issue. 03/31/2022 - R3.22 was promoted to production on 3/17/2022. There were reports of five (5) defects resulting from this deployment. Two were critical, one was high,		Issue	Medium			
18	12/31/2020	processes and technical execution issues, the Project may continue to encounter defects and challenges in meeting projected timelines for production and non-production deployments.	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented deployment script, or deployment notes, are being utilized	deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take	qualified resources to support the current deployment processes. This may require the support from RSM resources to provide assistance and knowledge transfer for some of the more complex deployment components. Work in collaboration with RSM to establish a transition plan for DOH to assume all deployment activities to ensure complete ownership of these processes. This should assist with consistency in approach and execution going forward. As appropriate, consult with RSM on best practices that BHA could employ to support deployment. Request the assistance of the RSM Solution Architect in reviewing and correcting issues associated with consistency of the configurations across environments, ensuring that the test environment is capable of testing ALL functions of	determined that root causes of the associated defects included deployment errors. Recommendations for improvement in this area included an increased level of smoke testing in subsequent releases. BHA learned that Microsoft's latest direction is to deprecate patch-only releases and move to full solution upgrades for each release. The timing of this guidance is still to be determined. The release of R3.23 was delayed a week due to unexpected issues identified during Deployment Planning. It is currently anticipated to be promoted to production on 5/5/2022. IV&V notes that based on current resource constraints, the project has determined that R3.24 will not be deployed as a solution upgrade. IV&V will continue to monitor this medium criticality issue. 03/31/2022 - R3.22 was promoted to production on 3/17/2022. There were reports of five (5) defects resulting from this		Issue	Medium			

19	3/28/2021 The pending RSM contract expiration will require BHA to perform transition of the D365 solution to the State prior to contract end.	currently planned to complete in September 2021. BHA will need a transition plan to ensure that it has all knowledge transfer and is fully capable of managing all aspects of supporting and maintaining the D365 solution without vendor support until at least the Phase 4 expansion effort is procured and initiated. The Phase 4 effort is currently expected to commence late in the 4th quarter of 2021, or early in the first quarter of 2022. The Phase 4 procurement scope is planned to include additional DD&I activities, as well as M&O support activities.	position to solely take on the development of user stories, testing, regression testing, deployment, and the support and maintenance of the entire system, there is a risk that environment stability may be challenged.	less releases in the summer months as the transition off of vendor support approaches.	05/31/2021 - Per CAMHD, the RSM contract amendments to extend the DD&I effort (Mod 5) to the end of December 2021 and also provide M&O services (Mod 6) through May 2022 were fully executed in May. IV&V is closing this preliminary concern. 04/30/2021 - The RSM contract amendment is still pending approval. This amendment will extend the DD&I effort (Mod 5) to the end of December 2021 and will also provide M&O services (Mod 6) through May 2022. Mod 5 is expected to be approved in May 2021. This will delay the near-term need for a Transition Plan until first quarter 2022. IV&V will continue to monitor this finding.		Preliminary Concern	N/A	Closed	Vic Dudoit	The RSM amendments were fully executed in May 2021.
20	4/30/2021 The DDD Project Manager will be on leave and unavailable to the project starting in May.	DDD and her absence may cause an increased level of risk to the project. DDD has commenced planning efforts and has assigned staff to backfill her, although they are currently assigned to other project tasks and activities.	The DDD Project Manager is critical to all daily project interactions affecting DDD from a functional and managerial perspective. If her duties are not re-assigned to capable staff prior to her planned absence, DDD will be in a challenged position to effectively contribute to at least the next several releases.	1) IV&V recommends DDD to continue to look for opportunities to augment the existing technical staff in order to fully support current DDI project work.2) IV&V recommends DDD to consider augmenting their current PM/Business staff in order to allow their technical staff to focus on technical duties.	08/31/2021 - The DDD Project Manager returned from her absence, alleviating the DDD technical staff bandwidth/workload challenges. IV&V is closing this finding.07/31/2021 - The DDD technical staff continued to face bandwidth/workload challenges during the month of July. Fortunately, the DDD Project Manager is scheduled to return to work on 8/2/2021 allowing the technical staff to return fully to their technical responsibilities.06/30/2021 - The absence of the DDD Project Manager continues to cause bandwidth/workload challenges for DDD technical staff. Time available for typical DDD CRM assignments was limited in June due to this resource constraint. IV&V has promoted this finding from a Preliminary Concern to a Medium criticality issue and will continue to monitor. 05/31/2021 - The highest priority tasks and activities typically accomplished by the DDD Project Manager have been re-assigned to other DDD staff. IV&V notes that this results in some level of bandwidth/workload challenges for DDD technical staff.	Project Management	Issue	N/A		Darren Macdonald	The DDD Project Manager has returned from her leave, fully mitigating this issue.

	6/20/2024	and the state of t	·· · · · · · · · · · · · · · · · ·			0.4/0.0/0.000 TI I I I DO 0.0 I	la ·			•	_	
21		Unplanned rework may have an	The continued volume of unplanned	Release defect metrics for unplanned	Reduce the amount of unplanned	04/30/2022 - The planned R3.23 release was	Project Management	Issue	Low	Open	Darren	
		impact on delivering DDI	rework may have an impact on	rework has been 30-40% of the total	rework by continuing to focus on	pushed out to early May 2022. As such, there					Macdonald	
			delivering planned DDI functionality	USPs for the last few releases.	quality improvement measures.	are no available defect percentages for the						
		period.	with only 4 possible DDI releases		Strive for defect performance	April reporting period. IV&V will continue to						
			remaining for completion.		metric not to exceed 20% of all	monitor this low criticality finding.						
					user story points in any given	03/31/2022 - The defect percentage (25%) in						
					release.	March was higher than February but remained						
						close to the target of 20% or less of the USPs						
						deployed to production. IV&V will continue to						
						monitor this finding.						
						02/28/2022 - The percentage of defects						
						versus planned user stories and requests						
						continued to improve during February. The						
						defect percentage (17%) in February was						
						lower than it has been in any of the previous 6						
						months and is currently in alignment with the						
						target of 20% or less of the USPs deployed to						
						production. IV&V will continue to monitor this						
						finding.						
						01/31/2022 - There were no substantive						
						changes to this finding in January. The						
						percentage of defects for R3.21 will be						
						available in February, when the release is						
						completed.						
						12/31/2021 - The percentage of defects vs						
						planned user stories and requests rose slightly						
						, , ,						
						during December. The defect percentage was						
22	7/30/2021	The project schedules for 'hig	The FHIR interface and CAFAS	Weekly RSM Status Report	Extend the current DDI timeframe		Project Management	Issue	High	Onen	Darren	
22		The project schedules for 'big	The FHIR interface and CAFAS	Weekly RSM Status Report	Extend the current DDI timeframe to allow for the completion of 'big	04/30/2022 - Project Roadmap for completion	Project Management	Issue	High	Open	Darren Macdonald	
22		boulder' interface functionality	interface are currently at risk of not	Weekly RSM Status Report	to allow for the completion of 'big	04/30/2022 - Project Roadmap for completion of high priority (big boulder) features	Project Management	Issue	High	Open	Darren Macdonald	
22			interface are currently at risk of not making the planned R3.17 release.	Weekly RSM Status Report	to allow for the completion of 'big boulder' interfaces functionality	04/30/2022 - Project Roadmap for completion of high priority (big boulder) features continued to be re-evaluated and re-	Project Management	Issue	High	Open		
22		boulder' interface functionality	interface are currently at risk of not making the planned R3.17 release. The Single Sign on components of the	Weekly RSM Status Report	to allow for the completion of 'big boulder' interfaces functionality development.	04/30/2022 - Project Roadmap for completion of high priority (big boulder) features continued to be re-evaluated and redetermined during April. Based on the latest	Project Management	Issue	High	Open		
22		boulder' interface functionality	interface are currently at risk of not making the planned R3.17 release. The Single Sign on components of the HHIE interface are also currently at	Weekly RSM Status Report	to allow for the completion of 'big boulder' interfaces functionality development. BHA to add more resources to	04/30/2022 - Project Roadmap for completion of high priority (big boulder) features continued to be re-evaluated and redetermined during April. Based on the latest roadmap information, implementation of key	Project Management	Issue	High	Open		
22		boulder' interface functionality	interface are currently at risk of not making the planned R3.17 release. The Single Sign on components of the HHIE interface are also currently at risk of not making the planned R3.17	Weekly RSM Status Report	to allow for the completion of 'big boulder' interfaces functionality development. BHA to add more resources to support the development of "big	04/30/2022 - Project Roadmap for completion of high priority (big boulder) features continued to be re-evaluated and redetermined during April. Based on the latest roadmap information, implementation of key features are likely to extend beyond the DDI	Project Management	Issue	High	Open		
22		boulder' interface functionality	interface are currently at risk of not making the planned R3.17 release. The Single Sign on components of the HHIE interface are also currently at risk of not making the planned R3.17 release, and the ADT/Labs	Weekly RSM Status Report	to allow for the completion of 'big boulder' interfaces functionality development. BHA to add more resources to	04/30/2022 - Project Roadmap for completion of high priority (big boulder) features continued to be re-evaluated and redetermined during April. Based on the latest roadmap information, implementation of key features are likely to extend beyond the DDI period. The Project's updated Draft Feature	Project Management	Issue	High	Open		
22		boulder' interface functionality	interface are currently at risk of not making the planned R3.17 release. The Single Sign on components of the HHIE interface are also currently at risk of not making the planned R3.17 release, and the ADT/Labs components have already missed	Weekly RSM Status Report	to allow for the completion of 'big boulder' interfaces functionality development. BHA to add more resources to support the development of "big	04/30/2022 - Project Roadmap for completion of high priority (big boulder) features continued to be re-evaluated and redetermined during April. Based on the latest roadmap information, implementation of key features are likely to extend beyond the DDI period. The Project's updated Draft Feature Roadmap currently includes the following:	Project Management	Issue	High	Open		
22		boulder' interface functionality development are slipping.	interface are currently at risk of not making the planned R3.17 release. The Single Sign on components of the HHIE interface are also currently at risk of not making the planned R3.17 release, and the ADT/Labs components have already missed needed intermediate target dates for	Weekly RSM Status Report	to allow for the completion of 'big boulder' interfaces functionality development. BHA to add more resources to support the development of "big	04/30/2022 - Project Roadmap for completion of high priority (big boulder) features continued to be re-evaluated and redetermined during April. Based on the latest roadmap information, implementation of key features are likely to extend beyond the DDI period. The Project's updated Draft Feature Roadmap currently includes the following: R3.23 (4/28/2022) - Golden Record Project,	Project Management	Issue	High	Open		
22		boulder' interface functionality development are slipping.	interface are currently at risk of not making the planned R3.17 release. The Single Sign on components of the HHIE interface are also currently at risk of not making the planned R3.17 release, and the ADT/Labs components have already missed needed intermediate target dates for the planned R3.17 release. The Project	Weekly RSM Status Report	to allow for the completion of 'big boulder' interfaces functionality development. BHA to add more resources to support the development of "big	04/30/2022 - Project Roadmap for completion of high priority (big boulder) features continued to be re-evaluated and redetermined during April. Based on the latest roadmap information, implementation of key features are likely to extend beyond the DDI period. The Project's updated Draft Feature Roadmap currently includes the following: R3.23 (4/28/2022) - Golden Record Project, DDD Provider Portal, Rollout, CAMHD	Project Management	Issue	High	Open		
22		boulder' interface functionality development are slipping.	interface are currently at risk of not making the planned R3.17 release. The Single Sign on components of the HHIE interface are also currently at risk of not making the planned R3.17 release, and the ADT/Labs components have already missed needed intermediate target dates for the planned R3.17 release. The Project will need to re-assess the planned	Weekly RSM Status Report	to allow for the completion of 'big boulder' interfaces functionality development. BHA to add more resources to support the development of "big	04/30/2022 - Project Roadmap for completion of high priority (big boulder) features continued to be re-evaluated and redetermined during April. Based on the latest roadmap information, implementation of key features are likely to extend beyond the DDI period. The Project's updated Draft Feature Roadmap currently includes the following: R3.23 (4/28/2022) - Golden Record Project, DDD Provider Portal, Rollout, CAMHD Customer Portal MVP, Automated Testing,	Project Management	Issue	High	Open		
22		boulder' interface functionality development are slipping.	interface are currently at risk of not making the planned R3.17 release. The Single Sign on components of the HHIE interface are also currently at risk of not making the planned R3.17 release, and the ADT/Labs components have already missed needed intermediate target dates for the planned R3.17 release. The Project will need to re-assess the planned implementation dates for these 'big	Weekly RSM Status Report	to allow for the completion of 'big boulder' interfaces functionality development. BHA to add more resources to support the development of "big	04/30/2022 - Project Roadmap for completion of high priority (big boulder) features continued to be re-evaluated and redetermined during April. Based on the latest roadmap information, implementation of key features are likely to extend beyond the DDI period. The Project's updated Draft Feature Roadmap currently includes the following: R3.23 (4/28/2022) - Golden Record Project, DDD Provider Portal, Rollout, CAMHD Customer Portal MVP, Automated Testing, Dashboards and Reports, Critical DDD Power	Project Management	Issue	High	Open		
22		boulder' interface functionality development are slipping.	interface are currently at risk of not making the planned R3.17 release. The Single Sign on components of the HHIE interface are also currently at risk of not making the planned R3.17 release, and the ADT/Labs components have already missed needed intermediate target dates for the planned R3.17 release. The Project will need to re-assess the planned implementation dates for these 'big boulder' interfaces, including	Weekly RSM Status Report	to allow for the completion of 'big boulder' interfaces functionality development. BHA to add more resources to support the development of "big	04/30/2022 - Project Roadmap for completion of high priority (big boulder) features continued to be re-evaluated and redetermined during April. Based on the latest roadmap information, implementation of key features are likely to extend beyond the DDI period. The Project's updated Draft Feature Roadmap currently includes the following: R3.23 (4/28/2022) - Golden Record Project, DDD Provider Portal, Rollout, CAMHD Customer Portal MVP, Automated Testing, Dashboards and Reports, Critical DDD Power BI Reports, and Integration of the DDD	Project Management	Issue	High	Open		
22		boulder' interface functionality development are slipping.	interface are currently at risk of not making the planned R3.17 release. The Single Sign on components of the HHIE interface are also currently at risk of not making the planned R3.17 release, and the ADT/Labs components have already missed needed intermediate target dates for the planned R3.17 release. The Project will need to re-assess the planned implementation dates for these 'big boulder' interfaces, including identification of the timing needs by	Weekly RSM Status Report	to allow for the completion of 'big boulder' interfaces functionality development. BHA to add more resources to support the development of "big	04/30/2022 - Project Roadmap for completion of high priority (big boulder) features continued to be re-evaluated and redetermined during April. Based on the latest roadmap information, implementation of key features are likely to extend beyond the DDI period. The Project's updated Draft Feature Roadmap currently includes the following: R3.23 (4/28/2022) - Golden Record Project, DDD Provider Portal, Rollout, CAMHD Customer Portal MVP, Automated Testing, Dashboards and Reports, Critical DDD Power BI Reports, and Integration of the DDD Provider Portal.	Project Management	Issue	High	Open		
22		boulder' interface functionality development are slipping.	interface are currently at risk of not making the planned R3.17 release. The Single Sign on components of the HHIE interface are also currently at risk of not making the planned R3.17 release, and the ADT/Labs components have already missed needed intermediate target dates for the planned R3.17 release. The Project will need to re-assess the planned implementation dates for these 'big boulder' interfaces, including identification of the timing needs by the business teams. At a minimum,	Weekly RSM Status Report	to allow for the completion of 'big boulder' interfaces functionality development. BHA to add more resources to support the development of "big	04/30/2022 - Project Roadmap for completion of high priority (big boulder) features continued to be re-evaluated and redetermined during April. Based on the latest roadmap information, implementation of key features are likely to extend beyond the DDI period. The Project's updated Draft Feature Roadmap currently includes the following: R3.23 (4/28/2022) - Golden Record Project, DDD Provider Portal, Rollout, CAMHD Customer Portal MVP, Automated Testing, Dashboards and Reports, Critical DDD Power BI Reports, and Integration of the DDD Provider Portal. R3.24 (6/9/2022) - Golden Record Project,	Project Management	Issue	High	Open		
22		boulder' interface functionality development are slipping.	interface are currently at risk of not making the planned R3.17 release. The Single Sign on components of the HHIE interface are also currently at risk of not making the planned R3.17 release, and the ADT/Labs components have already missed needed intermediate target dates for the planned R3.17 release. The Project will need to re-assess the planned implementation dates for these 'big boulder' interfaces, including identification of the timing needs by the business teams. At a minimum, the CAFAS and HHIE interfaces are	Weekly RSM Status Report	to allow for the completion of 'big boulder' interfaces functionality development. BHA to add more resources to support the development of "big	04/30/2022 - Project Roadmap for completion of high priority (big boulder) features continued to be re-evaluated and redetermined during April. Based on the latest roadmap information, implementation of key features are likely to extend beyond the DDI period. The Project's updated Draft Feature Roadmap currently includes the following: R3.23 (4/28/2022) - Golden Record Project, DDD Provider Portal, Rollout, CAMHD Customer Portal MVP, Automated Testing, Dashboards and Reports, Critical DDD Power BI Reports, and Integration of the DDD Provider Portal. R3.24 (6/9/2022) - Golden Record Project, CAMHD Customer Portal MVP, Transition	Project Management	Issue	High	Open		
22		boulder' interface functionality development are slipping.	interface are currently at risk of not making the planned R3.17 release. The Single Sign on components of the HHIE interface are also currently at risk of not making the planned R3.17 release, and the ADT/Labs components have already missed needed intermediate target dates for the planned R3.17 release. The Project will need to re-assess the planned implementation dates for these 'big boulder' interfaces, including identification of the timing needs by the business teams. At a minimum, the CAFAS and HHIE interfaces are needed by the program. IV&V also	Weekly RSM Status Report	to allow for the completion of 'big boulder' interfaces functionality development. BHA to add more resources to support the development of "big	04/30/2022 - Project Roadmap for completion of high priority (big boulder) features continued to be re-evaluated and redetermined during April. Based on the latest roadmap information, implementation of key features are likely to extend beyond the DDI period. The Project's updated Draft Feature Roadmap currently includes the following: R3.23 (4/28/2022) - Golden Record Project, DDD Provider Portal, Rollout, CAMHD Customer Portal MVP, Automated Testing, Dashboards and Reports, Critical DDD Power BI Reports, and Integration of the DDD Provider Portal. R3.24 (6/9/2022) - Golden Record Project, CAMHD Customer Portal MVP, Transition Billing Processes, MQD Eligibility Interface,	Project Management	Issue	High	Open		
22		boulder' interface functionality development are slipping.	interface are currently at risk of not making the planned R3.17 release. The Single Sign on components of the HHIE interface are also currently at risk of not making the planned R3.17 release, and the ADT/Labs components have already missed needed intermediate target dates for the planned R3.17 release. The Project will need to re-assess the planned implementation dates for these 'big boulder' interfaces, including identification of the timing needs by the business teams. At a minimum, the CAFAS and HHIE interfaces are needed by the program. IV&V also notes that there are several new high	Weekly RSM Status Report	to allow for the completion of 'big boulder' interfaces functionality development. BHA to add more resources to support the development of "big	04/30/2022 - Project Roadmap for completion of high priority (big boulder) features continued to be re-evaluated and redetermined during April. Based on the latest roadmap information, implementation of key features are likely to extend beyond the DDI period. The Project's updated Draft Feature Roadmap currently includes the following: R3.23 (4/28/2022) - Golden Record Project, DDD Provider Portal, Rollout, CAMHD Customer Portal MVP, Automated Testing, Dashboards and Reports, Critical DDD Power BI Reports, and Integration of the DDD Provider Portal. R3.24 (6/9/2022) - Golden Record Project, CAMHD Customer Portal MVP, Transition Billing Processes, MQD Eligibility Interface, IMHE Power App, Automated Testing,	Project Management	Issue	High	Open		
22		boulder' interface functionality development are slipping.	interface are currently at risk of not making the planned R3.17 release. The Single Sign on components of the HHIE interface are also currently at risk of not making the planned R3.17 release, and the ADT/Labs components have already missed needed intermediate target dates for the planned R3.17 release. The Project will need to re-assess the planned implementation dates for these 'big boulder' interfaces, including identification of the timing needs by the business teams. At a minimum, the CAFAS and HHIE interfaces are needed by the program. IV&V also notes that there are several new high priority requests related to the DDD	Weekly RSM Status Report	to allow for the completion of 'big boulder' interfaces functionality development. BHA to add more resources to support the development of "big	04/30/2022 - Project Roadmap for completion of high priority (big boulder) features continued to be re-evaluated and redetermined during April. Based on the latest roadmap information, implementation of key features are likely to extend beyond the DDI period. The Project's updated Draft Feature Roadmap currently includes the following: R3.23 (4/28/2022) - Golden Record Project, DDD Provider Portal, Rollout, CAMHD Customer Portal MVP, Automated Testing, Dashboards and Reports, Critical DDD Power BI Reports, and Integration of the DDD Provider Portal. R3.24 (6/9/2022) - Golden Record Project, CAMHD Customer Portal MVP, Transition Billing Processes, MQD Eligibility Interface, IMHE Power App, Automated Testing, ePrescribe, Independent Security Assessment,	Project Management	Issue	High	Open		
22		boulder' interface functionality development are slipping.	interface are currently at risk of not making the planned R3.17 release. The Single Sign on components of the HHIE interface are also currently at risk of not making the planned R3.17 release, and the ADT/Labs components have already missed needed intermediate target dates for the planned R3.17 release. The Project will need to re-assess the planned implementation dates for these 'big boulder' interfaces, including identification of the timing needs by the business teams. At a minimum, the CAFAS and HHIE interfaces are needed by the program. IV&V also notes that there are several new high priority requests related to the DDD Provider Portal and 27 production	Weekly RSM Status Report	to allow for the completion of 'big boulder' interfaces functionality development. BHA to add more resources to support the development of "big	04/30/2022 - Project Roadmap for completion of high priority (big boulder) features continued to be re-evaluated and redetermined during April. Based on the latest roadmap information, implementation of key features are likely to extend beyond the DDI period. The Project's updated Draft Feature Roadmap currently includes the following: R3.23 (4/28/2022) - Golden Record Project, DDD Provider Portal, Rollout, CAMHD Customer Portal MVP, Automated Testing, Dashboards and Reports, Critical DDD Power BI Reports, and Integration of the DDD Provider Portal. R3.24 (6/9/2022) - Golden Record Project, CAMHD Customer Portal MVP, Transition Billing Processes, MQD Eligibility Interface, IMHE Power App, Automated Testing, ePrescribe, Independent Security Assessment, Dashboards and reports, Critical DDD Power	Project Management	Issue	High	Open		
22		boulder' interface functionality development are slipping.	interface are currently at risk of not making the planned R3.17 release. The Single Sign on components of the HHIE interface are also currently at risk of not making the planned R3.17 release, and the ADT/Labs components have already missed needed intermediate target dates for the planned R3.17 release. The Project will need to re-assess the planned implementation dates for these 'big boulder' interfaces, including identification of the timing needs by the business teams. At a minimum, the CAFAS and HHIE interfaces are needed by the program. IV&V also notes that there are several new high priority requests related to the DDD Provider Portal and 27 production flow jobs that need to be reviewed for	Weekly RSM Status Report	to allow for the completion of 'big boulder' interfaces functionality development. BHA to add more resources to support the development of "big	04/30/2022 - Project Roadmap for completion of high priority (big boulder) features continued to be re-evaluated and redetermined during April. Based on the latest roadmap information, implementation of key features are likely to extend beyond the DDI period. The Project's updated Draft Feature Roadmap currently includes the following: R3.23 (4/28/2022) - Golden Record Project, DDD Provider Portal, Rollout, CAMHD Customer Portal MVP, Automated Testing, Dashboards and Reports, Critical DDD Power BI Reports, and Integration of the DDD Provider Portal. R3.24 (6/9/2022) - Golden Record Project, CAMHD Customer Portal MVP, Transition Billing Processes, MQD Eligibility Interface, IMHE Power App, Automated Testing, ePrescribe, Independent Security Assessment, Dashboards and reports, Critical DDD Power BI Reports, and Integration of the CAMHD	Project Management	Issue	High	Open		
22		boulder' interface functionality development are slipping.	interface are currently at risk of not making the planned R3.17 release. The Single Sign on components of the HHIE interface are also currently at risk of not making the planned R3.17 release, and the ADT/Labs components have already missed needed intermediate target dates for the planned R3.17 release. The Project will need to re-assess the planned implementation dates for these 'big boulder' interfaces, including identification of the timing needs by the business teams. At a minimum, the CAFAS and HHIE interfaces are needed by the program. IV&V also notes that there are several new high priority requests related to the DDD Provider Portal and 27 production flow jobs that need to be reviewed for replacement of older dataverse	Weekly RSM Status Report	to allow for the completion of 'big boulder' interfaces functionality development. BHA to add more resources to support the development of "big	04/30/2022 - Project Roadmap for completion of high priority (big boulder) features continued to be re-evaluated and redetermined during April. Based on the latest roadmap information, implementation of key features are likely to extend beyond the DDI period. The Project's updated Draft Feature Roadmap currently includes the following: R3.23 (4/28/2022) - Golden Record Project, DDD Provider Portal, Rollout, CAMHD Customer Portal MVP, Automated Testing, Dashboards and Reports, Critical DDD Power BI Reports, and Integration of the DDD Provider Portal. R3.24 (6/9/2022) - Golden Record Project, CAMHD Customer Portal MVP, Transition Billing Processes, MQD Eligibility Interface, IMHE Power App, Automated Testing, ePrescribe, Independent Security Assessment, Dashboards and reports, Critical DDD Power BI Reports, and Integration of the CAMHD Provider Portal.	Project Management	Issue	High	Open		
22		boulder' interface functionality development are slipping.	interface are currently at risk of not making the planned R3.17 release. The Single Sign on components of the HHIE interface are also currently at risk of not making the planned R3.17 release, and the ADT/Labs components have already missed needed intermediate target dates for the planned R3.17 release. The Project will need to re-assess the planned implementation dates for these 'big boulder' interfaces, including identification of the timing needs by the business teams. At a minimum, the CAFAS and HHIE interfaces are needed by the program. IV&V also notes that there are several new high priority requests related to the DDD Provider Portal and 27 production flow jobs that need to be reviewed for replacement of older dataverse connectors that are known by	Weekly RSM Status Report	to allow for the completion of 'big boulder' interfaces functionality development. BHA to add more resources to support the development of "big	04/30/2022 - Project Roadmap for completion of high priority (big boulder) features continued to be re-evaluated and redetermined during April. Based on the latest roadmap information, implementation of key features are likely to extend beyond the DDI period. The Project's updated Draft Feature Roadmap currently includes the following: R3.23 (4/28/2022) - Golden Record Project, DDD Provider Portal, Rollout, CAMHD Customer Portal MVP, Automated Testing, Dashboards and Reports, Critical DDD Power BI Reports, and Integration of the DDD Provider Portal. R3.24 (6/9/2022) - Golden Record Project, CAMHD Customer Portal MVP, Transition Billing Processes, MQD Eligibility Interface, IMHE Power App, Automated Testing, ePrescribe, Independent Security Assessment, Dashboards and reports, Critical DDD Power BI Reports, and Integration of the CAMHD Provider Portal.	Project Management	Issue	High	Open		
22		boulder' interface functionality development are slipping.	interface are currently at risk of not making the planned R3.17 release. The Single Sign on components of the HHIE interface are also currently at risk of not making the planned R3.17 release, and the ADT/Labs components have already missed needed intermediate target dates for the planned R3.17 release. The Project will need to re-assess the planned implementation dates for these 'big boulder' interfaces, including identification of the timing needs by the business teams. At a minimum, the CAFAS and HHIE interfaces are needed by the program. IV&V also notes that there are several new high priority requests related to the DDD Provider Portal and 27 production flow jobs that need to be reviewed for replacement of older dataverse connectors that are known by Microsoft to have limitations and	Weekly RSM Status Report	to allow for the completion of 'big boulder' interfaces functionality development. BHA to add more resources to support the development of "big	04/30/2022 - Project Roadmap for completion of high priority (big boulder) features continued to be re-evaluated and redetermined during April. Based on the latest roadmap information, implementation of key features are likely to extend beyond the DDI period. The Project's updated Draft Feature Roadmap currently includes the following: R3.23 (4/28/2022) - Golden Record Project, DDD Provider Portal, Rollout, CAMHD Customer Portal MVP, Automated Testing, Dashboards and Reports, Critical DDD Power BI Reports, and Integration of the DDD Provider Portal. R3.24 (6/9/2022) - Golden Record Project, CAMHD Customer Portal MVP, Transition Billing Processes, MQD Eligibility Interface, IMHE Power App, Automated Testing, ePrescribe, Independent Security Assessment, Dashboards and reports, Critical DDD Power BI Reports, and Integration of the CAMHD Provider Portal. R3.25 (7/21/2022) - Transition Billing Processes, Automated Testing, ePrescribe,	Project Management	Issue	High	Open		
22		boulder' interface functionality development are slipping.	interface are currently at risk of not making the planned R3.17 release. The Single Sign on components of the HHIE interface are also currently at risk of not making the planned R3.17 release, and the ADT/Labs components have already missed needed intermediate target dates for the planned R3.17 release. The Project will need to re-assess the planned implementation dates for these 'big boulder' interfaces, including identification of the timing needs by the business teams. At a minimum, the CAFAS and HHIE interfaces are needed by the program. IV&V also notes that there are several new high priority requests related to the DDD Provider Portal and 27 production flow jobs that need to be reviewed for replacement of older dataverse connectors that are known by Microsoft to have limitations and cause unplanned production issues.	Weekly RSM Status Report	to allow for the completion of 'big boulder' interfaces functionality development. BHA to add more resources to support the development of "big	04/30/2022 - Project Roadmap for completion of high priority (big boulder) features continued to be re-evaluated and redetermined during April. Based on the latest roadmap information, implementation of key features are likely to extend beyond the DDI period. The Project's updated Draft Feature Roadmap currently includes the following: R3.23 (4/28/2022) - Golden Record Project, DDD Provider Portal, Rollout, CAMHD Customer Portal MVP, Automated Testing, Dashboards and Reports, Critical DDD Power BI Reports, and Integration of the DDD Provider Portal. R3.24 (6/9/2022) - Golden Record Project, CAMHD Customer Portal MVP, Transition Billing Processes, MQD Eligibility Interface, IMHE Power App, Automated Testing, ePrescribe, Independent Security Assessment, Dashboards and reports, Critical DDD Power BI Reports, and Integration of the CAMHD Provider Portal. R3.25 (7/21/2022) - Transition Billing Processes, Automated Testing, ePrescribe, CAMHD Provider APIs, CAFAS Interface,	Project Management	Issue	High	Open		
22		boulder' interface functionality development are slipping.	interface are currently at risk of not making the planned R3.17 release. The Single Sign on components of the HHIE interface are also currently at risk of not making the planned R3.17 release, and the ADT/Labs components have already missed needed intermediate target dates for the planned R3.17 release. The Project will need to re-assess the planned implementation dates for these 'big boulder' interfaces, including identification of the timing needs by the business teams. At a minimum, the CAFAS and HHIE interfaces are needed by the program. IV&V also notes that there are several new high priority requests related to the DDD Provider Portal and 27 production flow jobs that need to be reviewed for replacement of older dataverse connectors that are known by Microsoft to have limitations and	Weekly RSM Status Report	to allow for the completion of 'big boulder' interfaces functionality development. BHA to add more resources to support the development of "big	04/30/2022 - Project Roadmap for completion of high priority (big boulder) features continued to be re-evaluated and redetermined during April. Based on the latest roadmap information, implementation of key features are likely to extend beyond the DDI period. The Project's updated Draft Feature Roadmap currently includes the following: R3.23 (4/28/2022) - Golden Record Project, DDD Provider Portal, Rollout, CAMHD Customer Portal MVP, Automated Testing, Dashboards and Reports, Critical DDD Power BI Reports, and Integration of the DDD Provider Portal. R3.24 (6/9/2022) - Golden Record Project, CAMHD Customer Portal MVP, Transition Billing Processes, MQD Eligibility Interface, IMHE Power App, Automated Testing, ePrescribe, Independent Security Assessment, Dashboards and reports, Critical DDD Power BI Reports, and Integration of the CAMHD Provider Portal. R3.25 (7/21/2022) - Transition Billing Processes, Automated Testing, ePrescribe,	Project Management	Issue	High	Open		

	7/24/2024 The suggest DDI society	The second Decided Chaffing No. 1	F. t-str t t t t t t	Obtain IARRII annual face Cont	02/20/2022 The IABBILLIAN AND II	Decises Manager	1	1	Classal	ln	
23	7/31/2021 The current DDI period expires at	The current Project Staffing Model	Existing contractual agreements.	Obtain IAPDU approval from CMS.	02/28/2022 - The IAPDU was approved by	Project Management	issue	Low	Closed	Darren	
		shows a planned reduction in RSM			Federal partners in early February, which					Macdonald	
	will require RSM to transition of	resources support starting in			extended the DD&I effort through October						
		September 2021 through December			2022. Transition from RSM will not be						
	·	2021. Prior to this timeframe, BHA			required until approximately August 2022.						
		should commence the development of			Based on the extended time being available						
		a transition plan to ensure the			for transition efforts, IV&V is closing this						
		appropriate replacement State			finding.						
		resources are identified/secured and			01/31/2022 - There were no substantive						
		the necessary knowledge transfer			changes to this finding observed during						
		sessions are planned and executed			January as BHA continues to pursue CMS						
		with RSM. BHA will need to be sure			Federal funding approval for extending DD&I						
		they are ready to take on the			through October 2022 followed by M&O						
		development of user stories, testing,			through September 2024. IV&V will continue						
		deployment, and the support and			to monitor this finding until Federal funding						
		maintenance of the entire system by			approved.						
		the end of the DDI period (December			12/31/2021 - There were no substantive						
		2021).			changes to this finding observed during						
					December as BHA continues to pursue CMS						
					Federal funding approval for extending DD&I						
					through October 2022 followed by M&O						
					through September 2024. IV&V will continue						
					to monitor this finding until Federal funding						
					approved.						
					11/30/2021 - There were no substantive						
					changes to this finding observed during						
					November. In late October, PAC approved the						
24	10/29/2021 The R3.19 Solution Upgrade	Solution upgrades are essential for	Daily Scrum Reporting	Ensure there are adequate and	11/30/2021 - R3.19 was promoted to	Project Management	Issue	High	Closed		Technical issue
	technical issues are delaying the	keeping the system current in order to		qualified resources to support the	production as an FSU on 11/14/2021 and						resolved and were
	implementation of the release and	gain access to new features that		current Solution Upgrade	access to the development and test						attributed to the
	the ability for staff to develop and	enhance productivity, eliminate		processes. This may require the	environments was again restored. Because						following:
	test code.	bottlenecks and govern sensitive		support from RSM resources to	the solution upgrade was the first in five (5)						 Import of solution
		information. The current R3.19		provide assistance and knowledge	releases, the deployment process took						taking 1-2 hours,
		solution upgrade work efforts that		transfer.	approximately 12 hours. This issue did have						timed out in PROD,
		includes patches for 5 releases (R3.15-		As appropriate, consult with RSM	an impact both on the amount of DDI						so had to restore
		R3.19) is causing technical issues. As a		on best practices that BHA could	functionality (reduced) included in					1	and then restart
		result, R3.19+ development and		employ to support the Solution	downstream releases and cost implications.						from a previous
		testing work is hampered until these		Upgrade.	IV&V has closed this finding, as it was						point in time
		testing work is nampered until these							ı	1	
		technical issues are resolved.			alleviated by the R3.19 release on						backup
		•			alleviated by the R3.19 release on						•
		•			alleviated by the R3.19 release on 11/14/2021.						• Errors are vague –
		•		7,000	alleviated by the R3.19 release on 11/14/2021. 10/31/2021 - Due to the current R3.19						• Errors are vague – sometimes
		•			alleviated by the R3.19 release on 11/14/2021. 10/31/2021 - Due to the current R3.19 Solution Upgrade technical issues, staff have						 Errors are vague – sometimes indicating "failure"
		•			alleviated by the R3.19 release on 11/14/2021. 10/31/2021 - Due to the current R3.19 Solution Upgrade technical issues, staff have been advised to stay out of the development						 Errors are vague – sometimes indicating "failure" but actually
		•			alleviated by the R3.19 release on 11/14/2021. 10/31/2021 - Due to the current R3.19 Solution Upgrade technical issues, staff have been advised to stay out of the development and test environments until the issues have						• Errors are vague – sometimes indicating "failure" but actually successful
		•			alleviated by the R3.19 release on 11/14/2021. 10/31/2021 - Due to the current R3.19 Solution Upgrade technical issues, staff have been advised to stay out of the development and test environments until the issues have been resolved. As a result, development and						 Errors are vague – sometimes indicating "failure" but actually successful MS moving away
		•			alleviated by the R3.19 release on 11/14/2021. 10/31/2021 - Due to the current R3.19 Solution Upgrade technical issues, staff have been advised to stay out of the development and test environments until the issues have been resolved. As a result, development and testing for R3.19 and forward are affected by						Errors are vague – sometimes indicating "failure" but actually successful MS moving away from Classic UI
		•			alleviated by the R3.19 release on 11/14/2021. 10/31/2021 - Due to the current R3.19 Solution Upgrade technical issues, staff have been advised to stay out of the development and test environments until the issues have been resolved. As a result, development and testing for R3.19 and forward are affected by this issue. IV&V will continue to monitor this						Errors are vague – sometimes indicating "failure" but actually successful MS moving away from Classic UI which is changing
		•			alleviated by the R3.19 release on 11/14/2021. 10/31/2021 - Due to the current R3.19 Solution Upgrade technical issues, staff have been advised to stay out of the development and test environments until the issues have been resolved. As a result, development and testing for R3.19 and forward are affected by						Errors are vague – sometimes indicating "failure" but actually successful MS moving away from Classic UI which is changing the availability of
		•			alleviated by the R3.19 release on 11/14/2021. 10/31/2021 - Due to the current R3.19 Solution Upgrade technical issues, staff have been advised to stay out of the development and test environments until the issues have been resolved. As a result, development and testing for R3.19 and forward are affected by this issue. IV&V will continue to monitor this						Errors are vague – sometimes indicating "failure" but actually successful MS moving away from Classic UI which is changing the availability of some functionality /
		•			alleviated by the R3.19 release on 11/14/2021. 10/31/2021 - Due to the current R3.19 Solution Upgrade technical issues, staff have been advised to stay out of the development and test environments until the issues have been resolved. As a result, development and testing for R3.19 and forward are affected by this issue. IV&V will continue to monitor this						Errors are vague – sometimes indicating "failure" but actually successful MS moving away from Classic UI which is changing the availability of some functionality / how
		•			alleviated by the R3.19 release on 11/14/2021. 10/31/2021 - Due to the current R3.19 Solution Upgrade technical issues, staff have been advised to stay out of the development and test environments until the issues have been resolved. As a result, development and testing for R3.19 and forward are affected by this issue. IV&V will continue to monitor this						Errors are vague – sometimes indicating "failure" but actually successful MS moving away from Classic UI which is changing the availability of some functionality / how Corrupt MDA
		•			alleviated by the R3.19 release on 11/14/2021. 10/31/2021 - Due to the current R3.19 Solution Upgrade technical issues, staff have been advised to stay out of the development and test environments until the issues have been resolved. As a result, development and testing for R3.19 and forward are affected by this issue. IV&V will continue to monitor this						Errors are vague – sometimes indicating "failure" but actually successful MS moving away from Classic UI which is changing the availability of some functionality / how Corrupt MDA encountered in SIT
		•			alleviated by the R3.19 release on 11/14/2021. 10/31/2021 - Due to the current R3.19 Solution Upgrade technical issues, staff have been advised to stay out of the development and test environments until the issues have been resolved. As a result, development and testing for R3.19 and forward are affected by this issue. IV&V will continue to monitor this						Errors are vague – sometimes indicating "failure" but actually successful MS moving away from Classic UI which is changing the availability of some functionality / how Corrupt MDA